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 Resume 
 
L’étude des précédents exemples de synthèse totale du rhazinilam et de ses analogues, 
nous a conduit à élaborer notre propre approche basée sur une réaction d’aldolisation 
croisée de Mukaiyama comme étape clé. La voie de synthèse est décrite (en partie) ci-
dessous : 
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La détermination de la diastéréosélectivité des reactions concernées est realizée par 
analyse des structures par diffractométrie de rayons-X. 
Les étapes suivantes ont été étudiées sur un modèle simplifié. Le composé 1 est obtenu 
par N-acylation du 1H-pyrrole-2(5H)-one suivie de la déprotection de la fonction alcool. 
L’oxydation controlée de la fonction alcool de 1 en aldéhyde suivie d’une réaction de 
Wittig permet d’obtenir le composé 2. 
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La méthodologie envisagée pour aboutir à la synthèse des analogues du rhazinilam est 
la suivante : on forme le cycle à six chaînons par une réaction d’addition de Michael 
suivie de la réduction du groupement nitro et, enfin, une réaction de lactamisation 
permet de former le cycle à neuf chaînons. 
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 Abstract 
 
Having studied the previous total syntheses of rhazinilam and of its analogues, we 
developed our own strategy based the crossed aldol Mukaiyama reaction as the key 
step. The synthetic pathway is depicted below: 
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The determination of the diastereoselectivity of the reactions reported above could be 
achieved with the help X-ray structures.     
Working with model molecules, by acylation of 1H-pyrrole-2(5H)-one to nitrogen, 
cleavage of hydroxyl group protection, we could obtain 1-(4-hydroxybutanoyl)-1H-pyrrol-
2(5H)-one (1). The oxidation of product 1 to aldehyde followed by Wittig reaction will 
lead to the compound 2. 
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The last steps planed for the synthesis of the rhazinilam analogues are: six membered 
ring formation by Michael reaction, reduction of nitro group and cyclisation to nine 
membered ring. 
 
N
NO2
O
O
O
O
C2H5O
N
NO2
O
O
O
O
C2H5O
HN
N
O
O
O
 
 
 
 
 
 Table of contents 
 
1. Introduction 1 
1.1. (-)-Rhazinilam: biosynthetic origins, semi-synthesis and structural elucidation .....1 
1.2. Biological activity of rhazinilam and its analogues .................................................4 
1.3. Previous total syntheses ......................................................................................11 
2. Goal 23 
3. Analysis of the Retrosynthesis of Rhazinilam 25 
3.1. Towards the Synthesis of the Skeleton of (-)-Rhazinilam: Mukaiyama Crossed 
Aldol Reaction Followed by the Staudinger Reaction for the Construction of the 
Pyrrolic C-Ring ............................................................................................................31 
3.2. Supporting Material ..............................................................................................53 
4. X-Ray Analysis of Some Synthetic Intermediates 82 
4.1. Rac-(2R*,3R*)-S-ethyl 4-chloro-3-hydroxy-2-phenylbuthanethioate and Rac-
(2R*,3R*)-S-ethyl 2-phenyl-3-(tosyloxy)buthanethioate: The dichotomy of the 
stereoselectivity of the Mukaiyama reaction ...............................................................86 
4.2. 4-Azido-3-hydroxy-3-(2-nitro-phenyl)-butyric acid methyl ester .........................107 
4.3. 5-Hydroxyalkyl Derivatives of tert-Butyl 2-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate ................................................................................................................120 
5. Conclusions 151 
6. Perspectives 154 
7. Experimental Section 155 
7.1. General remarks ................................................................................................155 
7.2. Syntheses ..........................................................................................................159 
 
 
 
 
 
 
 
 
  
 
 
 
 
 1
1. Introduction 
1.1. (-)-Rhazinilam: biosynthetic origins, semi-synthesis and structural elucidation 
 
(-)-Rhazinilam, a natural product, was isolated for the first time from Melodinus australis 
in 1965[1]. Later it has been found in other South-east Asian members of the specific 
family Apocynaceae[2]: Rhazya stricta, Aspidosperma quebracho-blanco, Leuconotis 
eugenifolia, Kopsia singapurensis and Kopsia teoi. More recently, (-)-rhazinilam was 
isolated from intergeneric somatic hybrid cell culture of two members of the same family: 
Rauvolfia serpentine and Rhazia stricta.   
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(-)-rhazinilam (1) 
 
The structure of (-)-rhazinilam 1 was initially established through spectroscopic analysis 
and chemical degradation studies[3] then confirmed using X-ray crystallographic 
techniques[4]. Compound 1 is characterized by the presence of four rings: the phenyl A-
ring, the nine-membered lactam B-ring, the pyrrole C-ring and the piperidine D-ring. 
Through X-ray analysis, it was determined that the A-C dihedral angle of rhazinilam is 
ca. 90°, the amide bond possesses a cis conformation and the median ring adopts a 
boat-chair conformation. This molecule bears two stereogenic elements: the quaternary 
carbon atom C-20 and the phenyl-pyrrole chirality axis. Unfortunately, it was not possible 
to determine the absolute configuration (R, aR) by X-ray analysis. Instead, it was 
established via semi-synthesis of 1 from an aspidosperma alkaloid (+)-1,2-
didehydroaspidospermidine (3)[5]. (-)-Rhazinilam is considered now as an artefact of the 
isolation procedure employed during the extraction from the source plant.  
The naturally occurring indole alkaloid (+)-1,2-didehydroaspidospermidine (3) was 
sequentially treated with m-CPBA and ferrous sulfate to give (-)-rhazinilam in ca. 30% 
yield (Scheme 1).   
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Scheme 1: Semi-synthesis of (-)-rhazinilam  
 
The mechanism of this stepwise conversion was first proposed by Smith and later 
confirmed by Baudoin[6, 7]. The reaction sequence begins with the acid-catalysed removal 
of the ester group in (+)-vincadifformine (2) providing (+)-1,2-didehydroaspidospermidine 
(3) quantitatively. The next step is m-CPBA oxidative cleavage of the C2-C3 indoline 
bond to produce the nine-membered ring in 4 in 65% yield. By treatement with Fe(II), 
compound 4 was reduced to a 9:1 mixture of rhazinilam (1) and 5,21-dihydrorhazinilam 
(2) (itself giving rhazinilam upon exposure to air for several days). This slow conversion 
5→1 suggested that the formation of rhazinilam from compound 4 occurred via a 
Polonovski-type reaction. Indeed, it was found that subjecting compound 4 to acetic 
anhydride and Et3N (standard Polonovski conditions) afforded (-)-rhazinilam (1) in 81%. 
These observations led to the conclusion that, in the plant, the direct biogenetic 
precursor of 1 is almost certainly the air-sensitive 5,21-dihydrorhazinilam (5). 
Nevertheless, since (+)-1,2-didehydroaspidospermidine (3) has never been found to co-
occur in vivo with alkaloids 1 or 5, the question if 3 is the actual biogenetic precursor of 
the compound 5 remains an open one. Since the absolute configuration of (+)-
vincadifformine (2) had been unambiguously determined, this semi-synthesis provided 
the first experimental evidence of the absolute configuration of (-)-rhazinilam (1).   
 3
Other alkaloids possessing the same tetracyclic-system as rhazinilam have been 
isolated from various members of the family Apocynaceae: 3-oxo-rhazinilam (6) 
(rhazinicine), 3-oxo-14,15-dehydrorhazinilam (7), (-)-leuconolam (8) and rhazinal (9). 
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Figure 1: Natural analogues of (-)-rhazinilam 1 
 
Such alkaloids are also likely to be derived from 5,21-dihydrorhazinilam (5) via oxidative 
pathways.  
Rhazinal (9) has a particular interest because it possesses similar properties to those of 
(-)-rhazinilam (1).  9 was prepared via Vilsmeier-Haack formylation of (-)-rhazinilam as 
part of a structure-activity relationship (SAR) study around this family of compounds. In 
1998, Kam and co-workers[8] reported the isolation of (-)-rhazinal (9) from stem extracts 
of a Malayan member of the Apocynaceae, Kopsia teoi, a plant that also produces (-)-
rhazinilam (1).  
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1.2. Biological activity of rhazinilam and its analogues 
 
Cancer is a class of diseases in which a group of cells shows uncontrolled growth 
(growth and division beyond the normal limits), invasion (intrusion on and destruction of 
adjacent tissues) and, sometimes, metastasis (spread to other locations in the body via 
lymph or blood)[9]. This disease causes about 13% of all deaths. According to the 
American Cancer Society[10], about 565’650 Americans are expected to die of cancer in 
2008 (more than 1500 people a day). Cancer can be treated by surgery, chemotherapy, 
radiation therapy, immunotherapy, photodynamic therapy, monoclonal antibody therapy 
or other methods. The choise of therapy depends upon the location and grade of the 
tumor[11] and the stage of the disease, as well as the general state of the patient. 
Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. The 
term “chemotherapy” usually refers to the use cytotoxic drugs which affect rapidly 
dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere 
with cell division in various possible ways: the duplication of DNA or the separation of 
newly formed chromosomes (mitosis). Most targets of chemotherapy are rapidly dividing 
cells and chemotherapy is usually not specific for cancer cells. Some degree of 
specificity may come from the inability of many cancer cells to repair DNA damage, while 
normal cells generally can. Hence, chemotherapy has the potential to harm healthy 
tissue, especially those tissues that have a high rate of cell division (e.g.: hair). These 
cells usually repair themselves after chemotherapy.  
Cell division is facilitated by the formation of the mitotic spindle apparatus which is 
constructed from a complex and ordered network of microtubules. Microtubules are 
themselves formed through the reversible dimerisation of a protein called tubulin. In 
mitotic process, a dynamic interconversion of tubulin and microtubules is required.           
Consequently, small molecules that disrupt the assembly (vinblastine, colchicine) (Figure 
2) or disassembly (paclitaxel, also known as Taxol, and docetaxel) of microtubules have 
shown a remarkable ability to suppress cell proliferation. Many of these molecules are 
derived from natural sources and, indeed, some of them, have been successfully 
employed in the treatment of certain cancers (Figure 3)[12].  
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                                    A                                                                             B 
Figure 2: (A) Normal assembly of the tubulin (dynamic instability)[13]; (B) 
Colchicine inhibits polymerization of tubuline in microtubules[14].  
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Figure 3 
 
The discovery of the tubulin-binding properties of rhazinilm was made through the 
screening of a number of Malaysian plant extracts by the Poitier group in Gif sur 
Yvette[15]. Indeed, this group established that (-)-rhazinilam mimics the effect of both 
vinblastin and paclitaxel: it exerts a vinblastine-like effect by inducing the non-reversible 
assembly (spiralisation) of tubulin, as well as inhibiting the cold-induced disassembly of 
microtubules in the same manner as the taxoids[16].(-)-Rhazinilam has also demonstrated 
a similarity to Taxol by inducing the formation of anomalous tubulin assemblies (Figure 
4)[17]. 
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Figure 4: Presence of spirals at the two extremities of a microtubule preincubated 
at 37 °C in the presence of rhazinilam (125 µM) and further submitted to a 30 min. 
treatment at 0 °C[17] 
 
As a consequence of its tubulin-binding properties, (-)-rhazinilam shows moderate 
cytotoxicity towards KB cell lines, with IC50values in the range 7 µM[6, 16]. 
 
Observing the novel mode of interaction of (-)-rhazinilam with tubullin, several structure-
activity relationship (SAR) studies seeking to identify analogues with improved 
pharmacological properties have been conducted. The analogues were prepared by 
semi-synthesis from (-)-rhazinilam itself or by “total” synthesis. Thus, for exemple, semi-
synthetic routes related to those employed for producing useful quantities of (-)-
rhazinilam have also been used for the generation of its enantiomer (+)-rhazinilam,  from 
the alkaloid (-)-tabersonine[15]. Significantly, the (+)-rhazinilam enantiomer failed to inhibit 
tubulin polymerization due to a lack of binding affinity for this protein. 
The Thal group was the first to conduct SAR studies[2] by total synthesis of phenyl-
pyrrole analogues[18, 19]. To study the role of the lactame B-ring of rhazinilam, they 
synthesized a number of achiral phenyl-pyrrole lacking this ring or having different 
lactame ring size (6 o 9-membered): 
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Scheme 2: Precursors of phenyl-pyrrole analogues 
 
Substituted phenyl-pyrrole such as 11 were prepared using the Barton-Zard[20] or the 
Gupton[21] methods. Functionalisation of the R3 chain and cyclisation afforded various 
tricyclic lactam 10. The fact that all intermediates such as 11 lacking the lactam B-ring 
were inactive on tubulin was confirmed in subsequent studies. Tricyclic analogues, 
including those having a 9-membered lactame ring such as rhazinilam showed a 200 
times smaller activity compared to rhazinilam. These important results provided the first 
evidence that both the lactame B-ring and the substitution at C-20 atom were essential 
for the interaction with tubulin. The presence of bulky substituents at C-20 induces the 
lactam ring of rhazinilam a rigid boat-chair conformation which is the active species in 
the term of the tubulin binding process.  
HN N
O
12
BocHN
NC
N
CO2CH3
Suzuki coupling
 
Scheme 3: Synthesis of phenyl-pyrrole analogues 
 
An achiral tricyclic 7-membered lactam 12 was inactive on the cold-induced disassembly 
of microtubules. It showed inhibition of tubulin polymerization with an IC50 value of 27 µM 
(IC50 = 7 µM for rhazinilam and a significant toxicity towards KB cells (IC50 = 7 µM, 1/14 
compared to  rhazinilam).    
Studies aimed at replacing the pyrrole C-ring of rhazinilam by other aromatic rings have 
been undertaken. In the first place, a number of racemic biphenyl analogues having the 
general structure 13 have been synthesized using a strategy similar to that leading to 12, 
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with construction of the biphenyl bond by a Stille or Suzuki-Miyaura coupling and final 
cyclisation to form the bridging ring[2]. 
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Some analogues like 13A, having the structure closest to rhazinilam, but with no D-ring, 
were less active than the natural product. Decreasing the size and the number of alkyl 
substituents R1 and R2 (entries 2 and 3, Table 1) a dramatic decrease of the antitubulin 
activity in accordance with observation from Thal and co-workers was observed. 
Replacing the lactam by a lactone (entry 4) or by urea (entry 5) proved unfruitful, but the 
replacement by a carbamate (entry 6) was particulary interesting. Indeed racemic 
compound (13F) was equipotent to rhazinilam on the inhibition of both microtubule 
assembly and disassembly and was twice less cytotoxic towards KB and MCF7 cells. It 
was shown also that the presence of a cyclohexane ring fused with C-ring as in 
rhazinilam (entry 7) is not essential. 
The next attempt was the  optimization of the structure 13F. To this purpose, a synthetic 
sequence based on a one-pot borylation Suzuki coupling strategy was proposed[16]. 
Racemic biaryl analogues 14 bearing substituents on the A-ring were thus synthesized 
in a direct procedure from substituted anilines. But all these analogues (entries 8-12) 
were less active than unsubstituted 13F on tubulin, pointing out the negative influence of 
increasing the steric bulk on this ring. The naphthyl-phenyl product 14F was more 
cytotoxic than (-)-rhazinilam and the most active analogue 13F towards the MCF7 cell 
line (entry 13), but its effect on tubulin could not be determined.  
Pyridine-phenyl analogues have been synthesized by Rocca and colaborators[22]. 
Unfortunately, these analogues (entries 14-15) were less active than their surrogates 
probably due to the basicity of the pyridine.  
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Figure 6 
entry No. product IMD IMA CT-KB CT-MCF7 
1 13A 1/8  1/11  
2 13B 1/21  inact.  
3 13C 1/17  1/26  
4 13D inact.  1/11  
5 13E 1/15  1/40  
6 13F 1 1 1/2 1/1.5 
7 13G 1/3  1/10  
8 14A inact. 1/24 1/5 1/4 
9 14B inact. 1/28 <1/30 1/5 
10 14C 1/55 1/15 1/18 1/1.6 
11 14D 1/1.7 1/1.8 1/6 1/2 
12 14E 1/5 1/11 1/7 1/2 
13 14F   1/9 1/3 
14 15A 1/10    
15 15B 1/6  1/8  
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(-)-Rhazinilam is a natural product with unique tubullin-binding properties. For this 
reason and due to its intriguing molecular structure, several synthetic groups were 
interested in synthesizing and studying the structure-activity relationship of rhazinilam 
analogues[16, 19, 23-26]. These total synthesis are discussed in the following section. 
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1.3. Previous total syntheses 
 
From the first extraction of Rhazinilam in 1965 till our days, seven total syntheses of 
rhazinilam have been reported: three of the racemic (±)-rhazinilam and four of the 
natural product or (-)-enantiomer. More than any medicinal chemistry issue, the main 
purpose of these studies was the synthetic challenge posed by the structure of this 
compound. The A-C biaryl axis of chirality, the quaternary-carbon centre at C-20, the 
5,6,7,8-tetrahydroindolizine C-D rings substructure and the nine-membered lactam B 
ring are all structural elements that present a significant challenge to those considering a 
new assembly of this intriguing natural product.   
 
The first total synthesis of the racemic (±)-rhazinilam was reported by G. F. Smith et al in 
1973[5]. The key step was the N-alkylation of 2-methoxycarbonyl-4-(2’-nitrophenyl)-
pyrrole 17 as the sodium salt by the tosyl derivative of 5-ethyl-5-(3-
hydroxypropyl)dihydrofural-2(3H)-one 18 to provide pyrrole 19 in 90%.  
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CO2CH3
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Scheme 4: Smith’s total synthesis of (±)-rhazinilam (1973) 
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This intermediate, containing all the carbons present in the target molecule plus an 
additional methyl ester group at the pyrrolic C-5 position, was then treated with 
aluminium chloride in nitromethane gave tetrahydroindolizine derivative in 50%. 
Subsequent reduction of the nitro-group on the phenyl ring using Adams’ catalyst 
afforded the corresponding aniline 20 in 86%. Lactamisation of intermediate 20 was 
effected with DCC at room temperature to provide compound (±)-21 in 95%. The 
synthesis was complete via a two-step procedure: saponification of the ester group to 
give the corresponding acid and then, subsequent thermally-induced decarboxylation of 
this acid to provide (±)-rhazinilam (1) in 86% yield over these final two steps. The identity 
of the racemic product with (-)-rhazinilam from Rhazya stricta  was established by 
complete identity of their UV, IR, 100 MHz NMR and mass spectra, together with 
identical TLC behavior in four different systems.  
 
In 2001, a straightforward and very elegant synthesis of (±)-rhazinilam was reported by 
Philip Magnus and Trevor Rainey[27]. Beginning with 2-piperidinone, two sequential α-
alkylation reactions provided the product 24. Thiophenyl iminoether 25 was then 
generated, by conventional means, from the 2-piperidinone derivate 24 in two steps and 
81% yield (Scheme 5).  
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Scheme  5: Preparation of thiophenyl iminoether 25 
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Scheme  6: Magnus’ total synthesis of (±)-rhazinilam (2001) 
 
N-alkylation of compound 25 with 1-(3—bromoprop-1-enyl)-2-nitrobenzene produced, 
after treatment with base, the ylide 26 which engaged in a Grigg-type 1,5-
electrocyclisation reaction[28], leading to intermediate 27 that subsequently underwent 
thiophenol elimination to generate compound 28 in 71% yield from imine 26. This 
intermediate, now containing all carbons necessary for the final target, was converted 
into the alcohol using standard hydroboration reaction conditions followed by oxidation 
work-up. Attempts to oxidize the alcohol to the acid using silver nitrate under alkaline 
conditions converted in 29 without any complications. Finally, Raney nickel reduction of 
the nitro group and lactamisation under Mukaiyama conditions afforded (±)-rhazinilam 
(1).   
 
Two other very elegant total syntheses of (-)-rhazinilam were reported, first in 2000 by 
Sames and co-workers[29]. Initial work was directed towards the preparation of the 
racemate and then, in 2002, an adaptation of this work leading to the natural (-)-
enantiomer, the first asymmetric total synthesis reported in the literature[30]. Both 
syntheses proceed through the achiral intermediate 34 which contain the three A-B-C 
rings present in (-)-rhazinilam.  
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1) CCl3COCl
2) NaOMe / MeOH
3) H2 / Pd/C
N
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O
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30 31 32
3334  
Scheme  7: Synthesis of the achiral intermediate 34 
 
Compound 34 was synthesized in an efficient sequence as depicted in Scheme 7. 
Iminium salt 31 was generated from readily available imine 30[31] and 1-(3—bromoprop-
1-enyl)-2-nitrobenzene. Heating of 31 in the presence of silver carbonate accomplished 
both cyclisation and aromatization yielding pyrrole intermediate 32 in 70% yield. The 
methyl carboxylate group was then installed as a temporary protection to stabilize the 
sensitive pyrrole ring, followed by reduction of the nitro group to furnish the amine 34. 
The completion of the synthesis of the racemic (±)-rhazinilam involved Schiff base 
condensation of compound 34 with an achiral ketone. 
 
N
NH2
O
OCH3
N
C6H5
O
1) TsOH, toluene
2) [Me2Pt(μ-SMe2)]2 N O
OCH3
N
N
Pt
C6H5
34 35  
 
Scheme  8: Preparation of the Pt-complex 35 
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The stereocontrol in the asymmetric version of the total synthesis was provided by Schiff 
base formation using the enantiopure ketone as a chiral auxiliary. Complexation of the 
ensuing imine with the dimethyl platinum reagent [Me2Pt(µ-SMe2)]2 afforded the complex 
35 in 29% yield over the two steps. Addition of triflic acid to the complex led to the rapid 
formation of the intermediate 36 with concomitant loss of methane. 
 
N O
OCH3
N
N
Pt
C6H5
TfOH / DCM N O
OCH3
N
N
Pt
C6H5
N O
OCH3
N
N
Pt
C6H5
N O
OCH3
NH2
TfO TfO
CF3CH2OH
70 °C
1) KCN
2) NH2OH
35 36 37 38
H
- CH4- CH4
 
Scheme  9: Synthesis of the chiral intermediate 38 
 
The thermolysis gave the platinum alkene-hybrid complex 37 as a mixture of 
diastereomers. The platinum metal was subsequently removed via treatment with 
aqueous potassium cyanide, followed by hydrolysis of the resulting Schiff base in the 
presence of hydroxylamine. To complete the total synthesis of (-)-rhazinilam, a one- 
 
N
NH2
O
OCH3
1) Boc2O / DMAP
2) OsO4 / NaIO4
3) Ph3P=CHCO2tBu
4) H2 / Pd/C
5) TFA / DCM
6) PyBOP / HOBT / iPr2NEt
7) NaOHaq. / MeOH then HCl
NNHO
38 39  
Scheme  10: Final steps in the Sames’ total synthesis of (-)-rhazinilam  
 
carbon extention of the vinyl group and the subsequent macrocycle closure was then 
carried out in a standard fashion. Transformation of the double bond of 38 to an 
aldehyde was followed by Horner-Emmons reaction, catalytic hydrogenation and, finally, 
a macrolactam formation.  
 
In 2005, Trauner and co-workers published the second total synthesis of enantiomer (±)-
rhazinilam[32] (the fifth total synthesis of rhazinilam reported till now in literature). They 
used an intramolecular Heck-type reaction as the key step. The starting compounds are 
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the same as in synthesis of Smith[5], enantiomer R of tosyl derivative of 5-ethyl-5-(3-
hydroxypropyl)dihydrofural-2(3H)-one. The tosyloxy group of 18 was readily displaced by 
the sodium salt of carbomethoxy pyrrole to give the N-alkylated pyrrole 40 in 94% yield. 
In an analogous fashion to the second transformation used in Smith’s total synthesis, 
compound 40 underwent an intramolecular Friedel-Crafts alkylation upon the treatment 
with aluminium chloride to afford, in 55% yield, tetrahydroindolizine carboxylic acid 41, a 
compound now bearing the requisite quaternary-stereocenter associated with final 
product rac-rhazinilam. Coupling of 41 with 2-iodoaniline under Mukaiyama’s conditions 
afforded amide 42 . Protection of the amide 42 as a methoxymethyl (MOM) derivative 
then gave key intermediate 43 in 85% yield. Heating of 43 with 10% of Buchwald’s 
“DavePhos” ligand 67 and Pd(OAc)2 in the presence of a base resulted in the clean 
formation of the strained, nine-membered lactam 46 in 47% yield. The removal of the 
methoxymethyl amide-protecting group was effected by treatment of intermediate 46 
with a large excess of boron trichloride at low temperature and thus afforded the 
previously reported ester 21[30] in 60% yield. Saponification of the ester moiety in 
compound 21 followed by immediate acid-catalysed decarboxylation, then gave the (-)-
rhazinilam (1) in 85% yield.   
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N
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H3CO2C
NH3CO2C
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N
H3CO2C
COOH
N
H3CO2C
N
R
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R=H 42
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I
H2N
I
NCl
I
NaH / MOMCl
18 40
41
 
 
Scheme  11: First steps in the Trauner’s total synthesis of (-)-rhazinilam  
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Scheme  12: Trauner’s total synthesis of (-)-rhazinilam (2005) 
 
In 2006, Nelson and co-workers reported an elegant and original enantioselective (the 
3rd) total synthesis of (-)-rhazinilam[33]. Their strategy was based on the  successful 
application of the Au(I)-catalyzed pyrrole-allene addition. Allenes offer the potential to 
relay the associated axial chirality to the ensuing bond forming process. The 3,4-cis-
disubstituted β-lactone 48, used as starting material, was obtained from propionyl 
chloride 2-pentynal in 76% yield (99% ee). β-Lactone ring opening with (3-(1H-pyrrole-1-
yl)propyl)magnesium bromide provides the allene 49 as a single diastereomer. To be 
sure that the methyl-bearing stereocenter had no effect on the stereoselection of the 
annulation, the methyl ester 49 was subjected to Ph3P.AuOTf-catalyzed cyclisation that 
provided tetrahydroindolizine 50 with nearly complete transmission of allene chirality 
(92%, 94% de).  
H
O
C2H5
EtCOCl / TMSQn
MgCl2 / iPr2NEt
O
O
H3C
C2H5
N
MgBr
CuCN
N
C
CH3
RO2C
R=H
R=CH3
TMSCHN2
Ph3P.AuOTf
N
C2H5
CH3
H3CO2CC2H5
47 48
49
50
 
Scheme  13: First steps in the Nelson’s total synthesis of (-)-rhazinilam  
 
After the construction of the tetrahydroindolizine and the installation of the quaternary 
carbon in the preparation of 50, introducing the aniline moiety represented the last 
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challenge to complete the total synthesis. To circumvent difficulties associated with the 
oxidation of the heterocycle, pyrrole basicity was effectively attenuated by regioselective 
carboxylation to provide 51. Oxidative olefin cleavage, Horner-Wittig homologation and 
catalyzed dehydrogenation afforded ester 53. Biaryl bond construction proceeded by 
regioselective pyrrole iodination (89%) and ensuing Suzuki-Miyaura cross-coupling of 
iodine 54 with N-Boc aniline boronic ester using Buchwald’s SPhos ligand[34] to afford the 
3-arylpyrrole 55 in 86% yield. Chemoselective ester saponification and aniline N-
deprotection (93% over two steps) induced the lactamisation of the resulting amino acid 
to deliver 10-(carbomethoxy)rhazinilam 21 in 74% yield over three steps. Pyrrole 
decarboxylation provided synthetic (-)-rhazinilam (1) in 96% yield (94% ee). 
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H3CO2C
H3C
N
H3CO2C
H3C
Cl3COCl
NaOCH3
CO2CH3
OsO4 / NMO
then NaIO4
NO 1) Ph3P=CHCO2CH3 N
H3CO2C2) H2 / Pd/C
I2
AgCO2CF3
N
H3CO2C
CO2CH3 CO2CH3
CO2CH3
B(OH)2
NH
Boc
I
N
CO2CH3
NH
H3CO2C
Boc Pd2(dba)3
SPhos, K2CO3
N
X
NHO
X=CO2CH3
X=H
1) Ba(OH)2
2) TFA
3) HATU / iPr3NEt
1) NaOH
2) aq. HCl
50 51 52 53
5455211  
Scheme  14: Nelson’s total synthesis of (-)-rhazinilam (2006) 
 
The last total synthesis (the 4th enantioselective synthesis) was reported in 2006 by 
Banwell et al[35]. Their key step was the intramolecular Michael addition reaction in an 
enantioselective fashion using MacMillan’s first generation organocatalyst ((5S)-2,2,3-
trimethyl-5-phenylmethyl-4-imidazolidinone monotrifluoroacetate). The reaction between 
potassium salt of pyrrole 56 with γ-butyrolactone 57 afforded, after acidic work up, the 
acid 58 (60-90%) which was converted into the amide in 87% yield. This amide was then 
treated with ethyl magnesium bromide giving ethyl ketone 59 (95%). The target aldehyde 
61 was synthesized after Horner-Wadsworth-Emmons-type olefination of ketone 59, 
reduction with DIBAL-H, the corresponding mixture of allylic alcohol was immediately 
oxidized with bariummanganate followed by intra-molecular Michael addition. The 
enantiomeric purity of this cyclisation product was established through its reduction with 
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Scheme  15: First steps in the Banwell’s total synthesis of (-)-rhazinilam 
 
sodium borohydride to the corresponding alcohol 62 (84%, 74% ee). The mesylate 
intermediate derived from the alcohol (95%) was subjected to reaction with sodium 
cyanide in DMPU giving the nitrile which was converted into the corresponding methyl 
ester 63 in 63% yield by reaction with KOH in aqueous methanol followed by acidic work 
up and reaction of the ensuing free-acid with DCC in methanol containing catalytic 
amounts of DMAP. Vilsmeier-Haack formylation of pyrrole 63 then afforded the aldehyde 
(78%) which was subjected to electrophilic iodination using molecular iodine in the 
presence of silver (I) trifluoroacetate and thereby affording iodide 64 (quant.) in a 
completely regioselective manner. Suzuki-Miyaura cross-coupling of 64 with pinacolate 
ester of o-aminophenylboronic acid afforded the arylated pyrrole 65 (64%) which 
engaged in a simple two-step lactamisation procedure to deliver synthetic (-)-rhazinal 9 
in 68% yield (74% ee). Decarboxylation of (-)-rhazinal was the final step needed for 
obtaining (-)-rhazinilam (1). 
 
N
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N
HO
N
H3CO2C
NaBH4 1) CH3SO2Cl / Et3N
2) NaCN / DMPU
3) KOH
1) DMF / POCl3
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N
H3CO2C I
CHO
NH2
B
O O Pd(PPh3)4 cat.
N
CHO
NH2
H3CO2C
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N
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NHO
N
NHO
cat.
61 62 63 64
6591  
 
Scheme  16: Banwell’s total synthesis of (-)-rhazinilam (2006) 
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Banwell’s strategy is the only one which allows to synthesize rhazinilam’s analogues: (-) 
rhazinal 9, (-)-leuconolam 8 (28%) and (+)-epi-leuconolam 66 (46%). 
 
N
NHO
N
NHO
N
NHO
PCC / MS
+
1 8 66
O O
OH OH
 
Scheme  17: Synthesis of rhazinilam analogues by Banwell’s strategy 
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Scheme 18: Survey of total syntheses of rhazinilam 
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2. Goal 
 
The goal of our work is the development of a novel methodology applicable to the 
synthesis of simplified analogues of (-)-rhazinilam (1). The attractiveness of the unusual 
tetracyclic structure of (-)-rhazinilam (1) lies in its unique biological effects exercised by a 
relatively simple biaryl structure. (-)-Rhazinilam (1) intervenes in mitosis. It resembles to 
simple biaryl foldamers and can therefore be considered as a mimic to α-helices of 
peptides. The scientific challenge of this relatively simple natural product is to 
understand and to explain in structural terms its activity. The chosen strategy must allow 
the synthesis of many derivatives to check structure activity relationships. It should also 
take into account sensitivity issues due to the presence of the pyrrole C-ring. 
 
NNH
O
O
R
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O
(-)-rhazinilam (1) rhazinilam analogues  
Figure 7 
 
The retrosynthesis of our target molecule is shown in Figure 8: 
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Figure 8:  
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The retrosynthesis of the target molecule includes the following steps : cyclisation of the 
nine-membered lactam ring, cyclisation of six-membered D-ring under Molander 
conditions (SmI2)[1, 2], N-alkylation of pyrrole, crossed aldol Mukaiyama reaction for 
introducing all the atom needed for nine-membered ring, dehydroxylation and N-Boc 
protection in “one-pot” reaction from five-membered lactame ring leadind to the N-
protected pyrrole-one, Mukaiyama reaction between 2-azido-1-(2-nitrophenyl)ethanone 
as electrophile and (1-methoxyvinyloxy)trimethylsilane as nucleophile.   
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3. Analysis of the Retrosynthesis of Rhazinilam 
 
In view of the relative simplicity of Rhazinilam it is surprising that only seven total 
syntheses have been reported so far. Out of the seven total syntheses four syntheses 
lead to the enantiomerically pure natural products. These four enantioselective 
syntheses have been reported only during the last five years. In view of the spectacular 
development of the available synthetic methodologies and of the art of natural products 
synthesis, the progress around the Rhazinilam synthesis has been slow. The question 
has to be asked, why is this so? 
 
Analysing the Rhazinilam structure using the classic retrosynthesis approach heralded 
by Correy, the following elements have to be considered to be challenging: the nine-
membered lactam B-ring, the quaternary center α to the pyrrole C-ring, the axial chirality 
and the enantioselective creation of the asymmetric center C-21. Following the 
traditional wisdom one would consider the aromatic benzene A-ring and the heterocyclic 
pyrrole C-ring to be elements which one should be able to introduce without any 
difficulties. 
 
Analysing the retrosyntheses which lead to successful total syntheses of the natural 
product 1, one comes up with a surprising conclusion: all the reported syntheses, with 
the exception of only one, have to introduce an additional electron attracting auxiliary 
substituent to the pyrrole C-ring, usually an ester. One of the reported syntheses uses an 
ester substituted pyrrole ring as starting material. The other syntheses have to introduce 
the stabilizing substituent in a separate additional step, which prolongs their synthetic 
approach. This auxiliary, stabilizing substituent is kept in place until one of the final 
steps. This additional functional group has then to be removed to liberate the structure of 
the natural product. 
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Figure 9: Survey of the introduction of ester or aldehyde function steps on pyrrole 
ring  
 
In view of today’s pressure to create the most efficient synthesis, which often means the 
shortest possible synthesis, it is surprising that five different groups had to introduce one, 
two or even three additional steps into their syntheses, which prolong the synthetic 
pathway without advancing the construction of the skeleton. The chosen protection 
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deprotection strategy prolongs most of these syntheses by at least two steps. Avoiding 
this strategy would considerably shorten the synthetic pathways and thereby increase 
the yields. Reading the reports it becomes clear that these protection-deprotection 
strategies were necessary to be able to execute the transformation needed, avoiding 
side reactions due to the sensitivity of the pyrrole C-ring. 
 
As it is known, the pyrrole is an electron rich heteroaromatic compound (six electrons 
distributed over five atoms). Without these stabilising substituents the pyrrole ring is 
easily attacked. Under the influence of small amounts of acids, unstabilised pyrroles are 
polymerised and autooxidised to give so called pyrrole black[1]. 
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Scheme 19: The behavior of pyrrole in acidic conditions 
 
Pyrrole can also be sulfonated in the 2-position by treatment with the pyridine-sulfur 
trioxide complex[2]: 
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Scheme 20: Sulfonation of pyrrole 
 
In conclusion the protection deprotection strategy chosen by the five groups mentioned 
above is a consequence of the sensitivity of the pyrrole C-ring and the additional steps 
needed can not be avoided. 
In view of the preceding arguments it is surprising that in the synthesis reported by the 
Magnus group, these protection-deprotection steps could be avoided. This is all the 
more surprising because the key intermediate reported by Magnus is structurally very 
similar to the intermediate reported by Sames. 
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Figure 10: Comparison Magnus – Sames strategies  
 
In view of the known sensitivity of pyrroles towards oxidation processes and to the 
treatment with acids it is highly interesting to observe that Magnus reports three 
oxidation processes, occurring with high yields. Reading carefully the experimental part it 
is not evident, how the Magnus group has been able to avoid the side reactions, which 
are usually induced under such conditions. 
 
Our group has developed a novel synthetic methodology leading in a convergent way to 
substituted pyrrole rings in the synthesis of phorphobilinogen, a precursor for many 
natural products. The key transformation is the use of the Mukaiyama crossed aldol 
reaction to assemble the adequately substituted skeleton, typically followed by (i) 
reduction using a Pd/C catalyst to transform the azido group into the amino function. The 
molecule is then set up in such a way that a cascade of reaction steps directly leads to 
the aromatic pyrrole ring. Once the amino group is set free, it reacts with the δ-keto 
function. The imine is in equilibrium with the corresponding enamine, which expulses the 
methoxy group leading to the protonated pyrrole, which is transformed into its tautomeric 
form, the heterocyclic aromatic pyrrole ring.  
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Scheme 21: Synthesis of protected porphobilinogen[3]  
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Or by (ii) the Staudinger reaction: 
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Scheme 22: Staudinger (Aza-Wittig) mechanism  
 
The method used to “deprotect” the azido function has no influence on the final outcome 
of the reaction sequence.  
 
The advantages of this methodology are the convergency of the sequence used to 
construct the skeleton, the availability of many easily available building blocks and the 
mild methodologies used for the formation of the pyrrole ring. Our method is 
complementary to the known classic literature procedures[4-7]. Mono-, di-, tri- and tetra-
alkylpyrroles can be synthesized using this method. The yields are good to excellent and 
the ease of the final reaction step allows to isolate these sensitive compounds in high 
purity. 
 
Based on this observation we were interested to test the scope and limitations of our 
methodology using (-)-rhazinilam as our goal. The hope was that our approach should 
allow to solve the sensitivity problem, using our mild method and avoiding degradation 
due to the use of too harsh reaction conditions. 
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Scheme 23: Retrosynthesis of rhazinilam analogue 
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ABSTRACT 
As a novel approach to biaryl core structure of rhazinilam different variants of the 
sequence crossed Mukaiyama aldol reaction followed by the Staudinger reaction were 
studied. The reaction sequence reacting the adequately substituted acetophenone with 
the O-methyl-O-trimethylsilyl ketene acetal gave in good to excellent yields the 
pyrrolidinones 12a and 12b. These intermediates could be transformed in four high-
yielding steps into the pyrrolic precursor 17 containing all atoms necessary for the 
construction of the rings A, B and C of rhazinilam. 
 
For a long time the number of natural products containing pyrrole rings as characteristic 
structural element was comparatively small[1]. The tetrapyrrolic “pigments of life”[2] were 
an important exception to this empirical observation. They represented on their own a 
major class of natural products with an impressive variation of the basic structural 
element and an even more remarkable variety of functions[3]. In contrast to the large 
number of pyrrole containing macrocyclic compounds found in nature, the simple 
heterocycle pyrrole itself had been identified only in a limited number of natural 
products[4-8]. Comparing the relative “rareness” of pyrrolic natural products with the 
ubiquitous presence of pyridine containing natural products[9-12] can be correlated with 
the high chemical stability of pyridine and its protonated form. In contrast non stabilized 
alkyl pyrroles are highly sensitive. Protonation leads to oligomer or polymer formation as 
was detected already in the 19th century[13]. This high inherent reactivity in the presence 
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of Broensted acids is used in the third dedicated step of the biosynthesis of the 
“pigments of life”[2]. 
The number of pyrrole containing natural products has steadily increased in recent 
years[1]. This constant increase of identified pyrrole containing natural products is 
certainly due to the combination of more efficient isolation methods with more 
sophisticated structure determination procedures[1]. The interest for a new natural 
product stems from their biological functions, their application in humans and for the 
chemist from their chemical structure[14]. In this context it is interesting to note, that the 
world’s largest selling drug, Lipitor®, contains a pyrrole as its central aromatic ring in a 
triaryl structural motive[15, 16]. 
(-)-Rhazinilam, a mono-pyrrolic natural product, was first isolated by Linde in 1965 from 
Melodinus australis well before the development of modern highly automatized isolation 
techniques[17]. The structure of (-)-rhazinilam was determined in the early seventies by a 
combination of chemical, NMR- and X-ray-analysis[18-20]. The structure of this compound 
isolated from natural sources is unusual in different respects. It contains a biaryl unit 
composed of a substitued benzene and a pyrrole ring, rings A and C of (-)-rhazinilam. In 
contrast to many other pyrrole containing natural products the pyrrole ring of (-)-
rhazinilam lacks a directly linked electron attracting substituent. The tetracyclic system is 
unusual, especially the nine membered ring containing the lactam function is an 
uncommon structural element in natural products[21]. Finally (-)-rhazinilam contains two 
elements of asymmetry, the chiral center at C(9) and the chiral axis fixed by the 
restricted conformational flexibility of the nine-membered lactam ring.  
Already during the process of isolation and structure determination it became evident 
that (-)-rhazinilam might be formed during the isolation procedure[22]. The first indication 
came from the observation that (-)-rhazinilam accumulated in vitro in a basic fraction of 
Rhazia stricta[19]. This hypothesis could be confirmed using different natural alkaloids like 
(+)-1,2-dehydroaspidospermidin as natural precursor. Oxidation followed by hydrolytic 
ring cleavage lead in acceptable yields to (-)-rhazinilam[23]. Due to these findings (-)-
rhazinilam has lost the status of a genuine natural product. It is however possible that 
small quantities of (-)-rhazinilam could be formed naturally under oxygen stress 
conditions without human intervention[24]. The usual assumption is that artifacts of the 
isolation process should not exercise a biological function as these artifacts of isolation 
do not evolve under the selection pressure of evolution. The change in biological 
properties generally admitted for artifacts formed by oxidation is an increase in solubility 
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due to the increased polarity of the oxidation products helping to excrete these 
degradation products[22]. It is however possible that small quantities of (-)-rhazinilam 
could be formed naturally under oxygen stress conditions without human intervention.[lit. 
ref.] 
It came therefore as a surprise, when almost twenty years later screening experiments 
gave evidence for interesting cytotoxic and pharmacological properties of (-)-rhazinilam 
in vivo due to its interference with the tubulin-microtubule equilibrium[25, 26]. A comparison 
of the mode of the antimitotic action of (-)-rhazinilam with other compounds intervening 
in this important process showed that (-)-rhazinilam had a specific profile. (-)-Rhazinilam 
combines a vinblastine-like activity provoking the aggregation of tubulin into spirales with 
a taxol-like activity inhibiting the disassembly of microtubules[27]. Taxol and vinblastine 
have structures which are considerably more complex than the tetracyclic structure of (-
)-rhazinilam[28, 29]. Colchicine, which represents also a “special” expanded biaryl 
skeleton[30], is the only known natural product of similar simplicity acting on the mitotic 
process. 
Microtubule formation through the assembly of tubulin must be a highly controlled 
process. Microtubules form the internal skeleton of cells sustaining their form and 
volume. More important and more visible is the role of the microtubules during mitosis, 
where the geometry and the timing of their formation has to be carefully controlled to 
guarantee the smooth proceeding of the process of cell division. Impressive progress 
has been made in understanding the structures of tubulin, its association into α-β-
heterodimers and the tubulin-microtubule equilibrium controlled by the association with 
GTP and its hydrolysis product GDP. Wheras the overall process is reasonably well 
understood on a molecular bases the detailed control elements necessary for the 
assembly and disassembly of mitotic spindle needed during mitosis are not known. 
Small molecules interfering with this process are not only excellent tools to provoke cell 
arrest and can therefore be used as anticancer drugs, but they give valuable hints at the 
complex control mechanism in charge of this intricate process. (-)-Rhazinilam obviously 
intervenes with the protein-protein interactions leading to the microtubule formation 
through the association of tubulin molecules. 
The protein-protein interactions are important factors as control elements in many 
biological processes such as signaling, skeleton formation, gene silencing, gene 
transcriptions and activation or silencing of enzymes[31, 32]. Studying of the effects of and 
the site of interaction of small (natural) molecules with these communication processes 
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has given important clues for the understanding of these processes[33]. In the 
classification of the crucial elements for the protein-protein interactions proposed by 
Clackson and used by Hamilton and collaborators one of the simpler recognition 
elements is the interaction between an α-helix and a protein surface[34, 35]. In a 
systematic empirical approach to imitate the sequence of recognition elements 
presented by α-helices Hamilton and his group synthesized specifically substituted 
biphenyls and terphenyls as analogues imitating α-helices[36]. The biphenyls and 
terphenyls are used as foldmers which are capable to imitate the geometry of one full or 
two full turns of substituted α-helices[37-39]. In this approach only two aspects of an α-
helix are imitated: the type and polarity of the side chains in positions i and i + 3 and the 
distance and the dihedral angle viewed along the cylinder axis. In view of the simplicity 
of the skeleton used to replace an α-helix turn composed of three amino acids bound 
through peptide bonds the inhibition results obtained by the Hamilton group are truly 
remarkable[40, 41]. As (-)-rhazinilam is formed during the “artificial” isolation process from 
plant material, it is not obvious how the biological properties of (-)-rhazinilam could have 
evolved in a “natural” selection process. At the moment one can not exclude that the 
structure of (-)-rhazinilam might be a chance finding not related to any “natural” process 
in the tubulin-microtubule equilibrium. If this should be the case the information one can 
deduce from (-)-rhazinilam is essentially a structural information, using the reasoning 
applied to artificial drugs in order to describe the receptor blocked by these drugs. As 
many small molecules playing the role of natural messengers are formed by oxidation 
processes[42, 43] one can not exclude the possibility that (-)-rhazinilam is playing the role 
of a specific recognition element in a protein-protein interaction as proposed by Hamilton 
and his group for their artificial molecules[40]. As a consequence one would expect (-)-
rhazinilam to be an α-helix mimick, which fills a more or less shallow pocket made for a 
“natural” protein-protein interaction based on the recognition of a natural α-helix element. 
Assuming this hypothesis to be true, one should be able to find the natural messenger, 
which is imitated by (-)-rhazinilam. This sort of “retrodesign” has been successfully 
applied to understand the physiological activities of morphine type molecules, which 
imitate the natural pharmacophore the endorphins[44-47].  
The systematic research undertaken by the group of Guénard to define the 
pharmacophore responsible for the action of (-)-rhazinilam showed, that the rings A, B 
and C are necessary for the pharmacological activity[48-51]. In contrast to these three 
cycles the six-membered ring D is optional. The pyrrolic ring C can be replaced by a 
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benzene ring without loss of activity[52]. The nine-membered ring B is crucial. The lactam 
function can be replaced by other functional groups which have similar polarity and 
hydrogen bond donating and accepting properties like carbamates. These results are 
compatible with the design principles proposed by Hamilton and his group[40, 41], and 
thereby add credit to the hypothesis that (-)-rhazinilam acts as an α-helix mimick. 
Due to the special pharmacological activities of (-)-rhazinilam the interest to develop total 
syntheses of this molecule has been kept alive over more than 30 years. Seven total 
syntheses have been reported so far, three of them leading to racemic rhazinilam and 
four recent synthesis allow to obtain enantiopure (-)-rhazinilam[22, 53-58]. 
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13 steps; 4.2% yield overall
2) Magnus’ total synthesis (2001)
8 steps; 7.8% yield overall
3) Sames’ total synthesis (2000) :17 steps; 9.3% yield overall
4) Sames’ total synthesis (2002) : 12 steps; 12.7% yield overall5) Trauner’s total synthesis (2005)7 steps; 7.9% yield overall
6) Nelson’s total synthesis (2006)
11 steps; 21.5% yield overall
7) Banwell’s total synthesis (2006)
16 steps; 3.7% yield overall
 
Figure 1. 
 
For obvious reasons the construction of the sensitive pyrrole ring is the key step in three 
of the reported total synthesis. These three syntheses take care of the sensitivity 
problem by forming the acid sensitive pyrrole ring relatively late in the synthesis. 
Introducing the pyrrole ring late, the lack of stability associated with the presence of the 
pyrrole ring can be avoided during the early steps in the synthesis. The two more recent 
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total syntheses introduce the pyrrole ring intact[57, 59]. In one approach a chiral auxiliary is 
fixed to the precursor and the enantiomerically pure intermediate is obtained by an 
organometallic C-H activation reaction. In the second approach an organocatalytic 
approach is used to induce an enantioselective Michael addition. We describe our 
approach to the rhazinilam skeleton synthesizing adequately substituted phenyl-pyrrole 
ring systems using the sequence developed in our group. The advantage of our 
approach is the wide variety of starting materials available and the mildness of the 
pyrrole building step.  
Our group has developed a versatile pyrrole synthesis based on the two steps sequence 
Mukaiyama crossed aldol reaction followed by the Staudinger reaction[60-63]. Our method 
allowed the synthesis of sensitive alkyl substituted pyrroles in good to excellent yields, 
complementing the classical Knorr pyrrole synthesis[64]. We decided to investigate a 
synthetic path towards the rhazinilam skeleton based on our pyrrole synthesis (Figure 2) 
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Figure 2. 
 
The key step of our proposed retrosynthesis was a novel variant of our pyrrole synthesis. 
To test the compatibility of our methodology with the high density of functional groups 
needed for the application of our strategy to a rhazinilam synthesis was an additional 
motivation for our studies.  
The condensation of III with IV should lead to the substituted pyrrole II, suitably 
protected. The introduction of the side chain necessary for the formation of ring B should 
be regioselective using this starting material. In the initial trials we were unable to control 
the reaction conditions adequately. We mostly isolated polymeric materials, probably 
due to the high reactivity of the substituted phenylacetaldehyde obtained after the 
crossed aldol reaction. To avoid this problem we modified the nucleophile, using O-
alklylketene-O-silylacetals of the type 3a – 3c instead of the silyl enol ether (Scheme 1). 
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Scheme 1. Reagents and conditions: TiCl4, CH2Cl2.  
 
Using the ketene-acetal 3a and the acetal 4c we could isolate small amounts of the aldol 
product 5. Using the aldehydes 6a – 6c improved the yields considerably (Scheme 1 and 
Table 1). Acetals react smoothly, as shown by Mukaiyama in his previous work[65, 66]. The 
major advantage of using acetals is the fact that the substituent in the β-position of the 
aldehyde is an ether, which exhibits a reduced reactivity compared to the β-hydroxy 
group. However aldehydes show an increased reactivity for these transformations. 
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Scheme 2. Reagents and conditions: 6 equiv. TiCl4, CH2Cl2, -78 °C. 
 
Entry Substrates Product Isolated yield (%) 
a1 3a 6a 7a 51 
a2 3b 6a 7b 34 
3 3c 6a 7c 70 
4 3c 6b 7d 51 
5 3c 6c 7e 13 
 
Table 1. 
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We therefore used simple aldehydes of the type 6a – 6b as electrophiles. The yields of 
the aldol products 7a – 7d obtained under these optimized conditions were satisfactory 
to excellent. Only the Mukaiyama reaction between the ketene acetal 3c and the 
aldehyde 6c was unsatisfactory. 6c was difficult to obtain in anhydrous form and the 
enolisation of the β-aldehydo ester occurs easily, diminishing the amount of active 
aldhyde present under the reaction conditions. 
In view of these results we decided to keep the retrosynthetic dissection of rhazinilam, 
but to invert the roles of the two fragments needed for the pyrrole synthesis (Figure 3). 
The part introducing the nitro substituted aromatic ring (VII) becomes the electrophile, 
whereas the aliphatic part becomes the nucleophile (VIII). 
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Figure 3. 
 
The inversion of the polarity should also allow to solve the problem of the regioselectivity 
for the introduction of the aliphatic side chain into the sterically more hindered α-position 
of the pyrrole ring. 
We initially used 6 equivalents of TiCl4  and near stoechiometric amounts of the reagent 
9. 
 
The reaction was initiated at – 78 °C, then allowed to warm up slowly to room 
temperature. Under these conditions moderate yields of the condensation products 10a 
and 10b were isolated (Table 2,). 
Careful studies indicated that the starting materials and the products are unstable if the 
temperature of the reaction mixture is too high. At temperatures above –10 °C the 
formation of side products and a corresponding reduction of the yield was observed. The 
presence of large quantities of the strong Lewis acid TiCl4, which had to be neutralized, 
rendered the work-up more difficult and lowered the yield. 
In a systematic study, the amount of TiCl4 was reduced from 6 equivalents to 0.5 
equivalents. The amount of the ketene acetal was increased to 3 equivalents and the 
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reaction temperature was kept between –30 °C and –15 °C. Under these conditions the 
reaction time could be kept just under 1 h allowing the isolation of the products in 
excellent yields of up to 87% (Table 2, entry 2). The reaction was allowed to run for 2 h 
without significant change in the yield. 
R
O
X
H3CO OTMS
R
CO2CH3X
HO+
8a - 8e 9 10a - 10e  
 
Scheme 3. Reagents and conditions: 0.5 equiv. TiCl4, CH2Cl2, -30 °C then -15 °C, 45 
min. 
 
Entry Substrates 8 Isolated yield 10 (%) 
a1 a X = Cl, R = H 20 
2 b X = Br, R = H 87 
3 c X = N3, R = H 74 
b4 d X = Br, R = NO2 48 
5 e X = N3, R = NO2 80 
Table 2. 
 
The Staudinger reaction transforming the aldol products 10c and 10e into the 
pyrrolidinones 11a and 11b occurred without any problems in good yields using 1.5 
equivalents of triphenylphosphine (Scheme 4).  
R
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10c R = H
10e R = NO2
11a R = H (76%)
11b R = NO2 (80%)  
 
Scheme 24. Reagents and conditions: PPh3, H2O, THF, RT. 
11a 11b 
≡
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The isolation of 11b was very expedient because the product is not soluble in THF. Just 
a filtration allowed to isolate the pure product. The X-ray crystallographic analysis of 11b 
revealed that all fonctionnal groups are implicated in a dense network of hydrogen bonds 
(Figure 4).  
 
Z
X
Y
 
Figure 4. 
 
Two chains of hydrogen bonds cross the whole crystal forming a sheet and further 
hydrogen bonds extand into the 3rd dimension (not shown in Figure 3). This particular 
arrangment is in accordance with the low solubility observed. 
 
Entry Atoms Distance (Å) Observation 
1 O(3)-H-O(4) 2.72 Normal length 
2 N(2)-H-O(1) 3.15 Normal length 
3 N(2)-H-O(2) 3.23 Unusual big length 
 
Table 3. 
 
On the opposite the solubility of 11a in organic solvents is sufficient and does not create 
any problems for further transformations. The X-ray analysis of 11a revealed that the 
  41
molecules are associated as dimers. A third hydrogen bond links these dimers together 
into an one-dimensional chain (Figure 5).  
 
Figure 5. 
 
Whereas 11b makes 6 hydrogen bonds per molecule the absence of the nitro group 
onto 11a reduces this number to 4.  
 
The elimination of the tertiary alcohol was more difficult than we had anticipated. The 
alcohol reacted only sluggishly, if at all with many of the reagents tried. Part of the 
problem is the low solubility of compound 11b. 
We tried to eliminate the tertiary alcohol of 11b under acidic conditions but we only 
observed the degradation of the starting material. Because of the slightly higher 
reactivity of the lactam compared to the alcohol and the problem of solubility we 
protected first this fonction with a benzyl group in good yield (Scheme 5).  
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Scheme 5. Reagents and conditions: NaH, DMF, -20 °C then -10 °C, 60%. 
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To eliminate the alcohol we decided to introduce a good leaving group. However the 
tertiary alcohol of 13 was very unreactive and the formation of a derivative could only be 
observed under very harsh conditions (table 4, entry 7). Only the acetate could be 
introduced in 73 % yield at 100 °C. No elimination of the acetyl group could be observed 
under these conditions. 
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Scheme 6. 
 
Entry Reagents T (°C) Isolated yield (%) 
1 Pyridine, Ac2O rt - 
2 NaH, Ac2O, DMF -20 then rt - 
3 Et3N, TMSCl, toluene rt - 
4 Pyridine,MsCl rt - 
5 Pyridine, Tf2O rt - 
6 NaH, Tf2O, CH2Cl2 -20 then rt - 
7 Ac2O 100 73% 
Table 4. 
 
However treating 11b with 2 equivalents of Boc-anhydride in the presence of DMAP 
using THF as a solvent introduced the Boc-protecting group on the lactam nitrogen and 
effected at the same time the elimination of the tertiary alcohol in almost quantitative 
yield to give the product 16b. This one-pot procedure was an elegant solution of the 
solubility and the correlated reactivity problem.  
A systematic study of this reaction revealed that we were able to isolate 3 different 
products changing the amount of Boc2O (Table 5). 
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Scheme 7. Reagents and conditions: x equiv. Boc2O, DMAP, RT. 
 
Entry Boc2O (eq.) Solvent Reaction time (h) 15 16b 17 Isolated yield (%) 
1 1 DMF 1 75 25 - - 
2 2.1 THF 24 - 98 2 98% 
3 3 DMF 2 - - 100 93% 
4 3 THF 2 - - 100 82-93% 
 
Table 5. 
 
With one equivalent of Boc2O we isolated a mixture of 15 and 16b. These conditions 
were not optimized. If 11b was treated with 3 equivalents of Boc2O we isolated the 
pyrrolic tautomer 17 in almost quantitative yield. We initially made this reaction in DMF 
because of the low solubility of 11b. However using THF as solvent the reaction has the 
same efficiency and the purification is easier. 
This study suggests that the first step is the N-bocylation followed by the O-bocylation. 
The elimination with the help of the third equivalent of Boc2O will produce the aromatic 
compound 17 (Scheme 8). 
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Scheme 8. 
 
In spite of our efforts we never isolated or observed the compound 18. Applying the 
same strategy for 11a we isolated 16a in almost quantitative yield (Scheme 9). The nitro 
group on the phenyl ring seems to have no direct impact on this reaction. 
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In order to introduce the four carbon side chain, the pyrrolinone was first silylated 
forming 19a and 19b, which correspond to a protected form of the pyrrolic tautomer of 
the pyrrolidinone[67, 68]. The compound 19a was more sensitive to hydrolysis than 19b. 
Whereas we were able to purify 19b by flash chromatography on silica gel, 19a was not 
stable under these conditions. We had to purify 19a by distillation to prevent any 
hydrolysis. The side chain was introduced using the aldehyde 20a-d as electrophile and 
BF3 etherate as catalyst[69-71]. The aldehyde 20a was obtained using a procedure 
described in literature[72]. Hydrolysis and esterification of γ-butyrolactone followed by 
Swern oxidation gave the ethyl derivative 20b in 75% yield over two steps. The 
derivatives 20c and 20b were synthesized using an equivalent strategy compare to 20b. 
First the hydrolysis of γ-butyrolactone followed by the esterification to give the 
corresponding alcohol which was oxidized using a Swern procedure. The respective 
yields over 3 steps were 70 and 75%. 
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Scheme 9. Reagents and conditions: (a) Boc2O, DMAP, THF, RT; (b)TBSOTf, 2,6-
lutidine, CH2Cl2; (c) BF3OEt2, CH2Cl2, -78 °C; (d) PDC, CH2Cl2, 0 °C. 
 
84 to 94% yield of aldol products 21a-d were obtained starting with the compound 19b. 
The diastereoselectivity of the reaction controlling the two newly formed chiral centers 
was low. In the next step the alcohols 21a-c were oxidized using PDC in the presence of 
molecular sieves. 
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No. R PDC (equiv.) Conc.(M) Temp.(°C) Time (h) MS4Å (g) Yield(%) 
1 Me 3.4 2.4 10-2 RT 1 2 23 
2 Me 2.5 1.6 10-2 RT 3 2 52 
3 Et 1.8 1.6 10-2 RT 3 2 43 
4 Et 1.1 1.6 10-2 RT 3 2.5 35 
5 Et 1.1 1.4 10-2 0 6 2 45 
6 Et 2 9 10-3 0 7 2 77 
7 Bz 2 1 10-2 0 7 2 78 
 
Table 6. 
 
The compounds 22a-c contain all the carbons necessary to form the 9 membered ring B 
(Scheme 10) . 
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Scheme 10. 
 
The hydrolysis of 22b under basic conditions gave the corresponding acid 24 but in 
moderate yield (Scheme 11).  
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Scheme 11. Reagents and conditions: MeOH, NaOH (50%), 1 h, RT, 40%. 
 
We were not able to improve this result changing the parameters of this procedure. Part 
of the problem could be the high acidity of the proton in position 5 of the pyrrolidinone. 
The best conditions for basic hydrolysis found were the treatment of 22b with and an 
excess of aqueous sodium hydroxide and MeOH at room temperature. The hydrolysis 
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under acidic conditions gave no better results. Compounds 22a-c were too sensitive to 
acids. Different other procedures as enzymatic hydrolysis or hydrogenation (22c) were 
tried to optimize this step but without any significant result.  
 
To reduce the pyrrolidinone 22b to the needed pyrrole we developed a method using 
Pd0 as catalyst starting from the triflate derivative 25d for the reductive elimination. We 
synthesized in good to moderate yields 4 different triflate derivatives (25a-d) (Scheme 
12). 
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25d R = EtCO2(CH2)2CO, X = NO2 (74%)  
 
Scheme 12. Reagents and conditions: Tf2O, Base, CH2Cl2. 
 
The choice of the base is critical for this reaction. By analogy with the synthesis of 19a,b 
we used 1,3-lutidine as base for the non substituted pyrrolidinones 16a,b giving the 
corresponding triflate 25a,b in good yield. But in presence of the side chain this base 
gave a moderate yield only (25c). Changing 1,3-lutidine for Et3N allowed to improve this 
reaction and to obtain 25d in good yield.  
 
We observed for all the compounds 25a-d a 6J coupling in the 1H-NMR between H(3) 
and the fluorines of the triflate group (Figure 5). The 1H-NMR of H(3) is a doublet of 
quadruplets. The coupling constant of the doublet is a classical 4J for pyrrole rings 
between H(3) and H(5) with a typical coupling constant of 2.3 Hz. The coupling constant 
of the quadruplet is much smaller (0.8 Hz) and is correlated with the coupling constant of 
the doublet (0.7 Hz) observed in 19F-RMN. 
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Figure 6. 
 
The X-ray analysis of the derivative 25a revealed that the triflate group is not in the same 
plane than the pyrrole ring (Figure 7). This conformation brings the fluorines into close 
van der Waals contact with H(3). 
 
Figure 7. 
 
The distance between H(3) and the nearest fluorine atom is rather short (2.80 Å). The 
triflate group in 25a is turned out of conjugation with the π-system of the adjacent pyrrole 
ring to avoid strong steric contact with the N-Boc group. The same conformation was 
observed for the O-Boc group in compound 17. The comparison of the X-ray analysis of 
N
3
OO
O
S
O
O
F
F
F
NO2
H
167b
H(3)
CF3
O2N
BocN
O S
H
O O
F
F F
25b
≡ 3
2.80 Å2.94 Å
O(3)
S
F
BocN
O S
O O
F
F F
25a
  48
17 and 25a revealed the same 3D arrangement for the two different O-substituants 
(Figure 8).  
 
Figure 11. 
 
The superposition of the structures 17 and 25a shows that the substituants on the 
nitrogen and the oxygen of the pyrrole ring have the same geometry. The bulky Boc-
group on the pyrrole nitrogen is in the plane of the pyrrole ring. This arrangement 
maximizes the overlap between the lone pair of the pyrrole nitrogen and the carbonyl of 
the Boc-group. To avoid the steric hindrance, the substituents on the vicinal oxygen of 
17 and 25a are pushed out of the plane. The oxygen Boc-group in 17 is arranged in a 
zig-zag conformation in the plane which is almost orthogonal to the plane of the pyrrole 
ring. The triflate on the oxygen does not show a streched conformation but the 
trifluoromethyl group is turned towards the pyrrole ring. 
 
The reduction of 25d using Et3SiH in the presence of Pd(OAc)2 and dppf as catalyst 
afforded the expected pyrrole in good yield (Scheme 13). This reduction was very fast at 
room temperature (less than 1 min.) and we had to lower the temperature to be able to 
control it. 
 
 
 
≡ 
BocN
OBoc
NO2
17
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BocN
OTf
NO2O
EtO2C HN
NO2O
EtO2C
25d 26
a, b
 
 
Scheme 13. Reagents and conditions: (a) 2.5 equiv. Et2SiH, 5% Pd(OAc)2, dppf, DMF,   
-10 °C (64%); (b) TFA, CH2Cl2, RT (88%). 
 
Finally the deprotection of the Boc group under standard conditions using TFA in CH2Cl2 
gave the compound 26 in 88% yield. 
 
In conclusion we have developed the synthesis of compound 26, an advanced synthetic 
intermediate for the rhazinilam analogue I. The total yield of 26 starting from 10e is 22%. 
The approach is convergent, starting from simple, inexpensive materials and allows to 
obtain structural variations of the skeleton. Further efforts towards the synthesis of the 
rhazinilam analogue are in progress. 
 
References: 
 
[1] A. Gossauer, Progress in the Chemistry of Organic Natural Products, 1st. ed., 
Vienna, Austria, 2003. 
[2] A. H. Jackson, Comprehensive Organic Chemistry, London, 1979. 
[3] B. Kraeutler, Chimia 1987, 41, 277. 
[4] P. Cironi, I. Manzanares, F. Albericio, M. Alvarez, Org. Lett. 2003, 5, 2959. 
[5] E. Fattorusso, O. Taglialatela-Scafati, Tetrahedron Lett. 2000, 41, 9917. 
[6] A. Fuerstner, Angew. Chem., Int. Ed. 2003, 42, 3582. 
[7] C. Peschko, C. Winklhofer, W. Steglich, Chem.--Eur. J. 2000, 6, 1147. 
[8] R. A. Davis, A. R. Carroll, G. K. Pierens, R. J. Quinn, J. Nat. Prod. 1999, 62, 419. 
[9] T. Kubota, T. Nishi, E. Fukushi, J. Kawabata, J. Fromont, J. i. Kobayashi, 
Tetrahedron Lett. 2007, 48, 4983. 
[10] M. Horiuch, C. Murakami, N. Fukamiya, D. Yu, T.-H. Chen, K. F. Bastow, D.-C. 
Zhang, Y. Takaishi, Y. Imakura, K.-H. Lee, J. Nat. Prod. 2007, 70, 142. 
  50
[11] E. L. Whitson, S. M. V. Damayanthi Mala, C. A. Veltri, T. S. Bugni, E. Dilip de 
Silva, C. M. Ireland, J. Nat. Prod. 2006, 69, 1833. 
[12] Y. Kariya, T. Kubota, J. Fromont, J. i. Kobayashi, Bioorg. Med. Chem. 2006, 14, 
8415. 
[13] A. Gossauer, Die Chemie der Pyrrole, Berlin, 1974. 
[14] V. Prelog, Citation: Die Beschäftigung mit Naturstoffen ist deshalb so lohnend, 
weil die Natur Milliarden Jahre Zeit hatte, diejenigen Substanzen auszuwählen, 
welche sich durch besondere Eigenschaften auszeichnen., unknown date. 
[15] S. Radl, J. Stach, J. Hajicek, Tetrahedron Lett. 2002, 43, 2087. 
[16] M. Hajkova, B. Kratochvil, S. Radl, Chem. Listy 2008, 102, 3. 
[17] H. H. A. Linde, Helv. Chim. Acta 1965, 48, 1822. 
[18] A. Banerji, P. L. Majumder, A. Chatterjee, Phytochemistry 1970, 9, 1491. 
[19] K. T. De Silva, A. H. Ratcliffe, G. F. Smith, G. N. Smith, Tetrahedron Lett. 1972, 
913. 
[20] D. J. Abraham, R. D. Rosenstein, R. L. Lyon, H. H. S. Fong, Tetrahedron Lett. 
1972, 909. 
[21] APRIL 14 2008, Searching in SciFinder (lactame nine-membered ring + phenyl), 
all results lead to rhazinilam and its analogues 
[22] A. H. Ratcliffe, G. F. Smith, G. N. Smith, Tetrahedron Lett. 1973, 5179. 
[23] B. David, T. Sevenet, O. Thoison, K. Awang, M. Pais, M. Wright, D. Guenard, 
Bioorg. Med. Chem. Lett. 1997, 7, 2155. 
[24] S. H. Goh, A. R. M. Ali, Tetrahedron Lett. 1986, 27, 2501. 
[25] O. Thoison, D. Guenard, T. Sevenet, C. Kan-Fan, J. C. Quirion, H. P. Husson, J. 
R. Deverre, K. C. Chan, P. Potier, C. R. Acad. Sci., Ser. 2, Comptes Rendus de 
l'Academie des Sciences, Serie II: Mecanique, Physique, Chimie, Sciences de la 
Terre et de l'Univers 1987, 304, 157. 
[26] B. David, T. Sevenet, M. Morgat, G. Guenard, A. Moisand, Y. Tollon, O. Thoison, 
M. Wright, Cell Motil Cytoskeleton 1994, 28, 317. 
[27] B. David, T. Sevenet, M. Morgat, G. Guenard, A. Moisand, Y. Tollon, O. Thoison, 
M. Wright, Cell Motil Cytoskeleton 1994, 28, 317. 
[28] J. A. Haugan, Kjemi 1994, 54, 10. 
[29] Y. Zu, Y. Fu, M. Luo, F. Mu, Huaxue Tongbao 2004, 67, w027/1. 
[30] M. J. S. Dewar, Nature (London, U. K.) 1945, 155, 141. 
[31] S. Jones, J. M. Thornton, Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 13. 
  51
[32] D. L. Boger, J. Desharnais, K. Capps, Angew. Chem., Int. Ed. 2003, 42, 4138. 
[33] S. L. Schreiber, Nat. Chem. Biol. 2005, 1, 64. 
[34] H. Yin, A. D. Hamilton, Angew. Chem., Int. Ed. 2005, 44, 4130. 
[35] T. Berg, Angew. Chem., Int. Ed. 2003, 42, 2462. 
[36] J. M. Davis, L. K. Tsou, A. D. Hamilton, Chem. Soc. Rev. 2007, 36, 326. 
[37] B. S. Nehls, F. Galbrecht, A. Bilge, D. J. Brauer, C. W. Lehmann, U. Scherf, T. 
Farrell, Org. Biomol. Chem. 2005, 3, 3213. 
[38] L. Sisson Adam, R. Shah Muhammad, S. Bhosale, S. Matile, Chem Soc Rev 
2006, 35, 1269. 
[39] N. Sakai, J. Mareda, S. Matile, Acc. Chem. Res. 2005, 38, 79. 
[40] J. M. Davis, A. Truong, A. D. Hamilton, Org. Lett. 2005, 7, 5405. 
[41] I. C. Kim, A. D. Hamilton, Org. Lett. 2006, 8, 1751. 
[42] E. Pichersky, P. Noel Joseph, N. Dudareva, Science 2006, 311, 808. 
[43] D. R. Bergey, G. A. Howe, C. A. Ryan, Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 
12053. 
[44] S. H. Snyder, Am. J. Psychiatry 1978, 135, 645. 
[45] J. Hughes, T. W. Smith, H. W. Kosterlitz, L. A. Fothergill, B. A. Morgan, H. R. 
Morris, Nature (London) 1975, 258, 577. 
[46] R. Simantov, S. H. Snyder, Proc Natl Acad Sci U S A 1976, 73, 2515. 
[47] C. Poeaknapo, J. Schmidt, M. Brandsch, B. Drager, H. Zenk Meinhart, Proc Natl 
Acad Sci U S A 2004, 101, 14091. 
[48] J. P. Alazard, C. Millet-Paillusson, O. Boye, D. Guenard, A. Chiaroni, C. Riche, 
C. Thal, Bioorg. Med. Chem. Lett. 1991, 1, 725. 
[49] J.-P. Alazard, C. Millet-Paillusson, D. Guenard, C. Thal, Bull. Soc. Chim. Fr. 
1996, 133, 251. 
[50] C. Dupont, D. Guenard, L. Tchertanov, S. Thoret, F. Gueritte, Bioorg. Med. 
Chem. 1999, 7, 2961. 
[51] C. Dupont, D. Guenard, C. Thal, S. Thoret, F. Gueritte, Tetrahedron Lett. 2000, 
41, 5853. 
[52] C. Pascal, J. Dubois, D. Guenard, F. Gueritte, J. Org. Chem. 1998, 63, 6414. 
[53] J. A. Johnson, D. Sames, J. Am. Chem. Soc. 2000, 122, 6321. 
[54] P. Magnus, T. Rainey, Tetrahedron 2001, 57, 8647. 
[55] J. A. Johnson, N. Li, D. Sames, J. Am. Chemi. Soc. 2002, 124, 6900. 
[56] A. L. Bowie, Jr., C. C. Hughes, D. Trauner, Org. Lett. 2005, 7, 5207. 
  52
[57] Z. Liu, A. S. Wasmuth, S. G. Nelson, J. Am. Chem. Soc. 2006, 128, 10352. 
[58] M. G. Banwell, D. A. S. Beck, A. C. Willis, ARKIVOC (Gainesville, FL, U. S.) 
2006, 163. 
[59] M. G. Banwell, D. A. S. Beck, A. C. Willis, ARKIVOC (Gainesville, FL, United 
States) 2006, 163. 
[60] A. Meunier, R. Neier, Synthesis 1988, 381. 
[61] H. Bertschy, A. Meunier, R. Neier, Angew. Chem. 1990, 102, 828. 
[62] A. R. Chaperon, T. M. Engeloch, R. Neier, Angew. Chem., Int. Ed. 1998, 37, 358. 
[63] R. Neier, C. Soldermann-Pissot, (Switz.). Application: EP 
EP, 2003, p. 27 pp. 
[64] V. F. Ferreira, M. C. B. V. De Souza, A. C. Cunha, L. O. R. Pereira, M. L. G. 
Ferreira, Org. Prep. Proced. Int. 2001, 33, 411. 
[65] T. Mukaiyama, Challenges in Synthetic Organic Chemistry, Oxford, New York, 
1990. 
[66] T. Mukaiyama, M. Murakami, Synthesis 1987, 1043. 
[67] P. A. Jacobi, R. W. DeSimone, I. Ghosh, J. Guo, S. H. Leung, D. Pippin, J. Org. 
Chem. 2000, 65, 8478. 
[68] G. Rassu, G. Casiraghi, P. Spanu, L. Pinna, G. G. Fava, M. B. Ferrari, G. Pelosi, 
Tetrahedron: Asymmetry 1992, 3, 1035. 
[69] W.-R. Li, S. T. Lin, N.-M. Hsu, M.-S. Chern, J. Org. Chem. 2002, 67, 4702. 
[70] I. Baussanne, J. Royer, Tetrahedron Lett. 1996, 37, 1213. 
[71] F. Zanardi, L. Battistini, G. Rassu, M. Cornia, G. Casiraghi, J. Chem. Soc., Perkin 
Trans. 1 1995, 2471. 
[72] M. A. Drinan, T. D. Lash, J. Heterocycl. Chem. 1994, 31, 255. 
 
 
 
 
 
 
 
 
 
  53
3.2. Supporting Material 
General procedure for 3a,b,c: 
 
A solution of LHMDS 1M in THF (15 mmol, 1.2 equiv.) is diluted in dry THF (50 mL) 
under N2. Ester (12.4 mmol, 1 equiv.) is added dropwise. After 15 min. at RT, the 
reaction is cooled to -78 °C and TMSCl (72.1 mmol, 5.8 equiv.) is added slowly. The 
reaction is kept under stirring at this temperature for 1 h. The solvent is evaporated 
under vacuum and salts are precipitated with pentane. The solution is filtered over celite 
and the solved is evaporated. Purification by distillation (P=0.07 mbar, T=76 °C) (93%). 
 
Synthesis of (1-methoxy-2-phenylvinyloxy)trimethylsilane (3a) 
 
A solution of LHMDS 1M in THF (34 mL, 34 mmol) is diluted in dry THF (100 mL) under 
N2. Methyl 2-phenylacetate (4.28 g, 28.6 mmol) is added dropwise. After 15 min. at RT, 
the reaction is cooled to -78 °C and TMSCl (18.02 g, 165.9 mmol) is added slowly. The 
reaction is kept under stirring at this temperature for 1 h. The solvent is evaporated 
under vacuum and salts are precipitated with pentane. The solution is filtered over celite 
and the solvent is evaporated. Purification by distillation (P=0.055 mbar, T=64-65 °C) 
(92%). 
1H-NMR (400 MHz, CDCl3) : isomer E : 7.44 (dd, 3J(4,5) = 8.1, 4J(4,6) = 1.3, 2H, H(4)), 
7.26 (tripletoide, 3J(5,4) = 8.1, 3J(5,6) = 7.4, 2H, H(5)), 7.04 (tt, 3J(6,5) = 7.4, 4J(6,4) = 
1.3, 1H, H(6)), 4.70 (s, 1H, H(2), 3.72 (s, 3H, H(1’)), 0.35 (s, 9H, H(1’’)). 
1H-NMR (400 MHz, CDCl3) : isomer Z : 7.44 (dd, 3J(4,5) = 8.1, 4J(4,6) = 1.3, 2H, H(4)), 
7.26 (dd, 3J(5,4) = 8.1, 3J(5,6) = 7.4, 2H, H(5)), 7.04 (tt, 3J(6,5) = 7.4, 4J(6,4) = 1.3, 1H, 
H(6)), 4.62 (s, 1H, H(2)), 3.71 (s, 3H, H(1’)), 0.31 (s, 9H, H(1’’)). 
13C-NMR (100 MHz, CDCl3) : 158.0 (C(1)) ; 137.2 (C(3)) ; 128.3 (C(5)) ; 126.5 (C(4)) ; 
123.7 (C(6)) ; 78.8 (C(2)) ; 55.3 (C(1’)) ; 0.6 (C(1’’)). 
ESI-MS : [M + H + TFA]+ = 337.4 
 
Synthesis of (1-ethoxy-2-phenylvinyloxy)trimethylsilane (3b) 
 
A solution of LHMDS 1M in THF (15 mL, 15 mmol) is diluted in dry THF (50 mL) under 
N2. Ethyl 2-phenylacetate (2.03 g, 12.4 mmol) is added dropwise. After 15 min. at RT, 
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the reaction mixture is cooled to -78 °C and TMSCl (7.84 g, 72.1 mmol) is added slowly. 
The reaction mixture is kept under stirring at this temperature for 1 h. The solvent is 
evaporated under vacuum and salts are precipitated with pentane. The solution is 
filtered over celite and the solvent is evaporated. Purification by distillation (P=0.07 
mbar, T=76 °C) (88%). 
1H-NMR (400 MHz, CDCl3) : isomer E : 4.72 (s, 1H, H(2)), 4.18 (q, 3J(1’,2’) = 7.1, 2H, 
H(1’)), 1.28 (t, 3J(2’,1’) = 7.1, 3H, H(2’)). 
Note : the signals for protons 4, 5, 6 et 1’’ are hided by the majority isomer Z 
13C-NMR (100 MHz, CDCl3) :isomer E : 128.5 (C(5)); 126.6 (C(4)); 123.8 (C(6)); 86.5 
(C(2)); 62.7 (C(1’)); 15.2 (C(2’)). 
Note : the signals for protons 4, 5, 6 et 1’’ are hided by the majority isomer Z 
1H-NMR (400 MHz, CDCl3) : isomer Z : 7.45 (dd, 3J(4,5) = 8.0, 4J(4,6) = 1.3, 2H, H(4)), 
7.26 (dd, 3J(5,6) = 7.5, 3J(5,4) = 8.2, 2H, H(5)), 7.03 (tt, 3J(6,5) = 7.4, 4J(6,4) = 1.3, 1H, 
H(6)), 4.59 (s, 1H, H(2)), 3.94 (q, 3J(1’,2’) = 7.1, 2H, H(1’)), 1.39 (t, 3J(2’,1’) = 7.1, 3H, 
H(2’)), 0.33 (s, 9H, H(1’’)). 
13C-NMR (100 MHz, CDCl3) : isomer Z : 157.0 (C(1)) ; 137.4 (C(3)) ; 128.2 (C(5)) ; 126.4 
(C(4)) ; 123.5 (C(6)) ; 79.2 (C(2)) ; 63.8 (C(1’)) ; 14.6 (C(2’)) ; 0.7 (C(1’’)). 
ESI-MS : [M + H]+ = 237.1 
 
Synthesis of (1-ethylthio-2-phenylvinyloxy)trimethylsilane (3c) 
 
A solution of LHMDS 1M in THF (15 mL 15 mmol) is diluted in dry THF (50 mL) under 
N2. Ethyl 2-phenylacetate (2.03 g, 12.4 mmol) is added dropwise. After 15 min. at RT, 
the reaction is cooled at -78 °C and TMSCl (7.84 g, 72.1 mmol) is added slowly. The 
reaction is kept under stirring at this temperature for 1 h. The solvent is evaporated 
under vacuum and salts are precipitated with pentane. The solution is filtered over celite 
and the solvent is evaporated. Purification by distillation (P=0.08 mbar, T=80-82 °C) 
(92%). 
1H-NMR (200 MHz, CDCl3, 298 K) : isomer E: 7.54-7.15 (m, 5H, H(ar)), 6.06 (s, 1H, 
H(2)), 2.79 (q, 3J(1’,2’) = 7.3, 2H, H(1’)), 1.34 (t, 3J(2’,1’) = 7.3, 3H, H(2’)). 
1H-NMR (200 MHz, CDCl3, 298 K) : isomer Z: 7.54-7.15 (m, 5H, H(ar)), 5.88 (s, 1H, 
H(2)), 2.79 (q, 3J(1’,2’) = 7.3, 2H, H(1’)), 1.28 (t, 3J(2’,1’) = 7.3, 3H, H(2’)). 
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Synthesis of 2-azido-1,1-dimethoxyethane (4c) 
 
NaN3 (3.00 g, 46.2 mmol) and KI (0.50 g, 3.0 mmol) are mixed in a flask with DMF (50 
mL). 2-bromo-1,1-dimethoxyethane (5.00 g, 29.6 mmol) is added and the solution is 
heated at 95 °C. After 6 h, the solution is cooled and H2O (100 mL) is added. The 
aqueous phase is extracted with Et2O. The combined organic phases are dried over 
MgSO4. The solvent is evaporated and a red oil is recuperated (79%). 
Synthesis of methyl 4-azido-3-methoxy-2-phenylbutanoate (5)  
TiCl4 (6.60 mL, 59.7 mmol) is added to a solution of acetal 4c (532 mg, 4.1 mmol) in dry 
CH2Cl2 (20 mL) under Ar. 3a (902 mg, 4.5 mmol) is then added dropwise. The mixture 
becomes green and is stirred at this temperature. After 1 h, H2O (100 mL) is added and 
phases are separated. Aqueous phase is extracted 3 times with CH2Cl2. The organic 
phases are successively washed with water and brine and dried over MgSO4. After 
concentration the residue is purified by flash chromatography (silica gel, EtOAc/hexane 
1:3) to give 200 mg of 5 (20%).  
1H-NMR (400 MHz, CDCl3, 298 K) : 7.38-7.24 (m, 5H, H(ar)), 4.37-4.34 (m (X part of the 
system ABX (partially solved)), 3J(3,2) ≈ 9.6, 3J(X,A) ≈ 5.6, 3J(X,B) ≈ 2.9, 1H, H(3)), 3.81 
(d, 3J(2,3) = 9.6, 1H, H(2)), 3.76 (s, 3H, H(2’)), 3.70 (s, 3H, H(1’)), 3.25, 3.24, 3.05 and 
3.03 (2xdd system ABX, 2J = 12.8, 3J(A,X) = 5.6, 3J(B,X) = 2.9, 2H, H(4)),  
Note : the signal due to an impurity: 7.38-7.24 (m, H(ar)) double intensity of integrals) 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.2 (C(1)) ; 138.1 (C(arq)) ; 129.3 (C(ar)) ; 128.7 
(C(ar)) ; 128.5 (C(ar)) ; 72.6 (C(3)) ; 54.8 (C(2)) ; 53.5 (C(4)) ; 52.4 (C(2’)) ; 52.4 (C(1’)). 
Note : the signal due to an impurity: for C(ar) the difference between product and 
impurity is not well difined 
ESI-MS : [M - H + H2O]- = 265.3; [[M + H + H2O] + H3COOH] = 278.4; [[M + H] + 
H3COOH] = 296.3 
General procedure for 7a,b: 
TiCl4 (60.8 mmol, 14.8 equiv.) is added to a solution of acetaldehyde 6a (4.1 mmol, 1 
equiv.) in dry CH2Cl2 (20 mL) under N2 at -78 °C. The enol 3a,b (4.1 mmol, 1 equiv.) 
dissolved in  dry CH2Cl2 (8 mL) is then added dropwise over 30 min. After 4 h water is 
added to the mixture until complete dissolution of the solid. The aqueous phase is 
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extracted 3 times with CH2Cl2 and the combined organic phases are washed 3 times 
with water and once with brine. After having dried the organic phase over MgSO4 and 
concentrated the mixture, the residue is purified by flash chromatography (silica gel, 40% 
EtOAc in hexane) to afford 7a,b as a yellow oil. 
Synthesis of methyl 3-hydroxy-2-phenylbutanoate (7a) 
Acetaldehyde (200 mg, 4.5 mmol) is dissolved in dry CH2Cl2 (20 mL) and TiCl4 (7.3 mL, 
66.1 mmol) is added at -78 °C under Ar. 1-Methoxy-2-phenyl-vinyloxy)trimethylsilane 
(1.00 g, 4.5 mmol) is added dropwise to the reaction. The solution becomes green and is 
kept at this temperature for 1 h, than H2O (100 mL) is added. The aqueous phase is 
extracted 3 times with CH2Cl2 and the combined organic phases are washed succesively 
with water and brine, dried over MgSO4 and concentrated under vacuum. The crude 
product is purified by flash chromatography (EtOAc/Hexane 2:3) (51%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.37-7.30 (m, 5H, H(ar)), 4.40-4.34 (m (partially 
solved), 3J(3,2) ≈ 6.6, 3J(3,4) = 6.2, 1H, H(3)), 3.69 (s, 3H, H(1’)), 3.55 (d, 3J(2,3) = 6.8, 
1H, H(2)), 2.41 (s, 1H, OH)), 1.21, (d, 3J(4,3) = 6.2, 3H, H(4)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.4 (C(1)) ; 135.0 (C(ar)) ; 129.1 (C(ar)) ; 128.6 
(C(ar)) ; 127.8 (C(ar)) ; 68.5 (C(3)) ; 58.6 (C(2)) ; 52.0 (C(1’)) ; 20.4 (C(4)). 
ESI-MS : [M+Na]+ = 217.3 
 Synthesis of Ethyl 3-hydroxy-2-phenylbutanoate (7b) 
Acetaldehyde (0.20 mL, 4.1 mmol) is dissolved in dry CH2Cl2 (20 mL) and TiCl4 (6.7 mL, 
60.8 mmol) freshly distilled over polyvinylpyridine is added to the reaction at -78 °C 
under Ar. The solution becomes yellow. (1-Ethoxy-2-phenyl-vinyloxy)trimethylsilane 
(976.5 mg, 4.1 mmol) dissolved in CH2Cl2 (8 mL) is added dropwise (during 
aproximatively 30 min.) to the reaction. After 4 h at -78 °C under stirring, 100 mL water 
are added. The aqueous phase is extracted 3×30 mL with CH2Cl2 and the combined 
organic phases are washed succesively 3×30 mL with water and 1×30 mL brine, dried 
over MgSO4 and concentrated under vacuum. The crude yellow product is purified by 
flash chromatography (EtOAc/Hexane 2:3) (34%). 
1H-NMR (400 MHz, CDCl3) : isomer 1 : 7.40-7.24 (m, 5H, H(ar)), 4.39 (dq, 3J(3,2) = 6.5, 
3J(3,4) = 6.3), 1H, H(3)), 4.24, 4.22, 4.21 and 4.20 (dxdq (ABX3, system) 2J = 10.8, 
3J(A,X3)(B,X3) = 7.2, 2H, H(1’)), 3.53 (d, 3J(2,3) = 6.7, 1H, H(2)), 2.35 (sbr, 1H, OH), 1.24 
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(t (X3 part of the system ABX3), 3J(X3,A)(X3,B) = 7.1, 3H, H(2’)), 1.23 (d, 3J(4,3) = 6.3, 
3H, H(4)). 
1H-NMR (400 MHz, CDCl3) : isomer 2 : 7.40-7.24 (m, 5H, H(ar)), 4.35 (dq, 3J(3,2) = 9.1, 
3J(3,4) = 6.3), 1H, H(3)), 4.15, 4.14, 4.12 and 4.11 (dxdq (ABX3 system) 2J = 10.8, 
3J(A,X3)(B,X3) = 7.1, 2H, H(1’)), 3.51 (d, 3J(2,3) = 9.1, 1H, H(2)), 1.22 (t (X3 part of the 
system ABX3) 3J(X3,A)(X3,B) = 7.1, 3H, H(2’)), 1.07 (d, 3J(4,3) = 6.3, 3H, H(4)). 
13C-NMR (100 MHz, CDCl3) : isomer 1 : 173.7 (C(1)) ; 136.4 (C(ar)) ; 128.8 (C(ar)) ; 
128.7 (C(ar)) ; 127.8 (C(ar)) ; 68.6 (C(3)) ; 61.1 (C(1’)) ; 58.7 (C(2)) ; 20.3 (C(4)) ; 14.0 
(C(2’)). 
13C-NMR (100 MHz, CDCl3) : isomer 2 : 173.1 (C(1)) ; 135.1 (C(ar)) ; 129.1 (C(ar)) ; 
128.3 (C(ar)) ; 127.6 (C(ar)) ; 69.7 (C(3)) ; 61.0 (C(1’)) ; 60.2 (C(2)) ; 20.4 (C(4)) ; 14.0 
(C(2’)). 
ESI-MS : [M + H]+ = 231.2 
General procedure for 7c-e: 
TiCl4 (24 mmol, 6 equiv.) is added to a solution of aldehyde 6a-c (4 mmol, 1 equiv.) in 
dry CH2Cl2 (20 mL) under N2 at -78 °C. The enol 3c (4 mmol, 1 equiv.) dissolved in dry 
CH2Cl2, (6 mL) is added dropwise over 30 min. After 1 h at this temperature, a saturated 
aqueous solution of NaHCO3 (50 mL) is added to the cold mixture and the aqueous 
phase is extracted 3 times with CH2Cl2. The combined organic phases are washed 3 
times with water and once with brine. After having dried the organic phase over MgSO4 
and concentrated the mixture, the residue is purified by flash chromatography (silica gel, 
EtOAc/hexane 1:3) to afford 7c-e. 
Synthesis of S-ethyl 3-hydroxy-2-phenylbutanethioate (7c) 
Acetaldehyde (0.23 mL, 4.1 mmol) is dissolved in dry CH2Cl2 (20 mL) and TiCl4 (2.70 
mL, 24 mmol) freshly distilled over polyvinylpyridine is added to the reaction at -78 °C 
under Ar. (1-Ethylsulfanyl-2-phenyl-vinyloxy)trimethylsilane (1 g, 4 mmol) dissolved in 
CH2Cl2 (6 mL) is added dropwise to the reaction. The solution becomes dark orange. 
After 1 h at -78 °C under stirring, sat. NaHCO3 (50 mL) is added to the cold solution. The 
aqueous phase is extracted 3 times with CH2Cl2 and the combined organic phases are 
washed succesively with water and brine, dried over MgSO4 and concentrated under 
vacuum. The crude yellow product is purified by flash chromatography (EtOAc/Hexane 
1:3) (70%) 
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1H-NMR (400 MHz, CD3OD, 298 K) : isomère 1 : 7.42-7.29 (m, 5H, H(ar)), 4.49-4.42 (m 
(partially solved), 3J(2,3) = 9.1, 3J(3,4) = 6.3, 1H, H(3)), 3.72 (d, 3J(2,3) = 9.0, 1H, H(2)), 
2.88 (q, 3J(1’,2’) = 7.4, 2H, H(1’)), 2.29 (s, 1H, OH), 1.24 (d, 3J(4,3) = 6.18, 3H, 
H(4)),1.22 (t, 3J(2’,1’) = 7.4, 3H, H(2’)). 
Note : OH signal of the 2nd isomer is hidden under H(1’) signal 
1H-NMR (400 MHz, CD3OD, 298 K) : isomer 2 : 7.42-7.29 (m, 5H, H(ar)), 4.49-4.42 (m 
(partially solved), 3J(2,3) ≈ 6.8, 3J(3,4) = 6.3, 1H, H(3)), 3.70 (d, 3J(2,3) = 7.1, 1H, H(2)), 
2.87 (q, 3J(1’,2’) = 7.5, 2H, H(1’)), 2.29 (s, 1H, OH)), 1.21 (t, 3J(2’,1’) = 7.4, 3H, H(2’)), 
1.03 (d, 3J(4,3) = 6.3, 3H, H(4)). 
13C-NMR (100 MHz, CD3OD, 298 K) : isomer 1 : 201.3 (C(1)) ; 136.1 (C(arq)) ; 128.8 
(C(ar)) ; 128.7 (C(ar)) ; 127.8 (C(ar)) ; 68.7 (C(3)) ; 68.2 (C(2)) ; 23.5 (C(1’)) ; 20.6 
(C(4)) ; 14.3 (C(2’)). 
13C-NMR (100 MHz, CD3OD, 298 K) : isomer 2 : 199.9 (C(1)) ; 134.9 (C(arq)) ; 129.1 
(C(ar)) ; 128.5 (C(ar)) ; 127.9 (C(ar)) ; 69.7 (C(3)) ; 67.3(C(2)) ; 23.6 (C(1’)) ; 20.5 (C(4)) ; 
14.3 (C(2’)). 
ESI-MS : [M + Na]+ = 247.3 
Synthesis of S-ethyl 4-chloro-3-hydroxy-2-phenylbutanethioate (7d) 
Chloro-acetaldehyde (306 mg, 3.9 mmol) is dissolved in dry CH2Cl2 (20 mL) and TiCl4 
(2.6 mL, 23.4 mmol) freshly distilled over polyvinylpyridine is added to the reaction at -78 
°C under Ar. 1-(Ethylsulfanyl-2-phenyl-vinyloxy)trimethylsilane (0.98 g, 3.9 mmol) 
dissolved in CH2Cl2 (6 mL) is added dropwise to the reaction. The solution becomes dark 
orange. After 1 h at -78 °C under stirring, sat. NaHCO3 (50 mL) is added to the cold 
solution. The aqueous phase is extracted 3 times with CH2Cl2 and the combined organic 
phases are washed succesively 3 times with water and brine, dried over MgSO4  and 
concentrated under vacuum. The crude yellow product is purified by flash 
chromatography (EtOAc/Hexane 1:3) (51%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.42-7.34 (m, 5H, H(ar)), 4.57-4.52 (m (X part of the 
system ABX (partially solved)), 3J(X,A) ≈ 5.5, 3J(3,OH) ≈ 3.9, 1H, H(3)), 4.10 (d, 3J(2,3) = 
6.4, 1H, H(2)), 3.58, 3.57, 3.52 et 3.51 (2xdd (ABX system), 2J = 11.3, 3J(A,X) = 5.6, 
3J(B,X) = 5.1, 2H, H(4)), 2.94, 2.91, 2.89 et 2.87 (2xdq (ABX3 system), 2J = 13.4, 
3J(A,X3)(B,X3) = 7.4, 2H, H(1’)), 2.67 (d, 3J(OH,3) = 4.0, 1H, H(OH)), 1.24 (t (X3 part of 
the system ABX3 ), 3J(X3,A)(X3,B) = 7.4, 3H, H(2’)). 
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13C-NMR (100 MHz, CDCl3, 298 K) : 199.9 (C(1)) ; 133.7 (C(arq)) ; 129.4 (C(ar)) ; 128.9 
(C(ar)) ; 128.3 (C(ar)) ; 71.9 (C(3)) ; 62.0 (C(2)) ; 46.4 (C(4)) ; 23.7 (C(1’)) ; 14.3 (C(2’)). 
ESI-MS : [M + Na]+ = 281.1 
Synthesis of ethyl 5-(ethylthio)-3-hydroxy-5-oxo-4-phenylpentanoate (7e) 
Ethyl 3-oxopropanoate (1.50 mL, 4 mmol) is dissolved in dry CH2Cl2 (20 mL) and TiCl4 
(2.60 mL, 23.4 mmol) freshly distilled over polyvinylpyridine is added to the reaction at -
78 °C under Ar. (1-Ethylsulfanyl-2-phenyl-vinyloxy)trimethylsilane (1.00 g, 4 mmol) 
dissolved in CH2Cl2 (6 mL) is added dropwise to the reaction. The solution becomes dark 
orange. After 1 h at -78 °C under stirring, sat. NaHCO3 (50 mL) is added to the cold 
solution. The aqueous phase is extracted 3 times with CH2Cl2 and the combined organic 
phases are washed succesively 3 times with water and brine, dried over MgSO4 and 
concentrated under vacuum. The crude yellow product is purified by flash 
chromatography (EtOAc/Hexane 1:3) (13%). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 1 : 7.42-7.28 (m, 5H, H(ar)), 4.80-4.4.71 (m 
(X part of the system ABX (partially solved)), 3J(3,2) = 9.6, 3J(X,A) ≈ 8.2, 3J(X,B) ≈ 4.2, 
1H, H(3)), 4.14 (q, 3J(1’’,2’’) = 7.1, 2H, H(1’’)), 3.89 (d, 3J(2,3) = 9.6, 1H, H(2)), 2.94, 
2.91, 2.90 and 2.87 (2xdq (ABX3 system), 2J = 13.3, 3J(A,X3)(B,X3) = 7.5, 2H, H(1’)), 
2.56, 2.53, 2.50 and 2.46 (2xdd (ABX system), 2J = 16.3, 3J(A,X) = 8.2, 3J(B,X) = 4.2, 
2H, H(4)), 1.24 (t, 3J(2’’,1’’) = 7.1, 3H, H(2’’)), 1.23 (t ( X3 part of the system ABX3), 
3J(X3,A)(X3,B) = 7.4, 3H, H(2’)). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 2 : 7.42-7.28 (m, 5H, H(ar)), 4.80-4.4.71 (m 
(X part of the system ABX (partially solved)), 3J(3,2) = 7.8, 3J(X,A) ≈ 7.2, 3J(X,B) ≈ 4.8, 
1H, H(3)), 4.13 (q, 3J(1’’,2’’) = 7.2, 2H, H(1’’)), 3.91 (d, 3J(2,3) = 7.7, 1H, H(2)), 2.90, 
2.87, 2.84 and 2.83 (2xdq (ABX3 system), 2J = 11.7, 3J(A,X3)(B,X3) = 7.5, 2H, H(1’)), 2.31 
and 2.26 (2xdd (ABX system), 2J = 16.5, 3J(A,X) = 7.5, 3J(B,X) = 4.6, 2H, H(4)), 1.24 (t, 
3J(2’’,1’’) = 7.1, 3H, H(2’’)), 1.22 (t (X3 part of the system ABX3), 3J(X3,A)(X3,B) = 7.4, 3H, 
H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 1 : 199.6 (C(1)) ; 172.0 (C(5)) ; 135.1 
(C(arq)) ; 129.3 (C(ar)) ; 128.7 (C(ar)) ; 128.1 (C(ar)) ; 69.9 (C(3)) ; 65.6 (C(2)) ; 60.8 
(C(1’’)) ; 38.9 (C(4)) ; 24.7 (C(1’)) ; 14.1 (C(2’)) ; 14.1 (C(2’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 2 : 199.6 (C(1)) ; 171.9 (C(5)) ; 134.6 
(C(arq)) ; 129.0 (C(ar)) ; 128.5 (C(ar)) ; 128.1 (C(ar)) ; 69.0 (C(3)) ; 64.5 (C(2)) ; 60.8 
(C(1’’)) ; 38.7 (C(4)) ; 23.7 (C(1’)) ; 14.1 (C(2’)) ; 14.1 (C(2’’)). 
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ESI-MS : [M + Na]+ = 319.1 
 
Synthesis of 2-azido-1-phenylethanone (8c) 
2-Bromo-1-phenylethanone (7.84 g, 39.3 mmol) dissolved in MeOH (27.7 mL) is added 
to a solution of NaN3 (3.93 g, 60.3 mmol) in H2O (11 mL). After 15 h under mechanical 
stirring at 4 °C, the solution is extracted 3 times with Et2O and the combined organic 
phases are wash succesively 3 times with water and brine, dried over MgSO4 and 
concentrated under vacuum. The crude yellow product is purified by flash 
chromatography (CH2Cl2/Hexane 7:3) (91%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.86-7.83 (m, 2H, H(2’)), 7.60-7.55 (m, 1H, H(4’)), 
7.46-7.42 (m, 2H, H(3’)), 4.52 (s, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 193.1 (C(1)) ; 134.0 (C(1’)) ; 133.9 (C(3’)) ; 128.7 
(C(4’)) ; 127.6 (C(2’)) ; 54.6 (C(2)). 
Synthesis of 2-Bromo-1-(2-nitrophenyl)ethanone (8d) 
1-(2-nitrophenyl)ethanone (1.00 g, 6 mmol) and AlCl3 (25 mg) are dissolved in dry Et2O 
at 0 °C . Bromine (0.31 mL, 6 mmol) is added dropwise. When the addition is completed, 
the temperature is brought to RT. After 3 h at this temperature, the organic phases are 
washed succesively 3 times with water and brine, dried over MgSO4 and concentrated 
under vacuum. The crude product is purified by flash chromatography (CH2Cl2/Hexane 
7:3) (73%) 
1H-NMR (200 MHz, CDCl3, 298 K) : 8.24 (dd, 3J(5,6) = 8.1, 4J(5,7) = 1.3, 1H, H(5)), 7.80 
(dt, 3J(7,6)= 3J(7,8) = 7.4, 4J(7,5) = 1.3, 1H, H(7)), 7.68 (ddd, 3J(6,5) = 8.2, 3J(6,7) = 7.5, 
4J(6,8) = 1.6, 1H, H(6)), 7.51 (dd, 3J(8,7) = 7.5, 4J(8,6) = 1.6, 1H, H(6)), 4.30 (s, 2H, 
H(2)). 
13C-NMR (50 MHz, CDCl3, 298 K) : 194.3 (C(2)) ; 145.6 (C(4)) ; 134.9 (C(3)) ; 134.7 
(C(7)) ; 131.2 (C(7)) ; 129.1 (C(6)) ; 124.4 (C(5)) ; 33.8 (C(1)). 
Synthesis of 2-bromo-1-(2-nitrophenyl)ethanone (8e) 
2-Bromo-1-(-2-nitrophenyl)ethanone (1.00 g, 4.1 mmol) dissolved in MeOH (20 mL) is 
added to a solution of NaN3 (0.40 g, 6.1 mmol) in H2O (11 mL). After 48 h under 
mechanical sttiring at 6 °C, the solution is extracted 3 times with Et2O and the combined 
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organic phases are washed succesively 3 times with water and brine, dried over MgSO4 
and concentrated under vacuum. The crude yellow product is purified by flash 
chromatography (CH2Cl2) (92%). 
1H-NMR (200 MHz, CDCl3, 298 K) : 8.24 (dd, 3J(5,6) = 8.1, 4J(5,7) = 1.5, 1H, H(5)), 7.81 
(dt, 3J(7,6)= 3J(7,8) = 7.7, 4J(7,5) = 1.5, 1H, H(7)), 7.70 (ddd, 3J(6,5) = 8.1, 3J(6,7) = 7.7, 
4J(6,8) = 1.7, 1H, H(6)), 7.43 (dd, 3J(8,7) = 7.7, 4J(8,6) = 1.7, 1H, H(6)), 4.32 (s, 2H, 
H(2)). 
13C-NMR (50 MHz, CDCl3, 298 K) : 197.1 (C(2)) ; 135.0 (C(3)) ; 134.8 (C(7)) ; 131.4 
(C(7)) ; 127.7 (C(6)) ; 124.5 (C(5)) ; 57.7 (C(1)). 
 
Synthesis of (1-methoxyvinyloxy)trimethylsilane (9) 
 
A solution of LHMDS 1M in THF (16.20 mL, 16.2 mmol) is diluted in dry THF (10 mL) 
and cooled to -78 °C. Methyl acetate (1.00 g,13.5 mmol) in THF (6 mL) is added 
dropwise. After 30 min. TMSCl (1.75 g, 16.2 mmol) is added and the resulting mixture is 
stirred for 1.5 h. The solvent is evaporated and the salts are precipitated with pentane. 
The solution is filtered over celite and the solvent is evaporated. Purification by 
distillation (P=45 mmHg, T=48-50 °C) (92%). 
1H-NMR (200 MHz, CDCl3, 298 K) : 3.54 (s, 3H, H(1’)), 3.21 and 3.11 (2xd (AB system), 
2H, 2J = 2.6, H(2)), 0.22 (s, 9H, H(2’)). 
13C-NMR (50 MHz, CDCl3, 298 K) : 162.1 (C(1)) ; 59.9 (C(2)) ; 55.1 (C(1’)) ; 2.5 (C(2’)). 
General procedure for 10a-e: 
A solution of compound 8a-e (2.4 mmol, 1 equiv.) in dry CH2Cl2 (15 mL) is added to a 
solution of keten acetal 9 (7.3 mmol, 3 equiv.) in dry CH2Cl2 (15 mL) at -30 °C under Ar. 
A solution of TiCl4 (1.2 mmol, 0.5 equiv.), freshly distilled over polyvinylpyridine, in dry 
CH2Cl2 (4 mL) is added slowly. The solution becomes immediately red and then dark 
red. The reaction mixture is stirred at –30 °C for 15 min and then at –15 °C for 30 min. 
The cold mixture is poured into an aqueous solution of NaOH 2N (2.4 mL) and is 
extracted with CHCl3. The combined organic layers are washed with brine, dried over 
MgSO4 and concentrated. Purification of the residue by flash chromatography (silica gel, 
CH2Cl2) followed by crystallization (ether/hexane) afford 10a-10e as a white solid. 
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Synthesis of methyl 4-chloro-3-hydroxy-3-phenyl)butanoate (10a) 
To a solution of (1-methoxyvinyloxy)trimethylsilane (9) (1.00 g, 6.5 mmol)) in dry CH2Cl2 
(20 mL), 2-chloro-1-phenylethanone (2.90 g, 19.5 mmol) is added at -78 °C. TiCl4 (4.30 
mL, 39.0 mmol), frashly distilled over polyvinylpyridine, dissolved in CH2Cl2 (6 mL) is 
added dropwise. After 1 h the temperature is rised to -40 °C and stirred for 20 h. The 
reaction is quenched with NaOH 2M (78 mL), the aqueous phase is extracted with 
CHCl3, dried over MgSO4 and concentrated under vacum. Purification by 
chromatography (CH2Cl2) (20%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.30-7.51 (m, 5H, H(ar)), 4.53 (s, 1H, OH), 3.78 and 
3.70 (2xd (AB system), 2J = 11.5, 2H, H(4)), 3.63 (s, 3H, H(1’)), 3.19 and 3.08 (2xd (AB 
system), 2J = 16.2, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.2 (C(1)) ; 142.9 (C(ar)) ; 128.9 (C(ar)) ; 128.4 
(C(ar)) ; 125.7 (C(ar)) ; 75.0 (C(3)) ; 53.4 (C(4)) ; 52.5 (C(1’)) ; 42.0 (C(2)). 
ESI-MS : [M(37Cl) + Na]+ = 253.0, [M(35Cl) + Na]+ = 251.1. 
 
Synthesis of methyl 4-bromo-3-hydroxy-3-phenylbutanoate (10b) 
2-Bromo-1-phenylethanone (1.00 g, 6.2 mmol) is dissolved in dry CH2Cl2 (20 mL) and 
the solution is cooled to -78 °C and (1-methoxyvinyloxy)trimethylsilane (9) (2.20 g, 18.6 
mmol) is added to the solution. TiCl4 (4.10 mL, 39.0 mmol), frashly distilled over 
polyvinylpyridine, dissolved in CH2Cl2 (6 mL) is added dropwise. After 1 h the 
temperature is rised to -25 °C and stirred for 6 h. The reaction is quenched with NaOH 
2M (74.4 mL), the aqueous phase is extracted with CHCl3, dried over MgSO4 and 
concentrated under vacum. Purification by chromatography (CH2Cl2) (39%) 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.28-7.50 (m, 5H, H(ar)), 4.53 (s, 1H, OH), 3.68 et 
3.63 (2xd (AB system), 2J = 10.9, 2H, H(4)), 3.63 (s, 3H, H(1’)), 3.24 et 3.09 (2xd (AB 
system), 2J = 16.2, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.2 (C(1)) ; 142.9 (C(ar)) ; 129.0 (C(ar)) ; 128.4 
(C(ar)) ; 125.6 (C(ar)) ; 74.3 (C(3)) ; 52.5 (C(1’)) ; 43.0 (C(4)) ; 42.9 (C(2)). 
ESI-MS : [M(81Br) + Na]+ = 296.9, [M(79Br) + Na]+ = 295.1, [M(81Br) - H2O]+ = 256.9, 
[M(79Br) - H2O]+ = 255.1. 
HR-MS : [M + Na]+ :calc. 294.9946; found 294.9931   
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Synthesis of methyl 4-azido-3-hydroxy-3-phenylbutanoate (10c) 
To a solution of (1-methoxyvinyloxy)trimethylsilane (9) (1.06 g, 7.3 mmol)) in dried 
CH2Cl2 (15 mL), 2-azido-1-phenylethanone (0.50 g, 2.4 mmol) is added at -30 °C. TiCl4 
(0.13 mL, 1.2 mmol), frashly distilled over polyvinylpyridine, dissolved in CH2Cl2 (4 mL) is 
added dropwise. After 15 min. the temperature is rised to -16 °C for 30 min. more. The 
reaction is quenched with NaOH 2M (2.4 mL), the aqueous phase is extracted with 
CHCl3, dried over MgSO4 and concentrated under vacum. Purification by 
chromatography (CH2Cl2) (74%) 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.48-7.43 (m, 2H, H(6)), 7.41-7.36 (m, 2H, H(7)), 
7.33-7.29 (m, 1H, H(8)), 4.64 (d, 4J(OH,4) ≅ 1.4, 1H, OH), 3.62 (s, 3H, H(1’)), 3.51 and 
3.27 (1xd et 1xdd (AB system), 2J = 12.7, 4J(4,OH) ≅ 1.3, 2H, H(4)), 3.10 and 3.00 (2xd 
(AB system), 2J = 16.2, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.0 (C(1)) ; 142.7 (C(5)) ; 128.6 (C(7)) ; 127.8 
(C(8)) ; 125.0 (C(6)) ; 75.7 (C(3)) ; 60.7 (C(4)) ; 52.0 (C(1’)) ; 41.2 (C(2)). 
ESI-MS : [M + Na]+ = 258.1 
CHN : calc. : 56.16; H: 5.57; N: 17.86; found : 55.69; H: 5.57; N: 17.81 
 
Synthesis of Methyl 4-bromo-3-hydroxy-3-(2-nitrophenyl)butanoate (10d) 
To a solution of (1-methoxyvinyloxy)trimethylsilane (9) (0.90 g, 6.2 mmol)) in dry CH2Cl2 
(6 mL), 2-bromo-1-phenylethanone (0.50 g, 2.1 mmol) is added at -30 °C. TiCl4 (0.11 
mL, 1.0 mmol), frashly distilled over polyvinylpyridine, dissolved in CH2Cl2 (4 mL) is 
added dropwise. After 1 h the temperature is risedd to -13 °C and stirred for 4.5 h. The 
reaction is quenched with NaOH 2M (2mL), the aqueous phase is extracted with CHCl3, 
dried over MgSO4 and concentrated under vacum. Purification by chromatography 
(CH2Cl2) (84%) 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.44-7.56 (m, 4H, H(ar)), 4.74 (s, 1H, OH), 3.95 (s, 
2H, H(4)), 3.67 (s, 3H, H(1’)), 3.27 and 3.24 (2xd (AB system), 2J = 16.6, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 172.7 (C(1)) ; 150.6 (C(ar)) ; 134.5 (C(ar)) ; 131.2 
(C(ar)) ; 129.7 (C(ar)) ; 128.9 (C(ar)) ; 124.8 (C(ar)) ; 74.9 (C(3)) ; 52.8 (C(1’)) ; 42.5 
(C(2)) ; 40.7 (C(4)). 
HR-MS : [M + Na]+ : calc. 339.9797; found 339.9790 
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Synthesis of methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)butanoate (10e) 
To a solution of (1-methoxyvinyloxy)trimethylsilane (9) (1.06 g, 7.3 mmol)) in dry CH2Cl2 
(15 mL), 2-azido-1-(2-nitrophenyl)ethanone (0.50 g, 2.4 mmol) is added at -30 °C. TiCl4 
(0.13 mL, 1.2 mmol), frashly distilled over polyvinylpyridine, dissolved in CH2Cl2 (6 mL) is 
added dropwise. After 15 minutes the temperature is riseed to -15 °C and stirred for 30 
min. The reaction is quenched with NaOH 2M (2.4 mL), the aqueous phase is extracted 
with CHCl3, dried over MgSO4 and concentrated under vacum. Purification by 
chromatography (CH2Cl2) (76%)  
1H-NMR (400 MHz, CDCl3, 298 K) : 7.43-7.56 (m, 4H, H(ar)), 4.86 (s, 1H, OH), 3.67 (s, 
3H, H(1’)), 3.82 and 3.59 (2xd (AB system), 2J = 12.8, 2H, H(4)), 3.18 and 3.08 (2xd (AB 
system), 2J = 16.7, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 173.0 (C(1)) ; 150.7 (C(ar)) ; 134.8 (C(ar)) ; 131.4 
(C(ar)) ; 129.7 (C(ar)) ; 128.3 (C(ar)) ; 124.7 (C(ar)) ; 76.4 (C(3)) ; 59.4 (C(4)) ; 52.8 
(C(1’)) ; 41.2 (C(2)). 
ESI-MS ; [M + Na]+ = 303.0 
CHN: calc.  : C: 47.15; H: 4.32; N: 19.99; found : C: 47.15; H: 4.39; N: 19.76 
General procedure for 11a-b: 
PPh3 (5.4 mmol, 1.5 equiv.) is added to a solution of azido 10c,e (3.6 mmol, 1 equiv.) in 
THF (15 mL). 0.15 mL of water (1%) is added and the mixture is stirred at RT for 3 days. 
The solution is concentrated and MeOH (10 mL) is added. The mixture is stirred at reflux 
for 30 min. The suspension is cooled to –20 °C overnight, filtered and the white powder 
is washed with EtOAc and dried to afford 11a-b. 
Synthesis of 3-hydroxy-3-phenylpyrrolidine-2-one (11a) 
P(n-Bu)3 (2.10 g, 8.55 mmol.) is added to a solution of methyl 4-azido-3-hydroxy-3-
phenylbutanoate (2.59 g, 12.8 mmol) in THF (30 mL). 0.3 mL of water (1%) is added and 
the resulting mixture is stirred at RT for 3 days. The solution is concentrated and MeOH 
(10 mL) is added. The mixture is stirred at reflux for 30 min. The suspension is cooled at 
–20 °C overnight, filtered and the white powder is washed with EtOAc (76%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.55-7.52 (m, 2H, HC(7)), 7.42-7.37 (m, 2H, HC(8)), 
7.32-7.28 (m, 1H, HC(9)), 3.58 and 3.75 (2xd (AB system), 2J = 10.1, 2H, H2C (3)), 2.58 
and 2.96 (2xd (AB system), 2J = 16.9, 2H, H2C (5)). 
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13C-NMR (100 MHz, CDCl3, 298 K) : 177.62 (C(2)) ; 144.28 (C(6)) ; 128.46 (2C(7)) ; 
127.56 (C(9)) ; 125.21(2C(8)) ; 77.69 (C(4)) ; 57.13 (C(3)) ; 46.38 (C(5)). 
CHN: calc. : C: 67.78; H: 6.26; N: 7.90; found : C: 67.66; H: 6.37; N: 7.57 
Synthesis of 3-hydroxy-3-(2-nitrophenyl)pyrrolidin-2-one (11b) 
PPh3 (1.4 g, 5.4 mmol,) is added to a solution of methyl 4-azido-3-hydroxy-3-(-
2nitrophenyl)butanoate (1.00 g, 3.6 mmol) in THF (15 mL). 0.15mL of water (1%) is 
added and the mixture is stirred at RT for 3 days. The solution is concentrated and 
MeOH (10 mL) is added. The mixture is stirred at reflux for 30 min. The suspension is 
cooled at –20 °C overnight, filtered and the white powder is washed with EtOAc and 
dried. 
1H-NMR (400 MHz, DMSO-d6, 298 K) : 7.79 (sbr, 1H, H(1)), 7.49-7.67 (m, 4H, H(ar)), 
6.08 (s, 1H, OH), 3.66 and 3.46 (2xd (AB system), 2J = 10.7, 2H, H(5)), 2.97 and 2.42 
(2xd (AB system), 2J = 16.6, 2H, H(3)). 
13C-NMR (100 MHz, DMSO-d6, 298 K) : 174.7 (C(2)) ; 151.0 (C(arq)) ; 137.8 (C(arq)) ; 
132.1 (C(ar)) ; 129.6 (C(ar)) ; 128.3 (C(ar)) ; 124.8 (C(ar)) ; 77.2 (C(4)) ; 56.3 (C(5)) ; 
46.5 (C(3)). 
CHN: calc. : C: 54.06; H: 4.54; N: 12.61; found : C: 54.00; H: 4.63; N: 12.50 
 
Synthesis of 1-benzyl-4-hydroxy-4-(2-nitrophenyl)pyrrolidin-2-one (13) 
 
4-Hydroxy-4-phenyl-pyrrolidine-2-one (0.10 g, 0.4 mmol) is dissolved in DMF (1 mL) 
under Ar at -20 °C. NaH (0.013 g, 0.5 mmol) suspension in DMF (0.5 mL) is added. After 
15 min., bromoethyl-benzen (92.4 mg, 0.5 mmol) is added.  In 10 min., the resulting 
mixture is cooled to -10 °C and the reaction mixture is stirred this temperature for 1 h. 
The solvent is evaporated. Purification of the crude product is made by chromatography 
(EtOAc/CH2Cl2 6:4) (60%). 
1H-NMR (400 MHz, CD3OD, 298 K) : 7.62 (m (patially solved), 3J(11,10) = 7.8, 4J(11,9) = 
1.4, 1H, H(11)), 7.61 (m (partially solved), 4J(8,10) = 1.8, 1H, H(8)), 7.58 (dxtripletoide, 
3J(9,8) = 8.0, 3J(9,10) = 7.1, 4J(9,11) = 1.4, 1H, H(9)), 7.50 (ddd, 3J(10,11) = 7.8, 3J(10,9) 
= 7.1, 4J(10,8) = 1.7, 1H, H(10)), 7.39-7.28 (m, 5H, H(ar)), 4.57 (2xd (AB system), 2J = 
16.00, 2H, H(1’)), 3.82 and 3.61 (2xd (AB system), 2J = 11.0, 2H, H(5)), 3.28 and 2.79 
(2xd (AB system), 2J = 17.2, 2H, H(3)). 
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13C-NMR (100 MHz, CD3OD, 298 K) : 173.4 (C(2)) ; 150.5 (C(6)) ; 137.0 (C(arq)) ; 136.2 
(C(arq)) ; 131.7 (C(9)) ; 129.1 (C(10)) ; 128.8 (C(ar)) ; 128.1(C(ar)) ; 128.1 (C(ar)) ; 127.8 
(C(11)) ; 127.5 (C(ar)) ; 124.6 (C(8)) ; 74.0 (C(4)) ; 60.8 (C(5)) ; 46.7 (C(3)) ; 46.2 (C(6)). 
ESI-MS : [M + Na]+ = 335.1, [M + H]+ = 313.2 
 
Synthesis of 1-benzyl-3-(2-nitrophenyl)-5-oxopyrrolidin-3-yl acetate (14) 
 
1-Benzyl-4-hydroxy-4-(2-nitrophenyl)pyrrolidin-2-one (100 mg, 0.3 mmol) is added to 
acetic anhydride (15 mL) under Ar and the temperature is brought to 100 °C. After 2 h at 
this temperature, the excess of acetic anhydride is evaporated and the crude product is 
purified by chromatography (EtOAc/Hexane 6:4) (73%). 
1H-NMR (400 MHz, CD3OD, 298 K) : 7.57-7.49 (m, 3H, H(ar)); 7.40-7.28 (m, 6H, H(ar)), 
4.56 (s, 2H, H(6)), 4.08 and 3.87 (2xd (AB system), 2J = 11.8, 2H, H(5)), 3.37 and 3.24 
(2xd (AB system), 2J = 17.6, 2H, H(3)), 1.93 (s, 3H, H(2’)). 
13C-NMR (100 MHz, CD3OD, 298 K) : 172.6 (C(1’)) ; 171.0 (C(2)) ; 150.1 (C(arq)) ; 137.0 
(C(arq)) ; 134.4 (C(arq)) ; 132.7 (C(ar)) ; 130.7 (C(ar)) ; 129.9 (C(ar)) ; 129.4 (C(ar)) ; 
129.1 (C(ar)) ; 127.5 (C(ar)) ; 125.2 (C(ar)) ; 80.9 (C(4)) ; 58.7 (C(5)) ; 46.9 (C(6)) ; 45.6 
(C(3)) ; 20.6 (C(2’)). 
 
Synthesis of tert-butyl 4-hydroxy-4-(2-nitrophenyl)-2-oxopyrrolidine-1-carboxylate 
(15) 
 
4-Hydroxy-4-(2-nitrophenyl)-pyrrolidine-2-one (0.10 g, 0.5 mmol) is dissolved in DMF (2 
mL) under Ar. DMAP (0.023 g, 0.2 mmol) and Boc2O (0.1 m, 0.5 mmol) are added 
successively to the reaction. After 24 h at RT, the solvent is evaporated and the crude 
product is purified by chromatography (EtOAc/CH2Cl2 8:2). 
1H-NMR (200 MHz, CD3OD, 298 K) : 7.65-7.47 (m, 4H, H(ar)), 4.11 and 5.05 (2xd (AB 
system), 2J = 12.6, 2H, H(5)), 3.43 and 2.75 (1xd and 1xdd (AB system), 2J = 17.0, 
4J(3b,OH) = 0.9, 2H, H(3)), 1.54 (s, 9H, H(3’)). 
General procedure for 16a-b: 
DMAP (0.023 mg, 0.2 mmol) and Boc2O (0.20 g, 1.0 mmol) are added to a supension of 
lactam 11a-b (0.5 mmol) in dry THF (10 mL) under Ar. The solution becomes clear 
immediately. The solution is stirred at RT for at least 2 h. After the removal of the 
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solvent, the residue is purified by flash chromatography (silica gel, 1% MeOH in CH2Cl2) 
to afford 12a-b as a white solid. 
 
Synthesis of tert-butyl 2-oxo-4-phenyl-2,5-dihydro-1H-pyrrole-1-carboxylate (16a) 
DMAP (0.50 g, 4.1 mmol) and Boc2O (0.43 g, 2.0 mmol) are added to a supension of 3-
hydroxy-3-phenylpyrrolidine-2-one (0.16 g, 1.0 mmol) in dry THF (24 mL) under Ar. The 
solution becomes clear immediately. The solution is stirred at RT for 24 h. After the 
removal of the solvent, the residue is purified by flash chromatography (silica gel, 1% 
MeOH in CH2Cl2) (93%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.55-7.30 (m, 5H, HC(7, 8, 9)); 6.42 (t, 4J(3,5) = 1.5, 
1H, H(3)); 4.72 (d, 4J(5,3) = 1.5, 2H, H(5)); 1.63 (s, 9H, H(3’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 169.9 (C(2)) ; 156.1 (C(1’)) ; 149.7 (C(6)) ; 131.3 
(C(4)); 131.2 (2C(7)) ; 129.2 (C(9)) ; 126.2 (2C(8)) ; 119.8 (C(3)) ; 83.0 (C(2’)) ; 51.0 
(C(5)) ; 28.2 (3C(3’)). 
ESI-MS : [M + Na]+ = 282.0 
Synthesis of tert-butyl 2-oxo-4-(2-nitrophenyl)-2,5-dihydro-1H-pyrrole-1-
carboxylate (16b) 
DMAP (0.02 g, 0.2 mmol) and Boc2O (0.20 g, 1.0 mmol) are added to a supension of 3-
hydroxy-3-(2-nitrophenyl)pyrrolidine-2-one (0.10 g, 0.5 mmol) in dry THF (10 mL) under 
Ar. The solution becomes clear immediately. The solution is stirred at RT for 2 h. After 
the removal of the solvent, the residue is purified by flash chromatography (silica gel, 1% 
MeOH in CH2Cl2) (98%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.10 (dd, 3J (8,9) = 8.1, 4J (8,10) = 1.3, 1H, H(8)), 
7.72 (dt, 3J (10, 11)= 3J(10, 9) = 7.6, 4J (10, 8) = 1.3, 1H, H(10)), 7.63 (dxtripletoide, 3J 
(9, 10) = 7.6, 3J (9, 8) = 8.1, 4J (9, 11) = 1.5, 1H, H(9)), 7.41 (dd, 3J (11, 10) = 7.6, 4J (11, 
9) = 1.5, 1H, H(11)), 6.13 (t, 4J (3, 5) = 1.6, 1H, H(3)), 4.55 (d, 4J (5, 3) = 1.6, 2H, H(5)), 
1.56 (s, 9H, H(3’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 168.0 (C(2)) ; 155.3 (C(1’)) ; 149.2 et 147.4 (C(6) et 
C(7)) ; 133.7 (C(10)) ; 130.7 (C(9)) ; 130.3 (C(11)) ; 128.3 (C(4)) ; 125.0 (C(8)) ; 124.9 
(C(3)) ; 83.3 (C(2’)) ; 53.0 (C(5)) ; 28.1 (C(3’)). 
CHN : calc. C: 59.21; H: 5.30; N: 9.21; found : C: 59.23; H: 5.39; N: 9.11. 
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Synthesis of tert-butyl 2-(tert-butoxycarbonyloxy)-4-(2- nitrophenyl)-1H-pyrrole-1-
carboxylate (17)  
 
4-Hydroxy-4-(2-nitrophenyl)pyrrolidine-2-one (0.10 g, 0.5 mmol) is  dissolved in dry THF 
(3mL) under Ar and a suspension is formed. DMAP (0.023 g, 0.2 mmol) and Boc2O (0.30 
g, 1.4 mmol) are added. The solution becomes clear. After 1 h at RT, the solvent is 
evaporated and the crude product is purified by chromatography (Hexane/EtOAc 7:3) 
(93%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.76 (ddd, 3J (8, 9) = 8.1, 4J (8, 10) = 1.3, 5J (8,11) = 
0.5, 1H, H(8)), 7.64 (dxtripletoide, 3J (10, 11) = 7.8, 3J (10, 9) = 7.1, 4J (10, 8) = 1.3, 1H, 
H(10)), 7.60 (ddd, 3J (11, 10) = 7.8, 4J (11, 9) = 1.8, 5J (11,8) = 0.5, 1H, H(11)), 7.49 
(ddd, 3J (9, 8) = 8.1, 3J (9, 10) = 7.1, 4J (9, 11) = 1.8, 1H, H(9)), 7.16 (d, 4J (5, 3) = 2.3, 
1H, H(5)), 5.97 (d, 4J (3, 5) = 2.3, 1H, H(3)), 1.62 (s, 9H, H(3’)), 1.55 (s, 9H, H(3’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 151.2 (C(1’’)) ; 149.6 (C(1’)) ; 147.7 et 137.9 (C(6) 
et C(7)) ; 132.2 (C(10)) ; 131.1 (C(11)) ; 128.2 (C(9)) ; 128.0 (C(4)) ; 123.6 (C(8)) ; 119.3 
(C(2)) ; 114.5 (C(5)) ; 100.6 (C(3)) ; 85.2 (C(2’)) ; 84.7 (C(2’’)) ; 27.1 (C(3’) ; 26.8 (C(3’’). 
ESI-MS : [M + Na]+ = 426.9 
CHN: calc: C: 59.40; H: 5.98; N: 6.93; found: C: 59.66; H: 6.16; N: 6.89. 
General procedure for 19a-b: 
2,6-Lutidine (0.20 mL, 1.7 mmol, 3.4 equiv.) and TBSOTf (0.5 mmol, 1 equiv.) are added 
at RT under Ar to a solution of pyrrolidinone 12a-b (0.5 mmol, 1 equiv.) in dry CH2Cl2 (5 
mL). The mixture is stirred for 1 h. After the removal of the solvent, purification of the 
residual oil by filtration over silica gel (20% EtOAc in hexane) afford silyl enol 13a-b as 
an orange oil. 
Synthesis of tert-butyl 2-(tert-butyldimethylsilyloxy)-4-phenyl-1H-pyrrole-1-
carboxylate (19a) 
2,6-Lutidine (0.38 mL, 3.3 mmol) and TBSOTf (0.28 mL, 1.2 mmol) are added at RT 
under Ar to a solution of tert-butyl 2-oxo-4-phenyl-2,5-dihydro-1H-pyrrole-1-carboxylate 
(0.28 g, 1.1 mmol) in dry CH2Cl2 (2.50 mL). After 40 min. of stirring at RT, the salts are 
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precipitated with pentane, filtered over celite and 2,6-lutidine is removed by bulb-to-bulb 
distillation (P=0.06 torr, T=60 °C). (62%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.50 (m, 2H, H(7,11)), 7.36 (m, 2H, H(8,10)), 7.23 
(m, 1H, H(9)), 7.04 (d, 4J(5, 3) = 2.3, 1H, H(5)), 5.63 (d, 4J(3, 5) = 2.3, 1H, H(3)), 1.63 (s, 
9H, H(3’)), 1.06 (s, 9H, H(3’’)), 0.31 (s, 6H, H(1’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 148.1 (C(1’)) ; 144.1 (C(6)) ; 134.6 (C(8,10)) ; 128.5 
(C(4)) ; 126.2 (C(9)) ; 125.0 (C(7,11)) ; 123.3 (C(2)) ; 108.6 (C(5)) ; 91.2 (C(3)) ; 83.0 
(C(2’)) ; 28.1 (C(3’)) ; 25.7 (C(3’’)) ; 18.4 (C(2’’)) ; -4.7 (C(1’’)). 
 
Synthesis of tert-butyl 2-(tert-butyldimethylsilyloxy)-4-(-nitrophenyl)-1H-pyrrole-1-
carboxylate (19b) 
2,6-Lutidine (0.2 mL, 1.7 mmol) and TBSOTf (1.27 mL, 0.5 mmol) are added at RT under 
Ar to a solution of tert-butyl 2-oxo-4-(2-nitrophenyl)-2,5-dihydro-1H-pyrrole-1-carboxylate 
(0.14 g, 0.5 mmol) in dry CH2Cl2 (5 mL). The mixture was stirred for 1 h. After the 
removal of the solvent, purification of the residual oil by filtration over silica gel (20% 
EtOAc in hexane) affords the product as an orange oil (80%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.69 (dd, 3J (8, 9) = 8.1, 4J (8, 10) = 1.2, 1H, H(8)), 
7.53 (dxtripletoide, 3J (10, 11) = 7.8, 3J (10, 9) = 6.9, 4J (10, 8) = 1.3, 1H, H(10)), 7.50 
(dd, 3J (11, 10) = 7.8, 4J (11, 9) = 2.0, 1H, H(11)), 7.37 (ddd, 3J (9, 8) = 8.1, 3J (9, 10) = 
6.9, 4J (9, 11) = 1.9, 1H, H(9)), 6.91 (d, 4J (5, 3) = 2.3, 1H, H(5)), 5.31 (d, 4J (3, 5) = 2.3, 
1H, H(3)), 1.61 (s, 9H, H(3’)), 1.02 (s, 9H, H(3’’)), 0.27 (s, 6H, H(1’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 149.1 (C(1’)) ; 147.8 et 144.0 (C(6) et C(7)) ; 131.8 
(C(10)) ; 130.8 (C(11)) ; 129.3 (C(4)) ; 127.2 (C(9)) ; 123.6 (C(8)) ; 118.7 (C(2)) ; 111.1 
(C(5)) ; 92.4 (C(3)) ; 83.5 (C(2’)) ; 28.1 (C(3’)) ; 25.7 (C(3’’)) ; 18.4 (C(2’’)) ; -4.8 (C(1’’)). 
 
Synthesis of methyl 4-oxobutanoate (20a) 
 
Methyl 4,4-dimethoxybutanoate (1.87 g, 11.5 mmol) is dissolved in acetone (10 mL) and 
a solution of HClconc./H2O 0.5:21 is added to the reaction. The mixture is stirred at RT. 
After 1 h, the aqueous phase is extracted once with CH2Cl2 and 3 times with a mixture of 
acetone/CH2Cl2 (1:2). The combined organic phases are washed with sat. K2CO3 and 
dried over MgSO4. After vacuum concentration, a light-yellow oil is obtained (87%). 
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1H-NMR (200 MHz, CDCl3, 298 K) : 9.82 (s, 1H, H(4)), 3.70 (s, 3H, H(1’)), 2.85-2.76 (m, 
4H, H(2,3)). 
 
Synthesis of ethyl 4-oxobutanoate (20b) 
 
Oxalyl dichloride (11.71 mL, 134.5 mmol) is dissolved in dry CH2Cl2 (110 mL) under Ar 
and the solution is cooled to -78 °C. DMSO (12.45 mL, 179.4 mmol) in CH2Cl2 (110 mL) 
is added to the reaction. After 10 min. at -78 °C, ethyl 4-hydroxybutanoate (11.84 g, 89.7 
mmol) in CH2Cl2 (350 mL) is added followed by Et3N (37.40 mL, 269.1 mmol). After 10 
min. the temperature is rised to 0 °C and kept fixed for 2 h. Water (50 mL) is added to 
the solution and the aqueous phase is extracted with CH2Cl2. The combined organic 
phases are dried over MgSO4, the solvent evaporated and the crude product is purified 
by chromatography (EtOAc/hexane 6:4) (82%). 
 
1H-NMR (400 MHz, CDCl3, 298 K) : 9.82 (t, 3J(4,3) = 0.7, 1H, H(4)), 4.10 (q, 3J(1’,2’) = 
7.1, 2H, H(1’)), 2.75 (m (partially solved), 3J(3,2) ≈ 6.6, 3J(3,4) ≈ 0.6, 2H, H(3)), 2.57 (t, 
3J(2,3) ≈ 6.7, 2H, H(2)), 1.21 (t, 3J(2’1’) = 7.1, 3H, H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 200.0 (C(4)) ; 172.2 (C(1)) ; 60.7 (C(1’)) ; 38.4 
(C(3)) ; 26.5 (C(2)) ; 14.0 (C(2’)). 
 
Synthesis of benzyl 4-oxobutanoate (20c) 
 
Oxalyl dichloride (2.69 mL, 30.9 mmol) is dissolved in dry CH2Cl2 (28 mL) under Ar and 
the solution is cooled to -78 °C. DMSO (2.86 mL, 41.2 mmol) in CH2Cl2 (110 mL) is 
added to the reaction. After 10 min. at -78 °C benzyl 4-hydroxybutanoate (4.00 g, 20.6 
mmol) in CH2Cl2 (100 mL) is added followed by Et3N (8.60 mL 61.9 mmol). After 10 min. 
the temperature is rised to 0 °C and kept fixed for 2 h. Water (50 mL) is added to the 
solution and the aqueous phase is extracted with CH2Cl2. The combined organic phases 
are dried over MgSO4, the solvent is evaporated and the crude product is purified by 
chromatography (EtOAc/hexane 1:1) (86%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 9.82 (t, 3J(4,3) = 0.7, 1H, H(4)), 7.40-7.31 (m, 5H, 
H(3’, 4’ et 5’)), 5.14 (s, 2H, H(1’)), 2.82 (m (partially solved), 3J(3,2) ≈ 6.8, 3J(3,4) ≈ 0.7, 
2H, H(3)), 2.69 (m (partially solved), 3J(2,3) ≈ 6.9, 2H, H(2)). 
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13C-NMR (100 MHz, CDCl3, 298 K) : 199.9 (C(4)) ; 172.1 (C(1)) ; 135.7 (C(2’)) ; 128.6 
(C(3’)) ; 128.3 (C(5’)) ; 128.2 (C(4’)) ; 66.6 (C(1’)) ; 38.5 (C(3)) ; 26.6 (C(2)). 
 
Synthesis of 4-methoxybenzyl 4-oxobutanoate (20d) 
 
Oxalyl dichloride (1.96 mL, 22.5 mmol) is dissolved in dry CH2Cl2 (20 mL) under Ar and 
the solution is cooled to -78 °C. DMSO (2.08 mL, 30.0 mmol) in CH2Cl2 (20 mL) is added 
to the reaction. After 10 min. at -78 °C benzyl 4-hydroxybutanoate (3.36 g, 15.0 mmol) in 
CH2Cl2 (65 mL) is added followed by Et3N (6.26 mL, 45.0 mmol). After 10 min. the 
temperature is rised to 0 °C and kept fixed for 2 h. Water (50 mL) is added to the 
solution and the aqueous phase is extracted with CH2Cl2. The combined organic phases 
are dried over MgSO4, the solvent is evaporated and the crude product is purified by 
chromatography (EtOAc/hexane 1:1) (79%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 9.82 (t, 3J(4,3) = 0.7, 1H, H(4)), 7.31 et 6.91 
(AA’XX’system (partially solved), J(A,X) = 8.4, J(A’X) = 0.3, 4H, H(AA’XX’)), 5.08 (s, 2H, 
H(1’)), 3.82 (s, 3H, H(6’)), 2.81 (m (partially solved), 3J(3,2) ≈ 6.8, 3J(3,4) ≈ 0.7, 2H, 
H(3)), 2.67 (m (partially solved), 3J(2,3) ≈ 6.9, 2H, H(2)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 199.9 (C(4)) ; 172.1 (C(1)) ; 159.6 (C(5’)) ; 130.1 
(C(AA’)) ; 127.8 (C(2’)) ; 113.9 (C(XX’)) ; 66.4 (C(1’)) ; 55.2 (C(6’)) ; 38.5 (C(3)) ; 26.6 
(C(2)). 
ESI-MS : [M + Na]+ = 245.0 
Synthesis of tert-butyl 2-(4-methoxy-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-
oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (21a)  
Methyl 4-oxobutanoate (0.35 g, 3.0 mmol) and BF3.OEt2 (0.38 mL, 2.3 mmol) are added 
dropwise to a solution of silyl enol 19b (0.96 g, 2.3 mmol) in dried CH2Cl2 (20 mL) at -78 
°C under Ar. The colour of the solution changes from yellow to light yellow. The mixture 
is stirred at -78 °C for 1 h. The reaction mixture is quenched with saturated aqueous 
solution of NaHCO3 (15 mL) at -78 °C and the aqueous layer is extracted with CH2Cl2. 
The combined organic layers are washed with brine, dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (silica gel, 
EtOAc/Ether 3:7) affords the aldol product as a white solid (84%). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 1 : 8.05 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.2, 
1H, H(12)), 7.69 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.59 
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(dxtripletoide, 3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.47 (dd, 
3J(15,14) = 7.7, 4J(15,13) = 1.4, 1H, H(15)), 6.20 (d, 4J(3,5) = 1.2, 1H, H(3)), 5.15 (t, 
3J(5,6) = 1.2, 4J(5,3) = 1.2, 1H, H(5)), 4.11 (m, 1H, H(6)), 3.60 (s, 3H, H(1’)), 2.72 (m, 1H, 
OH), 2.45-2.29 (m, 2H, H(8)), 1.71 (dtd, 2J(7a,7b) ≈ 14.3, 3J(7a,8) ≈ 6.9, 3J(7a,6) ≈ 2.4, 
1H, H(7a)), 1.57 (s, 9H, H(3’’)), 1.53-1.41 (m, 1H, H(7b)). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 2 : 8.14 (dd, 3J(12,13) = 8.2, 4J(12,14) = 1.2, 
1H, H(12)), 7.74 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.64 
(dxtripletoide, 3J(13,12) = 8.2, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.51 (dd, 
3J(15,14) = 7.6, 4J(15,13) = 1.4, 1H, H(15)), 6.08 (d, 4J(3,5) = 1.2, 1H, H(3)), 5.14 (t, 
3J(5,6) = 1.2, 4J(5,3) = 1.2, 1H, H(5)), 4.27 (d, 3J(OH,6) = 8.5, 1H, OH), 3.86 (m (partially 
solved), 3J(6,OH) ≈ 8.4, 1H, H(6)), 3.59 (s, 3H, H(1’)), 2.42 and 2.33 (ddx(AB system), 
2J(8a,8b) = 16.7, 3J(8ab,7a) = 3J(8b,7b) = 7.5, 3J(8a,7b) = 6.1, 2H, H(8ab)), 1.60 (s, 9H, 
H(3’’)), 1.59-1.51 (m (partially solved), 3J(7a,8ab) ≈ 7.6, 1H, H(7a)), 1.33-1.23 (m 
(partially solved), 3J(7b,8b) ≈ 7.5, 3J(7b,8a) = 6.2, 1H, H(7b)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 1 : 174.2 (C(9)) ; 168.2 (C(2)) ; 159.0 
(C(1’’)) ; 149.6 and 148.0 (C(10) and (C(11)) ; 133.6 (C(14)) ; 131.3 (C(15)) ; 130.6 
(C(13)) ; 129.3 (C(4)) ; 125.9 (C(3)) ; 124.9 (C(12)) ; 83.8 (C(2’’)) ; 70.4 (C(6)) ; 65.9 
(C(5)) ; 51.8 (C(1’)) ; 31.1 (C(8)) ; 28.1 (C(3’’)) ; 26.5 (C(7)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 2 : 173.6 (C(9)) ; 167.6 (C(2)) ; 157.7 
(C(1’’)) ; 151.4 and 147.2 (C(10) and (C(11)) ; 133.9 (C(14)) ; 131.5 (C(15)) ; 130.8 
(C(13)) ; 128.5 (C(4)) ; 125.5 (C(3)) ; 125.1 (C(12)) ; 84.5 (C(2’’)) ; 70.8 (C(6)) ; 69.2 
(C(5)) ; 51.5 (C(1’)) ; 30.3 (C(8)) ; 28.1 (C(3’’)) ; 26.6 (C(7)). 
HR-MS : [M + Na]+ : calc. 443.1430; found 443.1423 
Synthesis of tert-butyl 2-(4-ethoxy-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-oxo-
2,5-dihydro-1H-pyrrole-1-carboxylate (21b) 
Ethyl 4-oxobutanoate (0.76 g, 5.8 mmol) and BF3.OEt2 (0.87 mL, 6.9 mmol) are added 
dropwise to a solution of silyl enol 19b (2.22 g, 5.3 mmol) in dry CH2Cl2 (50 mL) at –78 
°C under Ar. The colour of the solution changes from yellow to pale yellow. The mixture 
is stirred at –78 °C for 1 h. The reaction mixture is quenched with saturated aqueous 
solution of NaHCO3 (15 mL) at -78 °C and the aqueous layer is extracted with CH2Cl2. 
The combined organic layers are washed with brine, dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (silica gel, 
CH2Cl2/EtOAc 6:4) afford the aldol product as a white solid (55%). 
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1H-NMR (400 MHz, CDCl3, 298 K) : isomer 1 : 8.05 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.2, 
1H, H(12)), 7.69 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.59 (ddd, 
3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.47 (dd, 3J(15,14) = 7.7, 
4J(15,13) = 1.4, 1H, H(15)), 6.21 (d, 4J(3,5) = 1.2, 1H, H(3)), 5.15 (dd, 3J(5,6) = 3.8, 
4J(5,3) = 1.2, 1H, H(5)), 4.12 (m (partially solved), 3J(6,OH) ≈ 5.7, 3J(6,5) ≈ 3.8, 1H, 
H(6)), 4.05 (q, 3J(1’,2’) = 7.2, 2H, H(1’)), 2.78 (d, 3J(OH,6) = 5.7, 1H, OH), 2.36 and 2.33 
(tx(AB system), 2J(8a,8b) = 16.7, 3J(8ab,7a) ≈ 3J(8ab,7b) ≈ 6.5, 2H, H(8a,8b)), 1.71-1.65 
(m (partially solved), 2J(7a,7b) ≈ 14.4, 3J(7a,8ab) ≈ 7.0, 1H, H(7a)), 1.57 (s, 9H, H(3’’)), 
1.50-1.42 (m (partially solved), 2J(7b,7a) ≈ 14.3, 1H, H(7b)), 1.19 (t, 3J(2’,1’) = 7.2, 3H, 
H(2’)). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 2 : 8.14 (dd, 3J(12,13) = 8.2, 4J(12,14) = 1.2, 
1H, H(12)), 7.73 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.64 (ddd, 
3J(13,12) = 8.2, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.53 (dd, 3J(15,14) = 7.6, 
4J(15,13) = 1.4, 1H, H(15)), 6.05 (d, 4J(3,5) = 1.3, 1H, H(3)), 5.09 (t, 3J(5,6)(5,3) = 1.2, 
1H, H(5)), 4.40-4.20 (br, 1H, OH), 4.02 (q, 3J(1’,2’) = 7.1, 2H, H(1’)), 3.93 (m, 1H, H(6)), 
2.36 and 2.32 (ABxdd (partially solved), 2J(8a,8b) = 16.6, 3J(8a,7ab) ≈ 7.7, 3J(8b,7ab) = 
6.1, 2H, H(8a,8b)), 1.57 (s, 9H, H(3’’)), 1.52-1.44 (m, 1H, H(7a)), 1.26-1.20 (m, 1H, 
H(7b)), 1.16 (t, 3J(2’,1’) = 7.2, 3H, H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 1 : 173.9 (C(9)) ; 168.2 (C(2)) ; 159.0 
(C(1’’)) ; 149.5 and 148.0 (C(10) and C(11)) ; 133.6 (C(14)) ; 131.3 (C(15)) ; 130.5 
(C(13)) ; 129.3 (C(4)) ; 125.9 (C(3)) ; 124.9 (C(12)) ; 83.8 (C(2’’)) ; 70.5 (C(6)) ; 65.9 
(C(5)) ; 60.7 (C(1’)) ; 31.4 (C(8)) ; 28.1 (C(3’’)) ; 26.4 (C(7)) ; 14.1 (C(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 2 : 173.1 (C(9)) ; 167.9 (C(2)) ; 157.9 
(C(1’’)) ; 150.8 and 147.1 (C(10) and C(11)) ; 134.0 (C(14)) ; 131.7 (C(15)) ; 130.7 
(C(13)) ; 128.7 (C(4)) ; 125.5 (C(3)) ; 125.0 (C(12)) ; 84.2 (C(2’’)) ; 70.7 (C(6)) ; 69.1 
(C(5)) ; 60.3 (C(1’)) ; 30.6 (C(8)) ; 28.6 (C(3’’)) ; 26.9 (C(7)) ; 14.1 (C(2’)). 
HR-MS : [M + Na]+ : calc. 457.1587; found 457.1584 
Synthesis of tert-butyl 2-(4-benzyloxy)-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-
oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (21c)  
Benzyl 4-oxobutanoate (0.68 g, 3.6 mmol) and BF3.OEt2 (0.54 mL, 3.2 mmol) are added 
dropwise to a solution of silyl enol 19b (1.25 g, 3.0 mmol) in dry CH2Cl2 (25 mL) at –78 
°C under Ar. The colour of the solution changes from yellow to light yellow. The mixture 
is stirred at –78 °C for 1 h. The reaction mixture is quenched at with saturated aqueous 
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solution of NaHCO3 (15 mL) at -78 °C and the aqueous layer is extracted with CH2Cl2. 
The combined organic layers are washed with brine, dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (silica gel, 
EtOAc/Ether 2:8) affords the aldol product as a white solid (55%). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 1 : 8.04 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.3, 
1H, H(12)), 7.66 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.57 
(dxtripletoide, 3J(13,12) ≈ 7.9, 3J(13,14) ≈ 7.7, 4J(13,15) = 1.5, 1H, H(13)), 7.45 (dd, 
3J(15,14) = 7.6, 4J(15,13) = 1.5, 1H, H(15)), 7.36-7.27 (m, 5H, H(3’,4’,5’)), 6.19 (d, 4J(3,5) 
= 1.1, 1H, H(3)), 5.16 (dd, 3J(5,6) = 3.7, 4J(5,3) = 1.1, 1H, H(5)), 5.03 (s, 2H, H(1’)), 4.12 
(m, 1H, H(6)), 2.89 (m, 1H, OH), 2.41 (t, 3J(8,7) = 7.0, 2H, H(8)), 1.72 (dtd, 2J(7a,7b) ≈ 
14.3, 3J(7a,8) ≈ 7.0, 3J(7a,6) ≈ 2.3, 1H, H(7a)), 1.55 (s, 9H, H(3’’)), 1.49 (dtd, 2J(7b,7a) ≈ 
14.4, 3J(7b,8) ≈ 7.2, 3J(7b,6) ≈ 3.5, 1H, H(7b)). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 2 : 8.13 (dd, 3J(12,13) = 8.2, 4J(12,14) = 1.2, 
1H, H(12)), 7.69 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.4, 1H, H(14)), 7.60 
(dxtripletoide, 3J(13,12) = 8.0, 3J(13,14) = 7.6, 4J(13,15) = 1.5, 1H, H(13)), 7.48 (dd, 
3J(15,14) = 7.7, 4J(15,13) = 1.4, 1H, H(15)), 7.37-7.31 (m, 2H, H(3’)), 7.30-7.27 (m, 3H, 
H(4’,5’)), 6.08 (d, 4J(3,5) = 1.4, 1H, H(3)), 5.15 (m, 1H, H(5)), 5.03 (s, 2H, H(1’)), 3.84 (m, 
1H, H(6)), 2.53-2.35 (m, 2H, H(8)), 1.59-1.54 (m, 1H, H(7a)), 1.59 (s, 9H, H(3’’)), 1.36-
1.27 (m, 1H, H(7b)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 1 : 173.5 (C(9)) ; 168.2 (C(2)) ; 159.0 
(C(1’’)) ; 149.5 and 147.9 (C(10) and (C(11)) ; 135.6 (C(2’)) ; 133.6 (C(14)) ; 131.3 
(C(15)) ; 130.5 (C(13)) ; 129.2 (C(4)) ; 128.5 (C(3’)) ; 128.2 (C(5’)) ; 128.2 (C(4’)) ; 125.8 
(C(3)) ; 124.8 (C(12)) ; 83.8 (C(2’’)) ; 70.3 (C(6)) ; 66.4 (C(1’)) ; 65.9 (C(5)) ; 31.2 (C(8)) ; 
28.0 (C(3’’)) ; 26.5 (C(7)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 2 : 173.0 (C(9)) ; 167.5 (C(2)) ; 157.6 
(C(1’’)) ; 151.5 and 147.2 (C(10) and (C(11)) ; 135.8 (C(2’)) ; 133.9 (C(14)) ; 131.4 
(C(15)) ; 130.8 (C(13)) ; 128.5 (C(3’)) ; 128.3 (C(4)) ; 128.1 (C(5)) ; 125.5 (C(3)) ; 125.1 
(C(12)) ; 84.5 (C(2’’)) ; 70.9 (C(6)) ; 69.1 (C(5)) ; 66.2 (C(1’)) ; 30.6 (C(8)) ; 28.0 
(C(7,3’’)). 
HR-MS : [M + Na]+ : calc. 519.1743; found 519.1739 
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Synthesis of tert-butyl 2-(1-hydroxy-4-(4-methoxybenzyloxy)-4-oxobutyl)-3-(2-
nitrophenyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (21d) 
4-Methoxybenzyl 4-oxobutanoate (0.75 g, 3.4 mmol) and BF3.OEt2 (0.43 mL, 3.4 mmol) 
are added dropwise to a solution of silyl enol 19b (1.29 g, 3.1 mmol) in dry CH2Cl2 (25 
mL) at -78 °C under Ar. The colour of the solution changes from yellow to light yellow. 
The mixture is stirred at   -78 °C for 1 h. The reaction mixture is quenched with saturated 
aqueous solution of NaHCO3 (15 mL) at -78 °C and the aqueous layer is extracted with 
CH2Cl2. The combined organic layers are washed with brine, dried over MgSO4 and 
concentrated. Purification of the residue by flash chromatography (silica gel, 
CH2Cl2/Ether 3:7) affords the aldol product as a white solid (91%). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomer 1 : 8.06 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.3, 
1H, H(12)), 7.69 (dt, 3J(14,13)= 3J(14,15) = 7.6, 4J(14,12) = 1.3, 1H, H(14)), 7.60 
(dxtripletoide, 3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.47 (dd, 
3J(15,14) = 7.6, 4J(15,13) = 1.4, 1H, H(15)), 7.24 and 6.87 (AA’XX’ system (partially 
solved), J(A,X) = 8.4, J(A’X) = 0.4, 4H, H(AA’XX’)), 6.21 (d, 4J(3,5) = 1.2, 1H, H(3)), 5.17 
(dd, 3J(5,6) = 3.7, 4J(5,3) = 1.2, 1H, H(5)), 4.98 (s, 2H, H(1’)), 4.13 (m, 1H, H(6)), 3.81 (s, 
3H, H(6’)), 2.79 (m, 1H, OH), 2.39 (tx(AB system), 2J(8a,8b) = 13.8, 3J(8ab,7a) ≈ 
3J(8ab,7b) ≈ 6.9, 2H, H(8ab)), 1.75-1.69 (m (partially solved), 2J(7a,7b) ≈ 14.3, 3J(7a,8ab) 
≈ 6.9, 1H, H(7a)), 1.57 (s, 9H, H(3’’)), 1.50-1.42 (m, 1H, H(7b)). 
1H-NMR (400 MHz, CDCl3, 298 K) : isomère 2 : 8.13 (dd, 3J(12,13) = 8.2, 4J(12,14) = 
1.3, 1H, H(12)), 7.73 (dt, 3J(14,13)= 3J(14,15) = 7.5, 4J(14,12) = 1.3, 1H, H(14)), 7.62 
(dxtripletoide, 3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.5, 1H, H(13)), 7.50 (dd, 
3J(15,14) = 7.6, 4J(15,13) = 1.5, 1H, H(15)), 7.24 et 6.87 (AA’XX’system (partially 
solved), J(A,X) = 8.4, J(A’X) = 0.4, 4H, H(AA’XX’)), 6.09 (d, 4J(3,5) = 1.3, 1H, H(3)), 5.15 
(dd, 3J(5,6) = 1.2, 4J(5,3) = 1.2, 1H, H(5)), 4.98 (s, 2H, H(1’)), 3.88 (m, 1H, H(6)), 3.82 (s, 
3H, H(6’)), 2.53-2.24 (m, 2H, H(8)), 1.60 (s, 9H, H(3’’)), 1.58-1.54 (m, 1H, H(7a)), 1.33-
1.29 (m, 1H, H(7b)). 
13C-NMR (100 MHz, CDCl3, 298 K) : isomer 1 : 173.7 (C(9)) ; 168.2 (C(2)) ; 159.6 
(C(5’)) ; 159.0 (C(1’’)) ; 149.5 and 147.9 (C(10) and (C(11)) ; 133.6 (C(14)) ; 131.3 
(C(15)) ; 130.5 (C(13)) ; 130.1 (C(AA’)) ; 129.3 (C(4)) ; 127.6 (C(2’)) ; 125.9 (C(3)) ; 
124.8 (C(12)) ; 113.9 (C(XX’)) ; 83.8 (C(2’’)) ; 70.4 (C(6)) ; 66.3 (C(1’)) ; 65.9 (C(5)) ; 55.2 
(C(6’)) ; 31.4 (C(8)) ; 28.0 (C(3’’)) ; 26.5 (C(7)). 
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13C-NMR (100 MHz, CDCl3, 298 K) : isomer 2 : 173.0 (C(9)) ; 167.6 (C(2)) ; 159.5 
(C(5’)) ; 157.7 (C(1’’)) ; 151.3 and 147.2 (C(10) and (C(11)) ; 133.9 (C(14)) ; 131.5 
(C(15)) ; 130.8 (C(13)) ; 129.9 (C(AA’)) ; 128.4 (C(4)) ; 127.9 (C(2’)) ; 125.5 (C(3)) ; 
125.1 (C(12)) ; 113.9 (C(XX’)) ; 85.5 (C(2’’)) ; 70.8 (C(6)) ; 69.1 (C(5)) ; 66.0 (C(1’)) ; 55.2 
(C(6’)) ; 30.6 (C(8)) ; 28.0 (C(3’’)) ; 26.7 (C(7)). 
HR-MS : [M + Na]+ calc. 549.1849; found 549.1842 
Synthesis of tert-butyl 2-(4-methoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-
dihydro-1H-pyrrole-1-carboxylate (22a) 
tert-Butyl 2-(4-methoxy-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (3.64 g, 8.7 mmol) is dissolved in dry CH2Cl2 (500 mL) under Ar 
with MS 4Å (3g). The suspension is cooled to 0 °C and PDC (6.31 g, 17.4 mmol) is 
added to the reaction mixture. After 6 h, the solution is filtered over a mixture of 
celite:silice:celite. The solvent is evaporeted under vacum and the crude product is 
purified by chromatography (CH2Cl2/Et2O 3:7) (76%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.13 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.2, 1H, 
H(12)), 7.68 (dt, 3J(14,13)= 3J(14,15) = 7.5, 4J(14,12) = 1.3, 1H, H(14)), 7.62 
(dxtripletoide, 3J(13,12) = 8.1, 3J(13,14) = 7.6, 4J(13,15) = 1.5, 1H, H(13)), 7.32 (dd, 
3J(15,14) = 7.5, 4J(15,13) = 1.4, 1H, H(15)), 6.18 (d, 4J(3,5) = 1.7, 1H, H(3)), 5.42 (d, 
4J(5,3) = 1.7, 1H, H(5)), 3.58 (s, 3H, H(1’)), 2.83 (dt, 2J(7a,7b) ≈ 19.1, 3J(7a,8) ≈ 6.4, 1H, 
H(7a)), 2.55 (ddd, 2J(7b,7a) ≈ 19.0, 3J(7b,8b) ≈ 7.0, 3J(7b,8a) ≈ 5.7, 1H, H(7b)), 2.41 and 
2.39 (ddx(AB system) (partially solved), 2J(8a,8b) ≈ 17.3, 3J(8a,7b) ≈ 5.7, 3J(8b,7a) ≈ 6.3, 
2H, H(8ab)), 1.53 (s, 9H, H(3’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 201.3 (C(6)) ; 172.2 (C(9)) ; 167.3 (C(2)) ; 153.8 
(C(1’’)) ; 148.6 and 147.2 (C(10) and (C(11)) ; 133.8 (C(14)) ; 131.2 (C(15)) ; 131.1 
(C(13)) ; 126.7 (C(4)) ; 125.8 (C(3)) ; 125.2 (C(12)) ; 84.7 (C(2’’)) ; 71.9 (C(5)) ; 51.8 
(C(1’)) ; 32.9 (C(7)) ; 27.9 (C(3’’)) ; 26.8 (C(8)). 
ESI-MS : [M + Na]+ = 440.9 
Synthesis of tert-butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-
dihydro-1H-pyrrole-1-carboxylate (22b) 
tert-Butyl 2-(4-ethoxy-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (0.22 g, 0.5 mmol) is dissolved in dry CH2Cl2 (60 mL) under Ar with 
MS 4Å (2g). The suspension is cooled to 0 °C and PDC (0.39 g, 1.0 mmol) is added to 
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the reaction. After 6 h, the solution is filtered over a mixture of celite:silice:celite. The 
solvent is evaporeted under vacum and the crude product is purified by chromatography 
(CH2Cl2/Et2O 3:7) (77%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.15 (dd, 3J(12,13) = 8.1, 4J(12,14) = 1.4, 1H, 
H(12)), 7.70 (dt, 3J(14,13)= 3J(14,15) = 7.5, 4J(14,12) = 1.4, 1H, H(14)), 7.63 
(dxtripletoide, 3J(13,12) = 8.0, 3J(13,14) = 7.6, 4J(13,15) = 1.5, 1H, H(13)), 7.34 (dd, 
3J(15,14) = 7.5, 4J(15,13) = 1.5, 1H, H(15)), 6.20 (d, 4J(3,5) = 1.7, 1H, H(3)), 5.44 (d, 
4J(5,3) = 1.7, 1H, H(5)), 4.05 (q, 3J(1’,2’) = 7.1, 2H, H(1’)), 2.84 (dt (partially solved), 
2J(7a,7b) ≈ 19.0, 1H, H(7a)), 2.55 (ddd, 2J(7b,7a) ≈ 19.0, 3J(7b,8b) ≈ 7.1, 3J(7b,8a) ≈ 5.7, 
1H, H(7b)), 2.41 and 2.40 (ddx(AB system) (partially solved), 2J(8a,8b) ≈ 17.2, 3J(8a,7b) 
≈ 5.7, 3J(8a,7a) ≈ 6.7, 3J(8b,7a) ≈ 6.2, 3J(8b,7b) ≈ 6.8, 2H, H(8a and b)), 1.55 (s, 9H, 
H(3’’)), 1.19 (t, 3J(2’,1’) = 7.2, 3H, H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 201.4 (C(6)) ; 171.8 (C(9)) ; 167.3 (C(2)) ; 153.8 
(C(1’’)) ; 148.7 and 147.2 (C(10) and (C(11)) ; 133.8 (C(14)) ; 131.3 (C(15)) ; 131.1 
(C(13)) ; 126.7 (C(4)) ; 125.8 (C(3)) ; 125.2 (C(12)) ; 84.7 (C(2’’)) ; 71.9 (C(5)) ; 60.7 
(C(1’)) ; 32.9 (C(7)) ; 27.9 (C(3’’)) ; 27.1 (C(8)) ; 14.1 (C(2’)). 
HR-MS : [M + Na]+ calc. 455.1430; found 455.1427. 
Synthesis of tert-butyl 2-(4-benzoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-
dihydro-1H-pyrrole-1-carboxylate (22c) 
tert-Butyl 2-(4-benzoxy-1-hydroxy-4-oxobutyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (0.30 g, 0.6 mmol) is dissolved in dry CH2Cl2 (70 mL) under Ar with 
MS 4Å (3g). The suspension is cooled to 0 °C and PDC (0.45 g, 1.2 mmol) is added to 
the reaction mixture. After 6 h, the solution is filtered over a mixture of celite:silice:celite. 
The solvent is evaporeted under vacuum and the crude product is purified by 
chromatography (Ether) (78%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.14 (dd, 3J(12,13) = 7.6, 4J(12,14) ≈ 1.8, 1H, H(12)), 
7.64 (dt, 3J(14,13)=3J(14,15) = 7.5, 4J(14,12) ≈ 1.6, 1H, H(14)), 7.60 (dt, 
3J(13,12)=3J(13,14) = 7.6, 4J(13,15) = 1.7, 1H, H(13)), 7.36-7.27 (m, 6H, H(15,Bn)), 6.20 
(d, 4J(3,5) = 1.7, 1H, H(3)), 5.46 (d, 4J(5,3) = 1.7, 1H, H(5)), 5.06 and 5.03 (2xd (AB 
system), 2J = 12.4, 2H, H(1’)), 2.87 (dt (partially solved), 2J(7a,7b) ≈ 18.8, 1H, H(7a)), 
2.57 (ddd (partially solved), 2J(7b,7a) ≈ 18.5, 1H, H(7b)), 2.50-2.46 (m, 2H, H(8)), 1.54 
(s, 9H, H(3’’)). 
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13C-NMR (100 MHz, CDCl3, 298 K) : 201.3 (C(6)) ; 171.7 (C(9)) ; 167.3 (C(2)) ; 153.9 
(C(1’’)) ; 148.7 and 147.2 (C(10) and (C(11)) ; 135.7 (C(2’)) ; 133.8 (C(14)) ; 131.3 
(C(15)) ; 131.1 (C(13)) ; 128.5 (C(3’)) ; 128.2 (C(5’)) ; 128.0 (C(4’)) ; 126.7 (C(4)) ; 125.8 
(C(3)) ; 125.2 (C(12)) ; 84.7 (C(2’’)) ; 71.9 (C(5)) ; 66.5 (C(1’)) ; 33.0 (C(7)) ; 27.9 
(C(3’’)) ; 27.1 (C(8)). 
HR-MS : [M + Na]+ calc. 517.1587; found 517.1577. 
 
Synthesis of 4-(1-(tert-butoxycarbonyl)-3-(2-nitrophenyl)-5-oxo.2,5-dihydro-1H-
pyrrol-2-yl)-4-oxobutanoic acid (24) 
 
Tert-Butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate (0.70 g, 1.6 mmol) is dissolved in MeOH (40 mL) and NaOH 50% (3 mL) is 
added. The solution becomes red and than dark brown. After 1 h, the aqueous phase is 
extracted once with Et2O, acidified with HCl 3.5N to pH ~ 1. The aqueous phase is 
extracted then 3 times with Et2O. The combined organic phases are dried over MgSO4 
and crude product is purified by chromatography (CH2Cl2/MeOH 95:5) (40%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.15 (dd, 3J(12,13) = 8.0, 4J(12,14) = 1.4, 1H, 
H(12)), 7.68 (dt, 3J(14,13)=3J(14,15) = 7.4, 4J(14,12) = 1.5, 1H, H(14)), 7.63 (ddd, 
3J(13,12) = 8.0, 3J(13,14) = 7.6, 4J(13,15) = 1.6, 1H, H(13)), 7.29 (dd, 3J(15,14) = 7.5, 
4J(15,13) = 1.6, 1H, H(15)), 6.22 (d, 4J(3,5) = 1.7, 1H, H(3)), 5.46 (d, 4J(5,3) = 1.7, 1H, 
H(5)), 1.55 (s, 9H, H(3’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 201.1 (C(6)) ; 177.1 (C(9)) ; 167.3 (C(2)) ; 153.9 
(C(1’)) ; 148.7 and 147.2 (C(10) and (C(11)) ; 133.9 (C(14)) ; 131.3 (C(15)) ; 131.3 
(C(13)) ; 126.5 (C(4)) ; 125.8 (C(3)) ; 125.3 (C(12)) ; 84.8 (C(2’)) ; 71.6 (C(5)) ; 32.7 
(C(7)) ; 27.9 (C(3’)) ; 26.7 (C(8)). 
ESI-MS : [M - H]- = 403.1 
 
Synthesis of tert-butyl 4-phenyl-2-(trifluoromethylsulfonyloxy)-1H-pyrrole-1-
carboxylate (25a) 
tert-Butyl 2-oxo-4-phenyl-2,5-dihydro-1H-pyrrole-1-carboxylate (0.10 g, 0.4 mmol) is 
dissolved in dry CH2Cl2 (15 mL) at RT. 2,6-Lutidine (0.09 mL, 0.8 mmol) is added to the 
solution followed by Tf2O (0.07 mL, 0.4 mmol). After 10 min. under stirring, the solution is 
washed with water and the aqueous phase is extracted with CH2Cl2. The combined 
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organic phases are dried over MgSO4 and concentrated. Purification of the residue by 
flash chromatography (silica gel, (i) EtOAc/hexane 1:4, (ii) CH2Cl2) (82%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.55 (m, 2H, H(7,11), 7.44 (m, 2H, H(8,10), 7.41 (d, 
4J(5,3) = 2.3, 1H, H(5)), 7.34 (m, 1H, H(9)), 6.43 (m, 4J(3,5) = 2.3, 6J(3,-F3) ≈ 0.8, 1H, 
H(3)), 1.72 (s, 9H, H(3’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 147.0 (C(1’)) ; 133.4 (C(6)) ; 132.8 (C(4)) ; 128.8 
(C(9)) ; 127.2 (C(2)) ; 125.3 (C(8,10)) ; 123.8 (C(7,11)) ; 118.7 (q, C(1’’)) ; 114.0 (C(5)) ; 
100.4 (C(3)) ; 86.5 (C(13)) ; 27.9 (C(14)). 
ESI-MS : [M + Na]+ = 413.9  
.Synthesis of tert-butyl 4-(2-nitrophenyl)-2-(trifluoromethylsulfonyloxy)-1H-pyrrole-
1-carboxylate (25b) 
tert-Butyl 4-(2-nitrophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (0.10 g, 0.3 
mmol) is dissolved in dry CH2Cl2 (15 mL) and the solution is cooled to 0 °C. 2,6-Lutidine 
(0.11 mL, 1.0 mmol) is added to the solution followed by Tf2O (0.07 mL, 0.4 mmol). After 
2 h, the temperature is allowed to reach the RT. The solution is quenched with sat. 
NaHCO3 (15 mL) and the aqueous phase is extracted with CH2Cl2. The combined 
organic phases are dried over MgSO4 and concentrated. Purification of the residue by 
flash chromatography (silica gel, CH2Cl2) (61%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 7.80 (dd, 3J(8,9) ≈ 8.2, 4J(8,10) ≈ 1.5, 1H, H(8)), 7.61 
(ddd (partially solved), 3J(10,9) and 3J(10,11) ≈ 7.1 and 7.6, 4J(10,8) ≈ 1.5, 1H, H(10)), 
7.47-7.43 (m (partially solved), 3J(9,10) ≈ 7.8, 4J(9,11) ≈ 1.5, 2H, H(9,11)), 7.23 (d, 
4J(5,3) = 2.3, 1H, H(5)), 6.12 (dq, 4J(3,5) = 2.3, 6J(3,CF3) = 0.8, 1H, H(3)), 1.64 (s, 9H, 
H(3’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 148.9 (C(1’)) ; 146.7 (C(7)) ; 133.1 (C(6)) ; 132.4 
(C(10)) ; 131.3 (C(11)) ; 128.5 (C(9)) ; 127.7 (C(4)) ; 124.1 (C(8)) ; 119.2 (C(2)) ; 118.7 
(q, 1J(C,F) = 321.5, CF3) ; 116.6 (C(5)) ; 102.9 (C(3)) ; 87.0 (C(2’)) ; 27.8 (C(3’)). 
19F-NMR (188 MHz, CDCl3, 298 K) : -72.3 (d, 6J(CF3,3) = 0.7, 3F, CF3). 
ESI-MS : [M + Na]+ = 458.7 
 Synthesis of tert-butyl 2-(4-methoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-
(trifluoromethyl sulfonyloxy)-1H-pyrrole-1-carboxylate (25c) 
tert-Butyl 2-(4-methoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate (0.11 g, 0.3 mmol) is dissolved into dry CH2Cl2 (15 mL) at RT. 2,6-Lutidine 
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(0.09 mL, 0.8 mmol) is added to the solution followed by Tf2O (0.07 mL, 0.4 mmol). After 
2 h under stirring, the solution is washed with water and the aqueous phase is extracted 
with CH2Cl2. The combined organic phases are dried over MgSO4 and concentrated. 
Purification of the residue by flash chromatography (silica gel, EtOAc/hexane 4:6) (21%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.06 (dd, 3J(12,13) = 8.0, 4J(12,14) = 1.2, 1H, 
H(12)), 7.69 (td, 3J(14,15)= 3J(14,13) = 7.5, 4J(14,12) = 1.4, 1H, H(14)), 7.61 (ddd, 
3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.6, 1H, H(13)), 7.48 (dd, 3J(15,14) = 7.5, 
4J(15,13) ≈ 1.5, 1H, H(15)), 5.03 (m (partially solved), 6J(3,CF3) ≈ 0.6, 1H, H(3)), 3.62 (s, 
3H, H(1’)), 2.64-2.60 (m, 2H, H(7)), 2,54-2.51 (m, 2H, H(8)), 1.64 (s, 9H, H(3’’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 190.0 (C(6)) ; 172.5 (C(9)) ; 149.0 (C(1’’)) ; 146.3 
(C(11)) ; 135.1 (C(10)) ; 133.0 (C(15)) ; 132.8 (C(14)) ; 129.9 (C(13)) ; 127.9 (C(4)) ; 
126.8 (C(5)) ; 124.6 (C(2)) ; 124.5 (C(12)) ; 120.7 (q, 1J(C,F) = 322.4, CF3) ; 101.9 
(C(3)) ; 88.2 (C(2’’)) ; 51.7 (C(1’)) ; 36.4 (C(7)) ; 27.8 (C(8)) ; 27.4 (C(3’’)). 
ESI-MS : [M + K]+ = 588.8, [M + Na]+ = 572.8 
Synthesis of tert-butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-
(trifluoromethyl sulfonyloxy)-1H-pyrrole-1-carboxylate (25d) 
tert-Butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate (1.52 g, 3.5 mmol) is dissolved into dry CH2Cl2 (80 mL) and the solution is 
cooled to   -10 °C. Et3N (0.71 mg, 7.04 mmol) is added to the solution followed by Tf2O 
(0.83 mL, 4.9 mmol). The reaction is followed by TLC until complete disappearing of the 
starting material. Then a saturated solution of NaHCO3 (40 mL) is added and the organic 
phase is washed with brine, dried over MgSO4 and concentrated. Purification of the 
residue by flash chromatography (silica gel, 40% EtOAc in hexane) affords the product 
as a slightly orange oil (71%). 
1H-NMR (400 MHz, CDCl3, 298 K) : 8.02 (ddd, 3J(12,13) = 8.1, 4J(12,14) = 1.4, 5J(12,15) 
= 0.3, 1H, H(12)), 7.65 (td, 3J(14,15)= 3J(14,13) = 7.5, 4J(14,12) = 1.4, 1H, H(14)), 7.57 
(ddd, 3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.6, 1H, H(13)), 7.43 (ddd, 3J(15,14) = 
7.5, 4J(15,13) = 1.6, 5J(15,12) = 0.3, 1H, H(15)), 5.99 (m (partially solved), 6J(3,CF3) ≈ 
0.7, 1H, H(3)), 4.02 (q, 3J(1’,2’) = 7.2, 2H, H(1’)), 2.58-2.54 (m, 2H, H(7)), 2,48-2.45 (m, 
2H, H(8)), 1.60 (s, 9H, H(3’’)), 1.16 (t, 3J(2’,1’) = 7.2, 3H, H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 190.0 (C(6)) ; 172.0 (C(9)) ; 148.9 (C(1’’)) ; 146.2 
(C(11)) ; 135.1 (C(10)) ; 133.0 (C(15)) ; 132.8 (C(14)) ; 129.9 (C(13)) ; 127.9 (C(4)) ; 
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126.7 (C(5)) ; 124.5 (C(2)) ; 124.5 (C(12)) ; 118.6 (q, 1J(C,F) = 321.1, CF3) ; 101.9 
(C(3)) ; 88.1 (C(2’’)) ; 60.5 (C(1’)) ; 36.3 (C(7)) ; 28.1 (C(8)) ; 27.3 (C(3’’)) ; 14.1 (C(2’)). 
ESI-MS : [M + Na]+ = 586.8 
Synthesis of ethyl 4-(3-(2-nitrophenyl)-1H-pyrrole-2-yl)-4-oxobutanoate (26) 
tert-Butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-1H-pyrrole-1-carboxylate (0.37 g, 
0.9 mmol) is dissolved in CH2Cl2 (10 mL) and TFA (2 mL) is added to the mixture at RT. 
After 20 min. the mixture is treated with a saturated solution of NaHCO3 (10 mL) and the 
organic phase is washed with brine, dried over MgSO4 and concentrated (88%).  
1H-NMR (400 MHz, CDCl3, 298 K) : 9.73 (s br, 1H, H(NH)), 7.95 (dd, 3J(12,13) = 8.1, 
4J(12,13) = 1.3, 1H, H(12)), 7.64 (dt, 3J(14,13)(14,15) = 7.5, 4J(14,12) = 1.4, 1H, H(14)), 
7.55 (dxtripletoide, 3J(13,12) = 8.1, 3J(13,14) = 7.5, 4J(13,15) = 1.6, 1H, H(13)), 7.50 (dd, 
3J(15,14) = 7.5, 4J(15,13) = 1.6, 1H, H(15)), 7.02 (tripletoide, 3J(2,NH) = 3.0, 3J(2,3) = 
2.6, 1H, H(2)), 6.20 (t, 3J(3,2)= 3J(3,NH) = 2.7, 1H, H(3)), 4.07 (q, 3J(1’,2’) = 7.1, 2H, 
H(1’)), 2.57-2.51 (m, 4H, H(7,8)), 1.20 (t, 3J(2’,1’) = 7.1, 3H, H(2’)). 
13C-NMR (100 MHz, CDCl3, 298 K) : 188.5 (C(6)) ; 172.7 (C(9)) ; 149.7 (C(11)) ; 132.8 
(C(15)) ; 132.3 (C(14)) ; 130.9 (C(10)) ; 128.9 (C(13)) ; 128.8 (C(5)) ; 125.8 (C(4)) ; 124.0 
(C(12)) ; 123.0 (C(2)) ; 112.8 (C(3)) ; 60.5 (C(1’)) ; 33.7 (C(7)) ; 28.0 (C(8)) ; 14.1 (C(2’)). 
HR-MS : [M + Na]+ calc. 339.0957; found 339.0952 
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4. X-Ray Analysis of Some Synthetic Intermediates 
 
During our studies towards the development of an efficient synthetic methodology of 
rhazinilam and rhazinilam analogues, the crossed Mukaiyama aldol reaction played a 
crucial role. This process has been widely used in synthesis and allows to create 
regioselectively carbon-carbon bonds. The importance of this process is increased by 
the fact that two asymmetric carbon centers are created. The relative configuration of the 
two newly formed asymmetric centers can often be controlled. Additional chiral centers 
in one of the two starting materials or chiral centers present in both starting materials 
exercice a high control over the newly formed centers. 
S
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Scheme 25: Stereodivergent route to both syn-aldol from the same chiral reagent[1] 
 
At several points in our synthetic endeavour we created aliphatic intermediates using a 
Mukaiyama type reaction containing two newly formed asymmetric centers. 
 
R
OSi(CH3)3
OH
R'
+
TiCl4
CH2Cl2
∗R
O OH
R'
∗
 
 
Scheme 26: Mukaiyama type reaction 
 
The diastereoselectivity of this process was of no importance for the continuation of our 
synthetic plan because we intended to transform the asymmetric centers in later states 
of the synthesis into sp2 hybridized carbon atoms. In view of the lack of direct impact on 
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the continuation of our synthetic plans, the determination of the diastereoselectivity of 
these processes has not been discussed extensively before. 
Another problem in this context is that despite the accumulation of a huge body of 
experimental data on the diastereoselectivity, extrapolation from the known to the 
unknown is often very difficult. Finally the attribution of the relative configuration of such 
compounds is not easy. Traditional NMR analysis often does not allow to attribute the 
relative configuration of the obtained diastereoisomers unequivocally. The coupling 
constants, which are usually the best experimental parameter to assign the dihedral 
angles between adjacent substituents on a carbon chain, depend often crucially on the 
solvent used, the sort and strength of the intra- versus intermolecular hydrogen bonds 
and sometimes also on the character of the other subtituents present. In view of this 
difficulty, we decided to determine the relative configuration of the series of compounds 
obtained during our synthetic studies with the help of X-ray diffraction studies on the 
crystals obtained from the reaction seen in the first publication in Acta Crystallographica. 
The result of the X-ray analysis confirms that the Mukaiyama type process using an 
unsubstituted aldehyde as electrophile gives the anti product as expected. Changing the 
electrophile to the chloro-acetaldehyde induces a switch of the diastereoselectivity to the 
syn product. 
 
(S) (S)
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S
O  
OSi(CH3)3
OH
Cl
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TiCl4
CH2Cl2
(S) (S)
S
O OH
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Scheme 27: The relative configuration of the Mukaiyama reaction products 
 
In our second generation approach to the phenyl-pyrrole intermediates we encountered 
a major difficulty to induce seemingly simple reactions after the formation of the γ-lactam 
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ring. The difficulty to bring these intermediates to react is probably to do with the lack of 
solubility of our intermediates. 
 
O
N3
NO2
O
OSi(CH3)3
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CH2Cl2
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HO
O O
PPh3 / THF/1% H2O NO2
HN
HO
O
11b10e  
 
Scheme 28: Synthesis of lactam (unsoluble) 
 
The structure determination of the compounds 11a and 11b (Full Paper) showed that the 
molecules formed highly ordered networks of intermolecular hydrogen bonds. The 
individual molecule of nitro compound 11b in the crystal is connected with hydrogen 
bonds to all surrounding molecules and is therefore firmly held in place. We interpreted 
this arrangement as the major factor limiting the solubility of these compounds and 
obstructing the reactivity of these molecules.  
 
The precursors of the lactam, the aldol products 10c,e are crystalline as well, but they 
are considerably more soluble. We therefore decided to determine the X-ray solid state 
structure of one of these compounds, molecule 10e in order to have a point of 
comparison. The major observation is, that the aldol product 10e shows only an 
intramolecular hydrogen bond, fixing the conformation of the chain between the tertiary 
alcohol function and the ester, whereas the lactams showed exclusively intermolecular 
hydrogen bonds. The intramolecular hydrogen bond of the aldol product forms a six 
membered ring between the alcohol hydrogen and the ester oxygen in an arrangement 
which corresponds to a boat-like conformation. These observations are compatible with 
the differences in solubility observed, even if the strength of the involved hydrogen 
bonds can not be quantified. 
One of the methods we have studied to introduce the side chain needed for the 
formation of the B-ring was the nucleophilic addition of activated equivalent of 2-
hydroxypyrroles 19a,b (Full Papers) to aldehydes. This type of reaction has been 
systematically studied by the group of Rassu. 
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Scheme 29: Diastereoselectivity in Rassu’s strategy towards carbasugars[2] 
 
This reaction is nothing else than the condensation of a deprotonated pyrrolinone with 
an aldehyde creating two new asymmetric centers, one α to the nitrogen and one at the 
exocyclic carbon. The group of Rassu has used these compounds for a series of elegant 
synthesis of natural products. To the best of our knowledge no reports have appeared 
where the 2-silyloxypyrrole was substituted by a phenyl ring. The phenyl ring in our 
compounds is positioned next to the newly formed chiral center. We thereby can not 
exclude an interaction of this bystanding substituend on the reaction process. The 
reports in the literature indicate also that the diastereoselectivity depends highly on the 
reaction conditions used, especially the Lewis acid added to induce the aldol type 
reaction can exercice a big influence on the diastereoselectivity. It is therefore not 
evident if we can extrapolate the synthetic and mechanistic results reported in the 
literature so far for this process. 
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4.1. Rac-(2R*,3R*)-S-ethyl 4-chloro-3-hydroxy-2-phenylbuthanethioate and Rac-
(2R*,3R*)-S-ethyl 2-phenyl-3-(tosyloxy)buthanethioate: The dichotomy of the 
stereoselectivity of the Mukaiyama reaction 
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4.2. 4-Azido-3-hydroxy-3-(2-nitro-phenyl)-butyric acid methyl ester 
 
 
  108
 
 
 
  109
 
 
 
  110
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  111
 
  112
 
 
 
 
 
  113
 
 
 
  114
 
 
 
  115
 
 
  116
 
 
  117
 
 
  118
 
 
 
  119
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  120
 
 
 
 
 
 
 
 
 
4.3. 5-Hydroxyalkyl Derivatives of tert-Butyl 2-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate 
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5. Conclusions 
 
(-)-Rhazinilam (1) is a natural product which interfers in the tubulin-microtubule 
equilibrium. It shows significant in vitro cytotoxicity, but, unfortunately, no activity in vivo. 
Due to this reason and to its intriguing molecular structure, this molecule raised the 
interest in several synthetic groups in the last ten years: a number of synthetic 
approaches to the natural product and analogues have been reported.  
 
In the absence of structural data regarding the active binding-site, the only way to 
improve our understanding is the testing of as many structural variants as possible. The 
goal of this approach is to identify more active structural analogues of rhazinilam. The 
discrepancy between in vitro and in vivo activity is not understood so far and new 
structural variants have the potential to solve this problem. 
 
Our group has developed a new strategy for the synthesis of rhazinilam analogues 
based on our methodology developed for the synthesis of highly sensitive unstabilized 
pyrroles. The key step is Mukaiyama reaction, which leads after condensation of the 
ester with the azido group followed by dehydration to the 1H-pyrrole-2(5H)-one 16a,b. In 
our synthetic strategy, the deprotected pyrrole-one as in 16a,b will replace the pyrrole C-
ring from rhazinilam, hopefully protecting this sensitive element from degradation. At the 
same time these derivatives can be used to create new analogues and to modify the 
structure of the natural product.  
 
 In the context of our synthetic studies we determined the relative configuration of the 
aldol products obtained, because the structure determination based on NMR analysis 
alone was not possible. The diastereoselectivity observed showed an interesting 
dichotomy as a function of the substituents in the α-position of the aldehyde. This 
dichotomy is compatible with the mechanistic picture of the Cornforth transition state 
model and the polar Felkin-Anh model.  
 
The X-ray analysis of the lactams and one of their precursors showed that the nicely 
soluble precursor forms intramolecular hydrogen bonds exclusively, whereas the purely 
insoluble lactams show a maximum number of intermolecular hydrogen bonds. We 
correlated this observation tentatively with the huge differences in solubility. 
  152
 
Having this key intermediate 16b in hand, the important challenges were to find good 
and efficient methodologies to introduce the B-ring and the D-ring as we had the A,B-
system firmly put in place. An important part of our efforts was dedicated to study 
independent methods for either the introduction of ring B or ring D. The goal of these 
studies was to find out, the best methods and to have in hands empirical data to make a 
decision on the best sequence for the introduction of the two missing rings. 
 
NO2
N
OTBDMSBoc
H
O
+
NO2
N
OBoc
HO
BF3.OEt
CH2Cl2/-78°C
O
O
O
O H
H
nine-membered lactam B-ring
N
OTBDMSBoc
H
O
+
N
OBoc
HO
BF3.OEt
CH2Cl2/-78°C
Br Br
H
H
six-membered D-ring
 
 
Scheme 30: Studies towards B- respectively D-ring  
 
The most advanced studies were pursuing the goal to introduce the side chain needed 
for the creation of the B-ring. A second aldol type Mukaiyama reaction allowed to 
introduce different side chains to the C-5 on the 1H-pyrrole-2(5H)-one (the 3rd publication 
in Acta Crystallographica). The diastereoselectivity of aldol products obtained during our 
studies could be ascertained based on the X-Ray structures of the crystalline 
compounds. We could show that for two of the compounds the diastereoselectivity is 
compatible with the results reported in the literature despite the fact that a phenyl 
substituent is present in the α-position to one of the newly formed chiral centers. 
However the third structure determined in this study showed an inversion of the 
diastereoslectivity. We have not been able to explain this switch of the 
diastereoselectivity. 
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N
OBoc
O
EtO
O
77%5 5
 
 
Scheme 31: Synthetic pathway to the formation of lactam B-ring 
 
In conclusion, we have been able to obtain advanced intermediates for the synthesis of 
rhazinilam and analogues of rhazinilam. Our efforts to synthesize the D-ring have not yet 
allowed us to develop a reliable methodology. For the synthesis of the B-ring we could 
introduce all the carbon atoms needed. To transform this intermediate into a simplified 
version of rhazinilam would require the reduction of the nitro group followed by lactam 
formation. These two processes have been accomplished in earlier syntheses. 
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6. Perspectives 
 
Because of the acidity of the proton in C-5, we have faced a lot of difficulties in building 
the D-ring of rhazinilam (six-membereed ring). Based on these observations our new 
strategy is N-acylation of 1H-pyrrole-2(5H)-one followed by Wittig and Michael reactions. 
Based on literature precedence the last steps will be the reduction of the nitro group and 
cyclisation of the nine-membered ring (Scheme 32).  
 
NO2
N
OBoc
TFA
75%
NO2
HN
O
NO2
N
O
O
TBSO
O
O
O
F
F
F
F
F
1)
BuLi / THF
2) TBAF / THF
3) Swern oxid.
NO2
N
O
O
O
O
EtO
Wittig rc.
NO2
N
O
O
O
O
EtO
Michael rc.
HN
N
O
O
O
O 1) reduction
2) cyclisation
  
 
Scheme 32: The presumed last steps in synthesis of rhazinilam analogue  
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7. Experimental Section 
7.1. General remarks 
 
Chromatography 
 
Thin layer chromatography 
 
Thin layer chromatography (TLC) was carried out in TLC plates made out of silica gel 60 
F254 (fluorescence indicator). The TLC plates are of 10 cm length and 0.2 mm thickness. 
After the elution in the eluent mentioned,  the plates were dried, looked under UV lamp 
(254 nm), marked and then looked for oxidized spots by spraying. 
 
Column chromatography 
 
Silica gel 60 Å, size of 0.04-0.063 mm (230-400 mesh ASTM) ( Merck, Darmstadt). 
Eluent proportions are mentioned in the experimental part. 
 
Gas chromatography 
 
Agilent 6850 Series chromatography. Column used was HP-5 capillary column: long 30 
m, interior diameter = 0.32 mm, film thickness = 0.25 μm. Nature of polymer: 
polysiloxane (crosslinked 5% Ph, Me silixane). Programme: injection at 150 °C or 170 
°C, 2 min, 10 °C/min till 290 °C. Helium gas: 1.0 mL/min. Injection temp.: 250 °C Detecto 
temp. (FID): 300 °C; ChemStation Programme. 
 
Infrared Spectroscopy (IR) 
 
Perkin Elmer Spectrum One version B FT-IR was used for obtained IR spectras with the 
resolution of 2 cm-1. Software used: Spectrum version 5.0.1. The solid substances and 
thick oil like substances were analyzed by preparing KBr pellets (KBr – Fluka puriss 
p.a.).Liquid samples were analyzed as film (sandwich) by applying between two KBr salt 
plates. The absorption bands between 4000 and 400 cm-1 were measured. The intensity 
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of the spectrum was divided into five equal parts for the abbreviations vs (very strong – 
the maximum intensity), s (strong), m (medium), w (weak), vw (very weak) and br 
(broad).  
 
Nuclear Magnetic Spectroscopy (NMR) 
 
The NMR spectras were measured using spectrometer Gemini XL-200 of Varian at 298 
K where 1H was measured at frequency of 200 MHz and 13C was measured at frequency 
of 50 MHz. Also NMR spectras were measured using spectrometer Bruker Avance-400 
at 298 K where 1H was measured at frequency of 400 MHz and 13C was measured at 
frequency of 100 MHz. The NMR solvents were purchased from Cambridge Isotope 
Laboratories. The internal standards for the spectras of 1H: TMS (d = 0.00 ppm) or 
CHCl3 (d = 7.26 ppm) or CH3OH (d = 3.31 ppm) or (CH3)2SO (d = 2.50 ppm) or H2O (d = 
4.79). The internal standards for the spectras 13C: TMS (d = 0.00 ppm) or CHCl3 (d = 
77.00 ppm) or CH3OH (d = 49.00 ppm) or (CH3)2SO (d = 39.52 ppm). The 13C spectras 
were measured by decoupling from 1H. The chemical shift is given in ppm in the 
decreasing order and the coupling constant J in Hz. The multiplicity of signals were given 
abbreviations s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), dt (doublet of 
triplet), br (broad) and m (multiplet). The sign “≈” denotes for the average value of J 
varying from 0.2 to 0.4 Hz. The ratio of α to β is measured by area integration in the 
case of 1H and by the intensity (height) of peak in the case of 13C.  
 
Mass Spectrometry 
 
The mass spectra measurements for ESI (electro-spray ionization) and for APCI 
(atmospheric pressure chemical ionization) were carried out by an instrument 
ThermoFinnigan LCQ (San Jose, California, USA). Software used: Tune Plus version 
1.2. The values given here are average mass of ion with precision in the range of ±0.1 
values. The nature of ion pattern is written in parenthesis with intensity. The ion peaks 
due to deuterium isotope (probably comes from proton exchange by deuterium as some 
samples were dissolved in deuteriated solvents) were not considered. The mass 
corresponding to the highest abundant isotope is written. 
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The high resolution mass spectrometry (HR-MS) was measured at University of Fribourg 
(Switzerland) in the group of Professor Gossauer by Mr. F. Nydegger. The instrument 
used was Brucker BioAPEX II daltonics. The ionization used was ESI (electro-spray 
ionization). 
 
Glass Apparatus 
 
For reactions where Ar or N2 was used, the glass apparatus were dried by keeping in the 
hot oven at 150 °C for at least 2 h. The apparatus were removed from hot oven and 
cooled to ambient temperature with Ar or N2 atmosphere. For rections at low 
temperature, ice bath with salt (0 °C to -5 °C) and aacetone/liquid nitrogen bath were 
used. For reactions of long maintenance hours (2 days) at low temperature, cryostat was 
used. For heating reactions, PEG bath was used. 
 
Karl-Fischer Titration 
 
For reactions where the moisture content is very critical such as Mukaiyama reaction, 
the purified solvents, reactants and reagents if possible were checked for moisture 
content using the Karl-Fischer coulometer (Metler Toledo DL 32). For the moisture 
critical reactions, reactants and solvents were dried till the moisture content is less than 
0.05% and then only reactions were carried out. 
 
Hydrogenation 
 
The hydrogenation reactions were carried out at room temperature under magnetic 
stirring with hydrogen filled “gas bag” (Aldrich) whose volume is approximately 1 gallon 
(3.8 L). 
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Solvents 
For the purpose of chromatography and extractions, technical grade solvents were 
distilled over drying agents: 
 
Solvent 
Ethyl acetate 
Hexane 
Dichloromethane 
Diethyl ether 
Methanol 
Chloroform 
Abbreviation used 
EtOAc 
hexane 
CH2Cl2 
Et2O 
MeOH 
CHCl3 
Drying agent 
K2CO3 
CaCl2 
CaCl2 
CaCl2 
CaO 
CaCl2 
 
Solvents for reactions – with distillation 
 
Solvent Abbreviation used Drying agent 
Pentane Pentane P2O5 
Dichloromethane CH2Cl2 P2O5 
Diethyl ether Et2O LiAlH4 
Tetrahydrofurane THF potasium/benzophenone 
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7.2. Syntheses 
Synthesis of ethyl 4-(3-(2-nitrophenyl)-5-oxo-4,5-dihydro-1H-pyrrole-2-yl)-4-
oxobutanoate 
 
NO2
N
OBoc
O
EtO2C
NO2
HN
O
O
EtO2C
TFA
CH2Cl2 / -40 °C / 30 min.
 
 
432.43 332.32 
 
tert-Butyl 2-(4-ethoxy-4-oxobutanoyl)-3-(2-nitrophenyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate (0.11 g, 0.3 mmol) is dissolved in CH2Cl2 (2 mL) and the temperature is 
brought to -40 °C. Triflouroacetic acid (TFA) (0.02 mL, 0.25 mmol) is added to the 
reaction. The mixture is kept under stirring to -40 °C for 30 min. The solution is 
quenched with sat. NaHCO3, the aqueous layers are extracted with CH2Cl2 and the 
solvent is concentrated under vacuum. The crude oil is purified by chromatography 
(CH2Cl2/Et2O 3:7) (75%). 
HN
OH
O
O
O
NO2
1
2
3
4
5
6
7
8
9
10
11
1213
1415
1617
 
 
1H-NMR: 8.25(s, 1H, NH); 8.20(dd, 3J(8,9)=8.2, 4J(8,10)=1.2, 1H, H(8)); 7.75(ddd, 
3J(10,11)=3J(10,9)=7.5, 4J(10,8)=1.2, 1H, H(10)); 7.64(ddd, 3J(9,8)=8.3, 3J(9,10)=7.4, 
4J(9,11)=1.4, 1H, H(9)); 7.49(dd, 3J(11,10)=7.6, 4J(11,9)=1.4, 1H, H(11)); 4.06(q, 
3J(16,17)=7.1, 2H, H(16)); 3.62(s, 2H, H(3)); 2,46(tripletoid, 3J(13a, 14a)=6.0, 3J(13b, 
14b)=6.6,  2H, H(13)); 2.31(tripletoid, 3J(14b, 13b)=6.6, 3J(14a, 13a)=6.0, 2H, H(19)); 
1.19(t, 3J(17,16)=7.1, 3H, H(17)); 
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13C-NMR: 189.8(C(12)); 174.6(C(15)); 172.1(C(2)); 148.1(C(7)); 136.3(C(6)); 
134.2(C(10)); 131.8(C(11)); 130.5(C(9)); 129.5(C(5)); 125.5(C(8)); 124.5(C(4)); 
60.9(C(16)); 45.0(C(3)); 34.7(C(14)); 27.7(C(13)); 14.2(C(17)). 
 
IR: 3132(s); 2927(w); 1729(m); 1602(m); 1574(w); 1525(s); 1401(vs); 1347(m). 
 
MS-ESI: 331.3[M-H]- 
 
Synthesis of ethyl 4-(7-(2-nitrophenyl)-3,4-dihydro-2H-pyrrolo[2,1-
b][1,3]oxazin-6-yl)-4-oxobutanoate 
 
NO2
HN
O
O
EtO2C
NO2
N
O
EtO2C
O
I I
NaH
DMF / 0 °C / 2h
 
332.32 372.13 
 
Ethyl 4-(3-(2-nitrophenyl)-5-oxo-4,5-dihydro-1H-pyrrole-2-yl)-4-oxobutanoate (0.23 g, 
0.69 mmol) is dissolved in DMF (20 mL) and the temperature is brought to 0 °C. NaH 
(0.02 g, 0.83 mmol) is added to the reaction and resulted mixture is kept under stirring 
for 15 min. 1,3-diiodopropan (0.20 mL, 1.7 mmol) is added dropwise to the solution. After 
2 h, the reaction is diluted with Et2O (150 mL) and washed with H2O and sat. NaHCO3. 
After extraction, the organic solvent is concentrated under vacuum. The crude product is 
purified by chromatography (Et2O) (60%).  
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N
O
O
O
O
NO2
1 2
3
4
5
6
7
8
9
10
11
1213
1415
1617
18
19 20  
 
1H-NMR: 7.93(dd, 3J(8,9)=8.0, 4J(8,10)=1.3, 1H, H(8)); 7.63(ddd, 3J(10,11)=3J(10,9)=7.5, 
4J(10,8)=1.3, 1H, H(10)); 7.54(ddd, 3J(9,8)=8.0, 3J(9,10)=7.5, 4J(9,11)=1.5, 1H, H(9)); 
7.47(dd, 3J(11,10)=7.5, 4J(11,9)=1.5, 1H, H(11)); 5.38(s, 1H, H(3)); 4.45(t, 3J(18,19)=6.0, 
2H, H(18)); 4.31(m, 2H, H(20)); 4.06(q, 3J(16,17)=7.1, 2H, H(16)); 2,54-2.31(m, 4H, 
H(13,14)); 2.19(m, 2H, H(19)); 1.20(t, 3J(17,16)=7.1, 3H, H(17)); 
 
13C-NMR: 187.1(C(12)); 173.4(C(15)); 149.8(C(2)); 149.0(C(7)); 133.0(C(11)); 
132.6(C(9)); 132.4(C(6)); 129.3(C(5)); 129.2(C(10)); 124.3(C(8)); 121.5(C(4)); 
93.7(C(3)); 65.6(C(20)); 60.7(C(16)); 44.2(C(18)); 34.8(C(14)); 28.8(C(13)); 22,3(C(19)); 
14.5(C(17)). 
 
IR: 3125(s); 3006(w); 2929(w); 1733(m); 1621(m); 1560(w); 1502(m); 1401(vs). 
 
MS-ESI: 373.1[M+H]+ 
 
Synthesis of tert-butyl 4-(2-aminophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate 
 
 
NO2
N
OBoc
NH2
N
OBoc
H2 / Pt/C
H3PO2 / VO3NH4
toluen / RT / 1h
 
 
304.10 274.13 
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Catalyst pre-treatment: Pt/C 5% (250 mg) and H2O (5 mL) are mixed in a test tube and 
an aqueous solution of H3PO2 5% (200 mg) is added. The resulting mixture is stirred for 
15 min. VO3NH4 (7.5 mg) is added and the reaction is stirred for 15 min. more. 
 
tert-Butyl 4-(2-aminophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (2.50 g, 8.2 
mmol) is dissolved in toluene (50 mL). The pre-treated catalyst is added to the solution. 
A “gas bag” with hydrogen is added to the installation (the air from flask is replaced by 
hydrogen). The mixture is kept under stirring at RT for 1 h. The solution is washed with 
H2O (100 mL), the aqueous layers are extracted with Et2O and the solvent is removed 
under reduced pressure for obtaining a yellow solid (93%). 
NH2
N
O
O
O
1 2
3
4
5
6
7
8
9
10
11
12
13
14
 
 
1H-NMR: 7.22(dd, 3J(11,10)=7.9, 4J(11,9)=1.3, 1H, H(11)) ; 7.12(m(partial solved), 
3J(9,8)=7.6, 4J(9,11)=1.4, 1H, H(9)); 6.80(dd, 3J(8,9)=7.7, 4J(8,10)=0.9, 1H, H(8)); 
6.61(m(partial solved), 3J(10,9)=7.5, 4J(10,8)=1.0), 1H, H(10)); 6,36(s, 1H, H(3)); 5,47(s, 
2H, NH2); 4.70(d, 4J(5,3)=1.1, 2H, H(5)); 1.48(s, 9H, H(14)). 
 
13C-NMR: 169.5 (C(2)) ; 155.7 (C(12)) ; 149.5 (C(4)) ; 148.2 (C(7)) ; 131.6 (C(9)) ;  128.6 
(C(11) ; 119.9 (C(3)) ; 117.4 (C(8)) ; 116.9 (C(10)) ; 115.7 (C(6)) ; 81.8(C(13)) ; 52.7 
(C(5)) ; 28.2 (C(14)).  
 
IR: 3458(w), 3344(m), 3223(w), 3074(vw), 3014(vw), 2984(w), 2930(w), 2854(w), 
2588(vw), 2422(vw), 1712(vs), 1637(s), 1608(s),  1589(m), 1561(s), 1499(m), 1360(vs), 
1330(vs), 1251(s), 1202(m), 1165(s), 1153(s), 1101(vs), 750(m), 740(m).  
 
HR-MS: calc. 297.1209; found 297.1199 
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Synthesis of 1H-pyrrole-2(5H)-one 
 
H
N
H
N OH2O2 / BaCO3
H2O / reflux / 4h  
 
67.09 83.09 
Pyrrole (5.00 g, 74.5 mmol) in dissolved in H2O (450 mL). H2O2 35% (6.18 mL, 74.5 
mmol) and BaCO3 (1.50 g, 7.6 mmol) is added to the reaction. The resulting mixture is 
kept under reflux for 4 h. The excess of oxidant is removed with small quantity of PbO2. 
The solution is filtered and the water is removed under reduced pressure. The crude oil 
is treated with dioxin till a precipitated is formed. It is filtered and the resulted oil is 
concentrated under vacuum. Purification under bulb-to-bulb distillation (T=100-130 °C, 
P=0.5 mmHg) to obtain a light yellow oil (29%). 
  
N
H
O
1
2
34
5
 
 
1H-NMR: 6.91(dq, 3J(3,4)=5.6, 4J(3,5)=4J(3,1)=1.7, 1H, H(3)); 5.85(d×quadrupletoid, 
3J(4,3)=5.6, 3J(4,5)≈4J(4,1)≈1.9, 1H, H(4)); 3.78(quadrupletoid, 3J(5,1)≈3J(5,4)≈4J(5,3) 
≈1.8, 2H, H(5)). 
 
13C-NMR: 175.9(C(2)); 146.5(C(3)); 127.6(C(4)); 49.3(C(5)). 
 
IR: 3271(m); 1672(vs)). 
 
MS-ESI: 84.1[M+H]+ 
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Synthesis of 4-ethoxy-4-oxobutanoic acid 
 
O
OH
O
O
O
O O EtOH
reflux, 1h
 
100.01 146.05 
Dihydrofuran-2,5-dione (5.00 g, 50.0 mmol) is dissolved in EtOH (3.50 mL, 60.7 mmol). 
The reaction is kept 1 h under reflux. The excess of ethanol is removed under vacuum 
and the product is directly used for the next step. 
HO
O
O
O
1 2 3 4 5
6
 
1H-NMR: 12.1(br, 1H, COOH); 4.3(q, 3J(5,6)=7.1, 2H, H(5)); 2.50-2.42(m, 4H, H(2,3)); 
1.15(t, 3J(6,5)=7.1, 3H, H(6)). 
13C-NMR: 173.8(C(1)); 172.5(C(4)); 60.4(C(5)); 29.1(C(3)); 29.1(C(2)); 14.4(C(6)). 
 
Synthesis of ethyl perflourophenyl succinate 
 
O
OH
O F
F
F
F
F
OH
DCC
O
O
O
F
F
F
F
F
OO
 
146.14 312.18 
4-ethoxy-4-oxobutanoic acid (1.37 g, 9.4 mmol) in CH2Cl2 (40 mL) is charged in a dry 
flusk under Ar atmosphere and cooled to 0 °C. Pentaflourophenol (1.89 g, 10.3 mmol) is 
added followed by DCC (2.16 g, 10.5 mmol). The reaction is brought to RT and kept 
fixed overnight. The reaction mass is then filtered over celite bed to get rid off DCC, 
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concentrated under vacuum and the crude product is purified by chromatography 
(hexane/CH2Cl2 3:1) (69%). 
O
O
O
O
F
F
F
F
F
123456
 
1H-NMR: 4.16(q, 3J(5,6)=7.1, 2H, H(5)); 2.97(tripletoid, 3J(2,3)≈7.1, 2H, H(2)); 
2.73(tripletoid, 3J(3,2)≈7.0, 2H, H(3)); 1.25(t, 3J(6,5)=7.1, 3H, H(6)). 
13C-NMR: 171.2(C(4)); 168.4(C(1)); 142.4-142.2(m, CArF); 140.9-140.5(m, CArF); 139.9-
139.7(m, CArF); 139.2-138.9(m, CArF); 138.3-138.1(m, CArF); 136.7-136.4(m, CArF); 
61.0(C(5)); 28.8(C(3)); 28.3(C(2)); 13.9(C(6)). 
 
Synthesis of 4-oxo-4-(2-oxo-2,5-dihydro-1H-pyrrole-1-yl)butanoate 
 
NH
O
O
O
O
F
F
F
F
F
+
BuLi
THF
0 °C then RT
N
O O
O
O
O
 
83.09                            312.18                                                                     211.21 
 
1H-pyrrole 2(5H)-one (0.43 g, 5.2 mmol) in THF (80 mL) is cooled to 0 °C under Ar. BuLi 
1.6M in hexane (3.61 mL, 5.8 mmol) is added slowly to the reaction. After 80 min. at 0 
°C, a solution of ethyl perfluorophenyl succinate (1.84 g, 5.9 mmol) in THF (30 mL) is 
added. The reaction is kept under stirring at 0 °C for 30 min. more, then the temperature 
is raided to RT and kept fixed for 2.5 h. The mixture is washed with sat. NH4Cl (20 mL), 
the organic layers are extracted with CHCl3 (3 times) and the solvent is evaporated 
under vacuum. The crude product is purified by chromatography (CH2Cl2) (66%). 
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N
O
O
O
O
12
3
4
5
6 7 8 9 10
11
 
 
1H-NMR: 7.27(dt, 3J(3,4)=6.0, 4J(3,5)=2.0 1H, H(3)); 6.13(dt, 3J(4,3)=6.1, 3J(4,5)=1.9, 
1H, H(4)); 4.37(dd, 3J(5,4)=4J(5,3)=2.0, 2H, H(5)); 4.12(q, 3J(10,11)=7.1, 2H, H(10)); 
3.24(t, 3J(7,8)=6.6, 2H, H(7)); 2.65(t, 3J(8,7)=6.6, 2H, H(8)); 1.22(t, 3J(11,10)=7.1, 3H, 
H(11)). 
 
13C-NMR: 172.6(C(9)); 171.7(C(6)); 170.0(C(2)); 127.5(C(4)); 60.6(C(10)); 50.5(C(5)); 
31.5(C(7)); 28.2(C(8)); 14.1(C(11)).  
 
HR-MS: calc. 234.0736; found 234.0731. 
 
Synthesis of perfluorophenyl 4-bromobutanoate 
 
Br
OH
O F
F
F
F
F
OH
DCC
Br
O
O
F
F
F
F
F
 
167.0 333.05 
4-bromobutanoic acid (1.67 g, 10.0 mmol) in CH2Cl2 (40 mL) is charged in a dry flusk 
under Ar atmosphere and cooled to 0 °C. Pentaflourophenol (2.02 g, 11.0 mmol) is 
added followed by DCC (2.31 g, 11.2 mmol). The reaction is brought to RT and kept 
fixed overnight. The reaction mass is then filtered over celite bed to get rid off DCC, 
concentrated under vacuum and the crude product is purified by chromatography 
(hexane/CH2Cl2 3:1) (90%). 
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F
F
F
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F
1
2
3
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1H-NMR: 3.53(t, 3J(4,3)=6.3, 2H, H(4)); 2.90(t, 3J(2,3)=7.1, 2H, H(2)); 2.32(tt, 3J(3,2)=7.0, 
3J(3,4)=6.5, 2H, H(3)). 
13C-NMR: 168.4(C(1)); 142.4-142.2(m, CArF); 140.9-140.6(m, CArF); 139.9-139.7(m, 
CArF); 139.2-139.0(m, CArF); 138.4-138.1(m, CArF); 136.8-136.4(m, CArF); 31.6(C(4)); 
31.5(C(2)); 27.3(C(3)). 
 
Synthesis of 1-(4-bromobutanoyl)-1H-pyrrole-2(5H)-one 
 
NH
O
Br
O
O
F
F
F
F
F
+
BuLi
THF
0 °C then RT
N
O O
Br
 
        83.09                         331.04                                                           232.07 
 
1H-pyrrole 2(5H)-one (0.60 g, 7.2 mmol) in THF (100 mL) is cooled to 0 °C under Ar. 
BuLi 1.6M in hexane (5.00 mL, 8.0 mmol) is added slowly to the reaction. After 80 min. 
at 0 °C, a solution of perfluorophenyl 4-bromobutanoate (2.73 g, 8.2 mmol) in THF (40 
mL). The reaction is kept under stirring at 0 °C for 30 min. more, then the temperature is 
raided to RT and kept fixed for 2.5 h. The mixture is washed with sat. NH4Cl (20 mL), the 
organic layers are extracted with CHCl3 (3 times) and the solvent is evaporated under 
vacuum. The crude product is purified by chromatography (CH2Cl2) (82%). 
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1H-NMR: 7.30(dt, 3J(3,4)=6.1, 4J(3,5)=2.0, 1H, H(3)); 6.12(dt, 3J(4,3)=6.1, 4J(4,5)=1.9, 
1H, H(4)) ; 4.36(dd, 3J(5,4)=4J(5,3)=2.0, 2H, H(5)) ; 3.45(t, 3J(9,8)=6.6, 2H, H(9)) ; 3.07(t, 
3J(7,8)=7.0, 2H, H(7)) ; 2.18(tt, 3J(8,7)≈4J(8,9)=6.8, 2H, H(8)). 
 
13C-NMR: 171.9(C(6)) ; 170.0(C(2)) ; 147.0(C(3)) ; 127.4(C(4)) ; 50.6(C(5)) ; 34.7(C(7)) ; 
32.9(C(9)) ; 27.0(C(8)). 
 
IR: 3363(w), 3102(w), 2924(w), 2687(vw), 1727(vs), 1693(vs), 1598(w), 1534(m), 
1517(s), 1441(m), 1384(s), 1349(s), 1335(vs), 1286(m), 1241(s), 1218(s), 1015(m), 
995(m), 979(m), 806(s).  
 
Synthesis of 4-(tert-butyldiphenylsilyloxy)butan-1-ol 
 
 
HO
OH
+ TBDPSCl
BuLi
THF
-78 °C then RT
TBDPSO
OH
 
                      
                        90.12                     274.87                                         328.53  
1,4-Butandiol (3.00 g, 33.3 mmol) in dried THF (18 mL) is cooled to -78 °C under Ar. 
BuLi 1.6M in hexane (7.00 mL, 11.1 mmol) is added dropwise to the white suspension 
under strong stirring. After 5 min., TBDPSCl (2.88 mL, 11.1 mmol), is added slowly to the 
solution. The temperature is raised to RT and the reaction is kept under stirring for 40 
min. The resulting mixture is washed with H2O (20 mL) and sat. NaCl (20 mL), the 
combined organic phases are dried over MgSO4 and the solvent is evaporated under 
vacuum. The crude product is purified by chromatography (hexane/EtOAc 100:15) 
(67%). 
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C6H5  
1H-NMR: 7.76-7.73(m, 4H, H(8)) ; 7.50-7.42(m, 6H, H(9,10)) ; 3.76(t, 3J(1,2)=5.7, 2H, 
H(1)) ; 3.70(t, 3J(4,3)=6.0, 2H, H(4)) ; 2.43 (s, 1H, OH)) ; 1.78-1.67(m, 4H, H(2,3)) ; 1.13 
(s, 9H, H(6)). 
13C-NMR: 135.6(C(8)); 133.7(C(7)); 129.7(C(10)); 127.7(C(9)); 64.0(C(1)); 62.7(C(4)); 
29.8(C(2)); 29.3(C(3)); 26.9(C(6)); 19.2(C(5)). 
 
Synthesis of 4-(tert-butyldiphenylsilyloxy)butanoic acid 
 
TBDPSO
OH PDC
DMF
0 °C then RT
TBDPSO
OH
O  
328.52 342.50 
4-(tert-Butyldiphenylsilyloxy)butan-1-ol (2.60 g, 7.9 mmol) in DMF (20 mL) is cooled to 0 
°C under Ar and treated portionwise with PDC (10.42 g, 27.7 mmol). After 1 h at 0 °C, 
the temperature is raised at RT and the reaction is kept under stirring at this temperature 
over night (15 h). The mixture is washed with H2O (150 mL) and the organic layer is 
extracted with Et2O (5 times). The combined organic phases are dried over MgSO4, 
filtered over celite:silice:celite and concentrated under vacuum giving the pur product 
(63%). 
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O
OH
O
Si
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1H-NMR: 11.51(br, 1H, COOH); 7.81-7.78(m, 4H, H(8)); 7.55-7.47(m, 6H, H(9,10)); 
3.83(t, 3J(4,3)=6.0, 2H, H(4)); 2.63(t, 3J(2,3)=7.3, 2H, H(2)); 2.01(tt, 3J(3,2)=7.2, 
3J(3,4)=6.0, 2H, H(3)); 1.19(s, 9H, H(6)). 
13C-NMR: 180.6(C(1)) ; 135.6(C(8)) ; 133.7(C(7)) ; 129.7(C(10)) ; 127.8(C(9)) ; 
62.8(C(4)) ; 30.95(C(2)) ; 27.6(C(3)) ; 26.9(C(6)) ; 19.31(C(5)). 
 
Synthesis of perfluorophenyl 4-(tert-butyldiphenylsilyloxy)butanoate 
 
TBDPSO
OH
O F
F
F
F
F
OH
DCC
TBDPSO
O
O
F
F
F
F
F
 
342.50 508.55 
4-(tert-butyldiphenylsilyloxy)butanoic acid (2.44 g, 7.1 mmol) in CH2Cl2 (50 mL) is 
charged in a dry flusk under Ar atmosphere and cooled to 0 °C. Pentaflourophenol (1.44 
g, 7.8 mmol) is added followed by DCC (1.64 g, 8.0 mmol). The reaction is brought to RT 
and kept fixed overnight. The reaction mass is then filtered over celite bed to get rid off 
DCC, concentrated under vacuum and the crude product is purified by chromatography 
(hexane/CH2Cl2 3:1) (92%). 
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1H-NMR: 7.74-7.72(m, 4H, H(8)) ; 7.51-7.42(m, 6H, H(9,10)) ; 3.83(t, 3J(4,3)=6.0, 2H, 
H(4)) ; 2.90(t, 3J(2,3)=7.3, 2H, H(2)) ; 2.07(tt, 3J(3,2)=7.3, 3J(3,4)=6.0, 2H, H(3)) ; 1.13(s, 
9H, H(6)). 
13C-NMR: 169.5(C(1)); 142.5-142.3(m, CArF); 140.8-140.5(m, CArF); 240.0-139.8(m, 
CArF); 139.3-138.9(m, CArF); 138.3-138.0(m, CArF); 136.8-136.4(m, CArF); 135.5(C(8)); 
133.5(C(7)); 129.7(C(10)); 127.7(C(9)); 62.2(C(4)); 29.8(C(2)); 27.5(C(3)); 26.8(C(6)); 
19.2(C(5)). 
IR: 3391(vw); 3235(vw); 3072(w); 3051(w); 2958(m); 2932(m); 2893(w); 2859(m); 
2668(vw); 2459(vw); 2143(vw); 1959(vw); 1891(vw); 1791(s); 1654(vw); 1589(w); 
1520(vs); 1472(m); 1428(m); 1112(vs); 1022(m); 1002(vs); 823(m); 742(m); 702(vs); 
614(m); 506(s). 
Synthesis of 1-(4-tert-butyldiphenylsilyloxy)butanoyl-1H-pyrrole-2(5H)-one 
NH
O
TBDPSO
O
O
F
F
F
F
F
N
OTBDPS
OO
+
BuLi
THF
0 °C then RT
 
               83.09                     508.55                                                  407.57 
 
1H-pyrrole 2(5H)-one (0.30 g, 3.5 mmol) in THF (50 mL) is cooled to 0 °C under Ar. BuLi 
1.6M in hexane (2.40 mL, 3.9 mmol) is added slowly to the reaction. After 80 min. at 0 
°C, a solution of perfluorophenyl 4-(tert-butyldiphenylsilyloxy)butanoate (2.02 g, 4.0 
mmol) in THF (20 mL). The reaction is kept under stirring at 0 °C for 30 min. more, then 
the temperature is raided to RT and kept fixed for 4.5 h. The mixture is washed with sat. 
NH4Cl (20 mL), the organic layers are extracted with CHCl3 (3 times) and the solvent is 
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evaporated under vacuum. The crude product is purified by chromatography (CH2Cl2) 
(38%).  
N
O O
O Si
C6H5
12
3
4
5
6 7
8
9
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1112
13
14
15
 
 
1H-NMR: 7.69-7.65(m, 4H, H(13)) ; 7.43-7.35(m, 6H, H(14,15)); 7.29(dt, 3J(3,4)=6.0, 
4J(3,5)=2.0, 1H, H(3) ; 6.19(dt, 3J(4,3)=6.0, 3J(4,5)=1.9, 1H, H(4)); 4.37(dd, 
4J(5,3)=3J(5,4)=2.0, 2H, H(5)); 3.75(t, 3J(9,8)=6.2, 2H, H(9)); 3.09(t, 3J(7,8)=7.3, 2H, 
H(7)); 1.97(tt, 3J(8,7)=7.3, 3J(8,9)=6.2, 2H, H(8)); 1.054(s, 9H, H(11)). 
13C-NMR: 173.0(C(6)); 169.8(C(2)); 146.4(C(3)); 135.6(C(13)); 133.8(C(12)); 
129.5(C(15)); 127.7(C(4)); 127.6(C(14)); 63.0(C(9)); 50.6(C(5)); 32.9(C(7)); 26.9(C(8)); 
26.87(C(11)); 19.2(C(10)). 
 
IR: 3433(vs, H2O); 3070(w); 2930(s); 2857(m); 1729(vs); 1696(vs); 1427(m); 1385(s); 
1348(m); 1333(s); 1260(m); 1216(m); 1109(s); 805(m); 702(s). 
 
HR-MS: calc. 430.1808; found 430.1800. 
 
Synthesis of ethyl triphenylphosphoranylidenepyruvate 
 
Br O
O
O
Ph3P
Ph3P O
O
O
THF
 
193.95 376.12 
Triphenylphosphine (1.90 g, 7.2 mmol) is dissolved in THF (15 mL). To the stirring 
solution, ethyl bromopyruvate (0.50 mL, 3.6 mmol) is added. The mixture is stirred at RT 
for 30 min. and then refluxed under Ar for 2 h. The solvent is removed under reduced 
pressure and the residue is triturated with Et2O (3 times), redissolved in water (20 mL) 
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and extracted with Et2O. The pH of the aqueous layer is adjusted with sat. NaHCO3 to 
ca. 8 when no more precipitate formed. It is filtered and the filter cake is washed 
thoroughly with water. After crystallization from EtOH, the yellow solid is obtained (36%). 
P
O
O
O
C6H5
C6H5
1
2
3 4
5
6
1'
2'
3'
4'
 
1H-NMR: 7.69-7.64(m, 6H, H(2’)) ; 7.61-756(m, 3H, H(4’)) ; 7.50-7.46(m, 6H, H(3’)) ; 
4.84(d, 2J(2,1)=23.3, 1H, H(2)) ; 4.26(q, 3J(5,6)=7.1, 2H, H(5)) ; 1.35(t, 3J(6,5)=7.1, 3H, 
H(6)). 
13C-NMR: 174.2(d, C(3)) ; 165.8(d, C(4)) ; 133.2(d, C(2’)) ; 132.5(d, C(4’)) ; 129.1(d, 
C(3’)) ; 125.8(d, C(1’)) ; 61.2(C(5)) ; 56.5(d, C(2)) ; 14.2(C(6)). 
IR: 3083(vw), 3051(vw), 2925(vw), 1703(vs), 1628(vw), 1577(s), 1558(vs), 1481(m), 
1437(m), 1217(vs), 1184(m), 1103(s), 1082(m), 754(m), 712(m), 694(s), 511(m). 
 
MS-ESI: 377[M+H]+(100%) ; 399[M+Na]+(60%).  
 
 
 
 
 
 
 
 
 
 
